[
    {
        "pmid": "40733519",
        "title": "Cellular and Humoral Immune Profiles After Hepatitis E Vaccination and Infection.",
        "abstract": "Hepatitis E virus HEV cause significant morbidity mortality globally particularly affecting vulnerable population pregnant women HEV239 Hecolinsup®sup recombinant vaccine containing immunodominant protruding E2 domain HEV capsid protein demonstrated effectiveness yet detailed human cellular immune response remain understudied study characterized humoral cellular immune response following vaccination HEV239 natural HEV infection healthy Bangladeshi woman aged 1639 years Using dual IFNγ IL4 ELISpot assays found robust predominantly Th1mediated cellular response 30 day third vaccine dose comparable response acute infection Longitudinal antibody assessment confirmed sustained antibody production primarily E2 domain genotype 1 3 persisting two year postvaccination Despite limitation related sample size assay sensitivity finding underscore immunogenic potential HEV239 support broader use HEVendemic regions",
        "mesh_terms": [
            "Humans",
            "Hepatitis E",
            "Female",
            "Hepatitis E virus",
            "Adult",
            "Adolescent",
            "Immunity, Humoral",
            "Young Adult",
            "Immunity, Cellular",
            "Vaccination",
            "Viral Hepatitis Vaccines",
            "Bangladesh",
            "Hepatitis Antibodies",
            "Antibodies, Viral",
            "Vaccines, Synthetic",
            "Capsid Proteins"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40733519/"
    },
    {
        "pmid": "40725984",
        "title": "The APLAR Recommendations for the Management of Psoriatic Arthritis.",
        "abstract": "auspex AsiaPacific League Associations Rheumatology APLAR aimed develop broad evidence consensusbased guideline aid health professional managing patient psoriatic arthritis PsA region working group 35 member comprising rheumatologists dermatologists patient research partner 18 APLAR country convened working group conducted systematic literature review derive quality evidence via GRADE method supporting efficacy safety class therapeutic agent management active PsA comorbidities screening specific infection concern region Recommendation statement principle management best use therapeutic drug developed Consensus within working group achieved external voting panel five 18 APLAR countries convened confirm agreement recommendation statements main literature review included 178 article clinical trial PsA Additional article evidence managing comorbidities uveitis inflammatory bowel disease screening chronic hepatitis B latent tuberculosis reviewed working group discussed reached consensus eight management principle 16 recommendation statement managing PsA Endorsement external voting panel n  90 response rate 80 achieved first recommendation management PsA patient APLAR region developed based best available evidence regionspecific consideration discussion among rheumatologists dermatologists patients strong agreement external expert panel",
        "mesh_terms": [
            "Humans",
            "Antirheumatic Agents",
            "Arthritis, Psoriatic",
            "Comorbidity",
            "Consensus",
            "Evidence-Based Medicine",
            "Rheumatology",
            "Treatment Outcome",
            "Systematic Reviews as Topic"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40725984/"
    },
    {
        "pmid": "40725544",
        "title": "The Angiography Pattern of Buerger's Disease: Challenges and Recommendations.",
        "abstract": "2023 VAS international working group Buergers Disease BD recommended two diagnostic criterion based prior Delphi study definitive suspected definitive criterion history smoking typical angiography typical histopathological features three feature mandatory confirm definitive diagnosis BD conundrum iswhat feature considered typical BD angiography According review segmental occlusion infrapopliteal arteries corkscrew collateral appear continue occluded arterial segment Martorells sign bypass segmental occlusion absence atherosclerotic plaque aneurysm could differentiate BD ASO Hence typical BD angiography manifestation certainly considered However data differentiating angiography pattern BD small mediumsized vasculitis including Behcets disease scleroderma hepatitis associated vasculitis antiphospholipid syndrome limited study investigating angiography pattern BD patient early late presentation BD particularly patient longterm follow up highly recommended",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40725544/"
    },
    {
        "pmid": "40714039",
        "title": "Let's break it down: combating hepatitis stigma and discrimination.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40714039/"
    },
    {
        "pmid": "40688748",
        "title": "A systematic review of the pivotal role of environmental toxicant exposure on infectious diseases in low- and middle-income countries.",
        "abstract": "objective review identify environmental toxicant linked infectious disease low middleincome country LMICs synthesizing available evidence aim summarize key findings identify research gap provide policy recommendation based association specific toxicant disease outcomes Systematic review conducted comprehensive search PubMed Scopus Web Science core collection CENTRAL the Cochrane Library identify study bacterial viral parasitic pathogenic activity search yielded 11468 studies 55 met inclusion criterion screening following standard methods consistent association found particulate matter PM25 PM10 exposure increased respiratory infection risk PM25 particularly linked increased incidence mortality disease like COVID19 tuberculosis Heavy metals including lead cadmium mercury worsen chronic infection HIVAIDS hepatitis increasing body burden inflammation review highlight air pollutants substantial impact infectious disease spread severity noting research gap pollutant including persistent organic pollutant POPs polycyclic aromatic hydrocarbon PAHs Bias assessment indicates around half study show low risk bias however potential bias noted confounding variable blinding outcome assessment systematic review emphasizes need research biological mechanism underlying association impact pollutants Findings advocate reducing environmental pollution exposure LMICs mitigate infectious disease risk",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40688748/"
    },
    {
        "pmid": "40678696",
        "title": "World health Organization's guidance for tracking non-communicable diseases towards sustainable development goals 3.4: an initiative for facility-based monitoring.",
        "abstract": "Noncommunicable disease NCDs account 60 annual global deaths disproportionately affecting low middleincome countries trend undermines progress toward Sustainable Development Goal SDG 34 seek reduce premature mortality NCDs onethird 2030 Despite availability effective relatively affordable interventions addressing NCDs requires sustained coordinated effort robust monitoring systems Facilitybased monitoring offer dynamic alternative static surveys enabling continuous assessment healthcare quality utilization study followed systematic approach develop standardized global national NCD monitoring indicators using Donabedian model conceptual framework focused four major NCD categories hypertension cardiovascular disease CVDs diabetes chronic respiratory diseases cancers methodology included systematic scoping review inception November 2021 multiround Delphi process involving global expert assess validity feasibility proposed indicators study funded internally WHO payment participants final output consisted 81 validated indicators22 core 59 optional indicator demonstrated high feasibility relevance facilitybased monitoring NCD service delivery provide actionable metric assessing improving quality care across diverse health system settings study highlight urgent need comprehensive contextsensitive NCD monitoring frameworks proposed set indicator offer validated foundation improving NCD care delivery aligns effort achieve SDG target 34 Ongoing update local adaptation essential ensure continued relevance effectiveness study funded internally WHO",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40678696/"
    },
    {
        "pmid": "40675253",
        "title": "Outbreak of leptospirosis caused by Leptospira wolffii with HAV coinfections in lower Assam, Northeast India in 2024: Clinical impact and public health implications.",
        "abstract": "FebruaryMarch 2024 outbreak unknown fever jaundice multiple fatality reported Goalpara District Assam India study aimed identify etiological agent responsible outbreak guide public health interventions Clinical sample 30 individual collected analyzed using serological molecular techniques Serological testing Hepatitis Virus HAV Hepatitis E Virus HEV Leptospira performed using IgM ELISA kits Leptospira DNA extracted amplified using PCR targeting 16S rRNA gene followed nextgeneration sequencing NGS analysis result revealed HAV IgM antibody 2333  case 730 40  1230 tested positive Leptospiraspecific IgM ELISA Additionally PCR targeting 16S rRNA gene confirmed Leptospira DNA 5333  urine sample 815 Notably 1667  530 case exhibited coinfection HAV Leptospira spp challenging clinical outcome Sequencing phylogenetic analysis PCRpositive sample identified Leptospira wolffii L wolffii causative agent marking first report L wolffii human clinical sample Northeastern India Recently L wolffii member P2 subclade Leptospira garnered attention due pathogenic potential finding along reported fatalities emphasize pathogenic potential L wolffii likely introduction region via crossborder transmission neighboring Bangladesh strain prevalent study highlight need enhanced surveillance research monitor emerging Leptospira strains particularly L wolffii human animal populations better understand epidemiology pathogenicity public health implications",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40675253/"
    },
    {
        "pmid": "40583684",
        "title": "Patterns of Presentation of Hepatocellular Carcinoma in a Tertiary Care Hospital in Bangladesh.",
        "abstract": "Hepatocellular carcinoma common primary liver cancer Chronic viral hepatitis alcohol abuse NAFLD common cause hepatocellular carcinoma Usually patient present advanced stage curative treatment longer possible study aimed find clinical presentation etiology stage presentation among patient hepatocellular carcinoma tertiary care center retrospective observational study conducted single tertiary care center July 2023 June 2024 study done among inpatient Department Hepatology 30 Cases recorded confirmed hepatocellular carcinoma period Among 30 patients 5333 patient 60 year age 7666 HBsAg positive 900 patient symptomatic among abdominal pain common Features cirrhosis hepatomegaly main physical findings Normal alphafetoprotein level 1333 patients 9666 patient advanced age curative treatment feasible Hepatocellular carcinoma significant concern crucial identify highrisk patients lead screening using serum alphafetoprotein level ultrasonography liver urgent need discover effective treatment method managing condition particularly advanced stages",
        "mesh_terms": [
            "Humans",
            "Carcinoma, Hepatocellular",
            "Liver Neoplasms",
            "Male",
            "Middle Aged",
            "Female",
            "Tertiary Care Centers",
            "Retrospective Studies",
            "Bangladesh",
            "Adult",
            "Aged",
            "alpha-Fetoproteins"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40583684/"
    },
    {
        "pmid": "40583660",
        "title": "Hepatitis C Seropositivity among Hospitalized Patients with Decompensated Chronic Liver Disease: An Observational Study in a Tertiary Care Hospital of Bangladesh.",
        "abstract": "Viral hepatitis due hepatitis B virus C virus HCV major contributor huge burden chronic liver disease Bangladesh study aimed investigate seroprevalence HCV among decompensated Chronic Liver Disease CLD patient admitted Sylhet MAG Osmani Medical College Hospital SOMCH Bangladesh crosssectional study conducted among 58 admitted patient SOMCH aged ≥18 year diagnosis decompensated CLD Detailed clinical data extracted hospital record physical examination immunochromatographic direct binding method used detection AntiHCV antibody mean age ±SD patient 457±133 year 860 male Seropositivity antiHCV antibody 172 predominance genotype3 Around 580 patient CLD class C ChildPugh scoring system Edema 910 testicular atrophy 810 leukonychia 720 jaundice 580 clubbing 580 palmar erythema 500 flapping tremor 430 ascites 400 common presentation patients HCV infection contributed almost onefifth decompensated CLD hospitaladmitted patients Mass screening adequate preventive measure recommended mitigate burden HCVinduced CLD",
        "mesh_terms": [
            "Adult",
            "Female",
            "Humans",
            "Male",
            "Middle Aged",
            "Bangladesh",
            "Cross-Sectional Studies",
            "Hepacivirus",
            "Hepatitis C",
            "Hepatitis C Antibodies",
            "Hospitalization",
            "Seroepidemiologic Studies",
            "Tertiary Care Centers"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40583660/"
    },
    {
        "pmid": "40534895",
        "title": "Improving Hepatitis B outcome prediction with ensemble machine learning: A study on predictive models and interpretability.",
        "abstract": "Hepatitis B virus HBV significant global health threat responsible severe liver disease liver failure cirrhosis hepatocellular carcinoma burden especially high lowincome regions early diagnosis treatment critical mitigating impact study investigates effectiveness various machine learning ML technique predicting patient outcome HBV infection Chisquared test used feature selection find important factors later applied train evaluate various ML models address class imbalance dataset Synthetic Minority Oversampling Technique SMOTE used balance data SHapley Additive exPlanations SHAP Local Interpretable Modelagnostic Explanations LIME used improve models interpretability Among individual models Support Vector Machine SVM Logistic Regression LR achieved accuracy 925 implementing Voting Classifier combined SVM LR overall accuracy improved 95 result showed higher level risk factors especially older patients greatly raise risk death insight provide healthcare professional policymakers valuable information develop predicting better patient outcome HBV infection patient care strategies",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40534895/"
    },
    {
        "pmid": "40532465",
        "title": "Prevalence of hepatitis B virus infection among pregnant women and cord blood hepatitis B surface antigen positive newborns in sub-Saharan Africa and South Asia.",
        "abstract": "Newborns infected Hepatitis B Virus HBV risk chronic liver disease hepatocellular carcinoma study investigated prevalence HBV infection among pregnant woman cord blood Hepatitis B surface antigen HBsAg positivity newborn Bangladesh Bhutan India Ethiopia Mozambique Kenya Nigeria Mali South Africa Randomly selected paired maternal cord blood sample n  101 site taken delivery tested HBsAg Hepatitis B extractable antigen HBeAg woman using chemiluminescent microparticle immunoassay Similarly cord blood sample newborn assessed HBsAg reactivity HBV DNA quantified using Xpert® HBV viral load assay followed genotyping overall prevalence maternal HBsAg positivity 55  95 CI 04 71  n  50909 HBsAg positivity higher African country 73  95 CI 54 96  n  44606 compared South Asian country 20  95 CI 08 43  n  6303 p  0002 Relative South Africa higher odds HBsAg seropositivity woman Mozambique aOR 77 95 CI 16 378  Mali aOR 57 95 CI 11 297  rate HBsAg positivity cord blood baby born HBsAg positive woman 280  95 CI 171 423  n  1450 including 318  95 CI 195474  n  1444 African countries cord blood HBsAg positivity observed South Asia Genotypic analysis revealed HBV genotype 417  E 583  predominant high rate cord blood positivity 280  HBsAg underscore urgency enhancing HBV prevention strategy meet World Health Organizations target 90  reduction new HBV infection 2030",
        "mesh_terms": [
            "Humans",
            "Female",
            "Hepatitis B Surface Antigens",
            "Pregnancy",
            "Fetal Blood",
            "Prevalence",
            "Infant, Newborn",
            "Hepatitis B",
            "Adult",
            "Hepatitis B virus",
            "Pregnancy Complications, Infectious",
            "Young Adult",
            "DNA, Viral",
            "Africa South of the Sahara",
            "Asia",
            "Genotype",
            "Viral Load",
            "Infectious Disease Transmission, Vertical",
            "Adolescent",
            "Hepatitis B e Antigens",
            "Asia, Southern"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40532465/"
    },
    {
        "pmid": "40483733",
        "title": "Synergistic effects of peptide mimics against enveloped viruses.",
        "abstract": "global health impact virus highlight urgent need innovative antiviral strategies study investigated synergistic potential two anthranilamidebased peptide mimic RK610 RK758 combination one peptide mimic RK610 combination cationic peptide Mel4 melimine murine hepatitis virus a coronavirus MHV1 influenza virus H1N1 Herpes simplex virus HSV1 Checkerboard assay demonstrated RK610RK758 synergy MHV1 H1N1 ∑FICI value 014 05 respectively RK610Mel4 showed potent synergy HSV1 ∑FICI  018 Cotreatment outperformed sequential application Transmission electron microscopy confirmed structural damage virions cytotoxicity assay indicated tested combination nontoxic MDCK A9 Vero cells except melimine RK610melimine A9 cells Biophysical analysis using DOPC 100  DOPC POPS 7030 lipid provided mechanistic idea peptidemimic interaction lipid envelopes Tethered bilayer lipid membrane tBLMs conjunction electrical impedance spectroscopy revealed peptide mimic combination reduced membrane conductance regardless lipid composition Quartz crystal microbalance dissipation monitoring QCMD revealed RK610 RK758 induced mass addition outer layer significantly increasing POPS DOPC RK610 increased surface pressure LangmuirBlodgett trough RK758 reduced it 610  758 610Mel4 combination raised maximum pressures DOPC  POPS RK758 destabilized monolayer 35 mNm plateau whereas combination restored stability finding highlight peptide mimic broadspectrum antiviral agent show synergy target viral envelopes paving way safer lowresistance therapeutics",
        "mesh_terms": [
            "Animals",
            "Antiviral Agents",
            "Peptides",
            "Influenza A Virus, H1N1 Subtype",
            "Chlorocebus aethiops",
            "Drug Synergism",
            "Dogs",
            "Vero Cells",
            "Murine hepatitis virus",
            "Cell Line",
            "Herpesvirus 1, Human",
            "Mice",
            "Madin Darby Canine Kidney Cells"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40483733/"
    },
    {
        "pmid": "40318686",
        "title": "Prevalence of hepatitis C virus seropositivity and active infection in a Rohingya refugee population in Cox's Bazar camps, Bangladesh: a cross-sectional study.",
        "abstract": "Hepatitis C virus HCV infection significant public health concern Limited data shown unusually high HCV seroprevalence among Rohingya refugee residing camp Coxs Bazar Bangladesh aimed assess prevalence HCV seropositivity active infection identify risk factor inform HCV response crosssectional survey conducted May 10 June 14 2023 adult ≥18 years resident seven camp Coxs Bazar Households selected simple random geosampling one participant per household selected random Participants screened HCV antibody rapid finger prick blood test and seropositive venous sample tested HCV viral load structured questionnaire collected information demographics HCV knowledge exposure risks Surveyadjusted prevalence estimate HCV seropositivity active infection generated applying sampling weights Factors associated HCV seropositivity identified using univariable multivariable current status analysis associated active infection via logistic regression survey included 641 participants 425 66 woman median age 34 year IQR 2846 191 individual tested positive HCV antibodies 187 individual tested active infection 124 detectable HCV viral load surveyadjusted prevalence estimate HCV seropositivity 30·4 95 CI 26·534·5 active infection 19·8 95 CI 16·523·4 Current status analysis identified higher odds HCV seropositivity among individual reporting medical injections adjusted odds ratio 1·8 95 CI 1·22·8 surgery 5·9 1·918·4 among woman 2·1 1·33·2 328 51 641 participant never heard hepatitis C Five 4 124 participant HCV viraemia reported previous HCV treatment substantial burden active HCV infection among adult Rohingya camp residents highlighting urgent need scale testing treatment capacities survey constraint identifying risk factor could provide data HCV incidence Reassessing infection prevalence mass intervention prospective surveillance recommended monitor ongoing transmission wellconcerted multistakeholder action plan needed prevent future largescale burden severe liver disease halt ongoing transmission Médecins Sans Frontières",
        "mesh_terms": [
            "Humans",
            "Cross-Sectional Studies",
            "Female",
            "Bangladesh",
            "Male",
            "Adult",
            "Refugees",
            "Hepatitis C",
            "Prevalence",
            "Middle Aged",
            "Seroepidemiologic Studies",
            "Risk Factors",
            "Hepacivirus",
            "Hepatitis C Antibodies",
            "Young Adult",
            "Viral Load",
            "Adolescent",
            "Refugee Camps",
            "Myanmar"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40318686/"
    },
    {
        "pmid": "40295852",
        "title": "Effects of oxidative stress on viral infections: an overview.",
        "abstract": "Viral infection trigger increased reactive oxygen specie ROS production reduced antioxidant response host leading redox stress inflammation apoptosis ultimately cell tissue damage contribute disease development better understanding ROS contributes viral pathogenesis critical development novel therapeutic interventions review discus current knowledge ROS production effect across various viral infections including severe acute respiratory syndromecoronavirus2 influenza virus dengue virus Zika virus hepatitis B virus hepatitis C virus human immunodeficiency virus infections improve future therapeutic preventive strategy infections",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40295852/"
    },
    {
        "pmid": "40190944",
        "title": "Duodenal Amyloidosis Inducing Malabsorption in Hepatitis B-Related Liver Cirrhosis: A Rare Case Presentation.",
        "abstract": "Chronic hepatitis B virus HBV infection major cause liver cirrhosis worldwide hepatic complication welldocumented extrahepatic manifestation secondary amyloidosis less common lead diverse complex clinical outcomes Here present case 60yearold male history chronic hepatitis B progressed liver cirrhosis presented chronic unexplained intractable diarrhea unresponsive standard treatments also experienced significant unintentional weight loss generalized weakness investigation revealed amyloid deposition duodenum confirming secondary amyloidosis affecting gastrointestinal tract cause malabsorption Persistent diarrhea malabsorption necessitated nutritional support symptomatic management case highlight rare association chronic liver disease CLD secondary amyloidosis malabsorption syndrome emphasizing importance clinical suspicion timely diagnosis Early recognition prompt intervention crucial managing complex cases improving outcomes preventing complications",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40190944/"
    },
    {
        "pmid": "40173410",
        "title": "Enlightened prognosis: Hepatitis prediction with an explainable machine learning approach.",
        "abstract": "Hepatitis widespread inflammatory condition liver presenting formidable global health challenge Accurate timely detection hepatitis crucial effective patient management yet existing method exhibit limitation underscore need innovative approaches Earlystage detection hepatitis possible recent adoption machine learning deep learning approaches mind study investigates use traditional machine learning models specifically classifier logistic regression support vector machine SVM decision trees random forest multilayer perceptron MLP models predict hepatitis infections extensive data preprocessing including outlier detection dataset balancing feature engineering evaluated performance models explored three modeling approaches machine learning default hyperparameters hyperparametertuned model using GridSearchCV ensemble modeling techniques SVM model demonstrated outstanding performance achieving 9925 accuracy perfect AUC score 100 consistency metric 9927 precision 9924 recall F1measure MLP Random Forest proved pace superior performance SVM exhibiting accuracy 9900 ensure robustness employed 5fold crossvalidation technique deeper insight model interpretability validation employed explainability analysis bestperformed model identify effective feature hepatitis detection proposed model particularly SVM exhibit better prediction performance regarding different performance metric compared existing literature",
        "mesh_terms": [
            "Humans",
            "Prognosis",
            "Machine Learning",
            "Support Vector Machine",
            "Hepatitis",
            "Decision Trees",
            "Logistic Models"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40173410/"
    },
    {
        "pmid": "40161035",
        "title": "Unmasking the Duo: Wilson's Disease in the Context of Lupus and Existing Hepatitis E Coinfection.",
        "abstract": "report case 19yearold woman presented plethora overlapping symptom complex etiology final diagnosis concurrent Wilsons disease background Systemic Lupus Erythematosus Hepatitis E infection affect similar organ lead presentation jaundice fever neuropsychiatric symptoms personality changes unique case manifestation symptom specifically related Wilsons disease bizarre behavior initial mutism followed irrelevant speech SLE symptom present oral ulcers alopecia arthralgia affecting small joint hand foot along palpitation shortness breath key clinical message need thorough diagnostic evaluation WD masked mistaken autoimmune conditions SLE early identification treatment condition crucial preventing disease progression improving patient outcomes",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40161035/"
    },
    {
        "pmid": "40131873",
        "title": "Low Hepatitis B vaccination rates among medical students in South Asia: A systematic review and meta-analysis.",
        "abstract": "Current future healthcare professionals medical students risk contracting Hepatitis B virus infection Vaccination Hepatitis B effective mean prevention However study reported variable vaccination rate among medical student different region South Asia Understanding vaccination rate barrier guide effective intervention protect future doctors Therefore aimed find vaccination rate among medical student South Asia comprehensive literature search conducted across multiple database PubMed PubMed Central Scopus Embase CINAHL Google Scholar MEDLINE sources beginning inception July 15 2024 Observational study reporting vaccination rate among Bachelor Medicine Bachelor Surgery MBBS student South Asia included Two reviewer independently screened performed quality assessment Pooled vaccination rate calculated visualized using randomeffects model R Studio Version 2023120 Subgroup analysis performed based country year publication studies Fifty study South Asian region including 12231 participants included quantitative analysis overall pooled Hepatitis B vaccination rate using randomeffects model 56 CI 4963 significant heterogeneity among included study I2  98 P  0 Subgroup analysis based country revealed significant regional variation vaccination rate 59 Pakistan 57 India 55 Nepal 41 Bangladesh P  001 Lack awareness perceived low risk necessity concern side effects logistical challenges lack motivation reported barrier vaccination overall vaccination rate relatively low South Asia significant regional variation Based reported barriers recommend relevant authority focus vaccination awareness motivation costeffectiveness logistics management policy formulation monitoring",
        "mesh_terms": [
            "Humans",
            "Students, Medical",
            "Hepatitis B",
            "Vaccination",
            "Hepatitis B Vaccines",
            "Asia",
            "Asia, Southern"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40131873/"
    },
    {
        "pmid": "40107226",
        "title": "Burden of acute hepatitis E virus in South Asia: Insights from Global Burden of Disease study 2021.",
        "abstract": "Despite global progress South Asian country account disproportionate burden Acute hepatitis E AHE Understanding burden AHE region crucial targeted interventions used Global Burden Disease GBD 2021 data assess burden AHE across eight South Asian country 1990 2021 Joinpoint regression used analyze temporal trend Estimated Annual Percentage Change EAPC calculated quantify trends relationship agestandardized disabilityadjusted life year rate ASDR sociodemographic index SDI assessed using smoothing spline model Spearman rank correlation Rates expressed per 100000 population Bangladesh highest agestandardized prevalence rate ASPR 3327 95  Uncertainty Interval 2764 3995 agestandardized incidence rate ASIR 43301 35961 51976 India highest ASDR 952 433 1842 Males higher ASIR ASPR female South Asian countries except Bhutan India higher ASDR except Nepal Pakistan Bhutan highest EAPC sex ASPR ASIR India highest EAPC ASDR closely followed Bhutan sexes Age group 59 highest ASPR ASIR whereas 1year age group highest ASDR inverse relationship ASDR SDI R  049 p  001 South Asia bear high burden AHE variation across countries Improvements Water Sanitation Hygiene WASH service needed achieve Sustainable Development Goals 3 6",
        "mesh_terms": [
            "Humans",
            "Hepatitis E",
            "Male",
            "Female",
            "Global Burden of Disease",
            "Adult",
            "Prevalence",
            "Middle Aged",
            "Asia",
            "Adolescent",
            "Disability-Adjusted Life Years",
            "Young Adult",
            "Incidence",
            "Child, Preschool",
            "Child",
            "Infant",
            "Hepatitis E virus",
            "Aged",
            "Cost of Illness",
            "Acute Disease",
            "Infant, Newborn",
            "Asia, Southern"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40107226/"
    },
    {
        "pmid": "40102552",
        "title": "Distinct phylogeographic distributions and frequencies of precore and basal core promoter mutations between HBV subgenotype C1 rt269L and rt269I types.",
        "abstract": "Hepatitis B virus HBV genotype C exhibit two distinct polymorphism viral polymerase rt269I rt269L Recently reported distinct virological clinical profile chronic patient subgenotype C2 rt269I polymorphism rt269L polymorphism latter closely related liver disease severity study explored phylogenetic geographic distributions well mutation frequencies precore T1858CG1896A basal core promoter BCP A1762TG1764A mutation two type within HBV subgenotype C1 Analysis 408 HBVC1 fullgenome sequence GenBank revealed clear phylogenetic separation rt269L rt269I subgenotype C1 Geographically rt269I strain within subgenotype C1 predominant Southwest Asia eg Thailand Bangladesh whereas rt269L strain common East Asia Southeast Asia eg Vietnam China Hong Kong Notably compared rt269L subgenotype C2 rt269I presented higher frequency C1858 BCP mutation lower frequency G1896A mutation finding suggest significantly distinct phylogeographic mutational characteristic rt269L rt269I type subgenotype C1 impacting clinical outcome evolutionary trajectories",
        "mesh_terms": [
            "Hepatitis B virus",
            "Humans",
            "Promoter Regions, Genetic",
            "Phylogeography",
            "Genotype",
            "Mutation",
            "Phylogeny",
            "Hepatitis B, Chronic",
            "Genome, Viral",
            "Male",
            "Hepatitis B"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40102552/"
    },
    {
        "pmid": "40080680",
        "title": "Population-Based Estimates of Hepatitis E Virus-Associated Mortality in Bangladesh.",
        "abstract": "Hepatitis E virus HEV endemic many resourcepoor countries Despite available vaccine data HEVassociated mortality scarce hindering informed decisions study aim estimate populationbased rate HEVspecific mortality Bangladesh December 2014 September 2017 conducted surveillance 6 tertiary hospital Bangladesh Patients aged ≥14 year acute jaundice recruited tested IgM antiHEV followed postdischarge mortality survey hospital catchment area identified death associated acute jaundice including maternal deaths stillbirths neonatal death delivered mother acute jaundice pregnancy confirmed 2 independent physician reviewing verbal autopsy data 1925 patient acute jaundice enrolled surveillance hospitals 302 died 28 9 testing positive IgM antiHEV hospital catchment areas team identified 587 jaundiceassociated deaths including 25 maternal deaths Combining hospitalbased surveillance mortality survey data study estimated 986 95 CI 5991338 HEVassociated death annually among individual aged ≥14 year Bangladesh including 163 95 CI 57395 maternal deaths Additionally 279 95 CI 101664 stillbirth 780 95 CI 3651297 neonatal death attributed HEV infection annually Prior Global Burden Disease study presented wildly varying modeling estimate HEVassociated annual deaths ranging 50 000 2013 1932 2019 study first directly measure populationbased estimate mortality Bangladesh used determine costeffectiveness hepatitis E vaccination interventions",
        "mesh_terms": [
            "Humans",
            "Bangladesh",
            "Hepatitis E",
            "Female",
            "Adult",
            "Hepatitis E virus",
            "Male",
            "Young Adult",
            "Adolescent",
            "Middle Aged",
            "Pregnancy",
            "Immunoglobulin M",
            "Infant, Newborn",
            "Jaundice",
            "Infant",
            "Hepatitis Antibodies"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40080680/"
    },
    {
        "pmid": "40076932",
        "title": "Characterization of Exhausted T Cell Signatures in Pan-Cancer Settings.",
        "abstract": "cell play diverse role cancer immunology acting tumor suppressors cytotoxic effectors enhancer cytotoxic lymphocyte response immune suppressors providing memory surveillance modulating tumor microenvironment TME activating innate immune cells However cancer cell disrupt cell function leading cell exhaustion weakened immune response tumor expression exhausted cell Tex marker play pivotal role shaping immune landscape multiple cancers aim systematically investigate role known cell exhaustion Tex marker across multiple cancer exploring molecular interactions mutation profiles potential implication immunotherapy mRNA expression profile six Tex markers iLAG3i iPDCD1i iTIGITi iHAVCR2i iCXCL13i iLAYNi investigated pancancer Utilizing data Cancer Genome Atlas TCGA Gene Expression Omnibus GEO Cancer Proteome Atlas TCPA repositories characterized differential expression Tex markers association patients survival outcome mutation profile multiple cancers Additionally analyzed effect cancerrelated pathway immune infiltration within TME offering valuable insight mechanism cancer immune evasion progression Finally correlation expression sensitivity multiple anticancer drug investigated extensively Differential expression six marker significantly associated KIRC poor prognosis several cancers also played potential activating role apoptosis EMT hormone ER pathways well potential inhibitory role DNA damage response RTK oncogenic pathways Infiltration different immune cell also found associated expression Texrelated gene cancer types finding underline reviving exhausted cell used enhance efficacy immunotherapy cancer patients",
        "mesh_terms": [
            "Humans",
            "Neoplasms",
            "Tumor Microenvironment",
            "T-Lymphocytes",
            "Biomarkers, Tumor",
            "Gene Expression Regulation, Neoplastic",
            "Lymphocyte Activation Gene 3 Protein",
            "Mutation",
            "Programmed Cell Death 1 Receptor",
            "Hepatitis A Virus Cellular Receptor 2",
            "Antigens, CD",
            "Receptors, Immunologic"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40076932/"
    },
    {
        "pmid": "40062742",
        "title": "Global Burden of Major Chronic Liver Diseases in 2021.",
        "abstract": "study utilised Global Burden Disease data 20102021 analyse rate trend point prevalence annual incidence year lived disability YLDs major chronic liver diseases hepatitis B hepatitis C metabolic dysfunctionassociated liver disease cirrhosis chronic liver diseases Agestandardised rate per 100000 population prevalence annual incidence YLDs compared across region countries well sociodemographic index SDI Trends expressed percentage change PC estimate reported uncertainty interval UI Globally 2021 agestandardised rate per 100000 population prevalence hepatitis B hepatitis C MASLD cirrhosis chronic liver disease 35836 95UI 3293638877 17178 1385520753 150181 137565163614 203026 188452217919 respectively 2010 2021 PC agestandardised prevalence rate were204 hepatitis B 51 hepatitis C 112 MASLD  26 cirrhosis chronic liver diseases period PC agestandardized incidence rate 247 68 32 30 respectively Generally negative associations fluctuations found agestandardised prevalence rate hepatitis B hepatitis C cirrhosis chronic liver disease SDI global level However MASLD prevalence peaked moderate SDI levels global burden chronic liver disease remains substantial Hepatitis B C decreased prevalence incidence last decade MASLD cirrhosis chronic liver disease increased necessitating targeted public health strategy resource allocation",
        "mesh_terms": [
            "Humans",
            "Global Burden of Disease",
            "Prevalence",
            "Incidence",
            "Male",
            "Middle Aged",
            "Female",
            "Adult",
            "Global Health",
            "Liver Diseases",
            "Liver Cirrhosis",
            "Chronic Disease",
            "Aged",
            "Young Adult",
            "Hepatitis C, Chronic",
            "Hepatitis B, Chronic",
            "Disability-Adjusted Life Years",
            "Adolescent"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40062742/"
    },
    {
        "pmid": "40051950",
        "title": "Unmasking Portal Colopathy: A Case of Rectal Bleeding in a Patient With Liver Cirrhosis Misdiagnosed as Ulcerative Colitis.",
        "abstract": "report outline diagnostic journey 31yearold female patient chronic hepatitis B virus HBV infection presented acute rectal bleeding Initially misdiagnosed ulcerative colitis primary care center though underlying cause symptom related cirrhosis complication portal hypertensive colopathy PHC presentation revealed history ascites month onset rectal bleeding managed diuretics Subsequent investigation led revised diagnosis decompensated cirrhosis secondary chronic HBV infection PHC identified cause rectal bleeding case highlight diagnostic challenge faced managing patient coexisting cirrhosis gastrointestinal bleeding initially misdiagnosed ulcerative colitis",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40051950/"
    },
    {
        "pmid": "40016576",
        "title": "The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease.",
        "abstract": "Metabolic dysfunctionassociated fatty liver disease MAFLD affect onefourth global adult population leading cause liver disease worldwide address this Asian Pacific Association Study Liver APASL created clinical practice guideline focused MAFLD guideline cover various aspect disease epidemiology diagnosis screening assessment treatment guideline aim advance clinical practice knowledge research MAFLD particularly special groups guideline designed advance clinical practice provide evidencebased recommendation assist healthcare stakeholder decisionmaking improve patient care disease awareness guideline take account burden clinical management healthcare sector",
        "mesh_terms": [
            "Humans",
            "Fatty Liver",
            "Non-alcoholic Fatty Liver Disease"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40016576/"
    },
    {
        "pmid": "39988206",
        "title": "Adeno-associated virus 2 CRISPR/Cas9-mediated targeting of hepatitis B virus in tree shrews.",
        "abstract": "Chronic hepatitis B virus HBV infection global health issue limited therapeutic option given persistence viral episomal DNA cccDNA Previously investigated effect adenoassociated virus 2 AAV2 vectormediated delivery three guide gRNAsCas9 selected 16 gRNAs AAV2WJ11Cas9 effectively suppressed HBV replication vitro humanized chimeric mouse livers present study examined effect AAV2WJ11Cas9 acute phase HBV genotype F infection immunocompetent northern tree shrew Tupaia belangeri hereafter tupaia model AAV2WJ11Cas9 treatment significantly reduced HBV viral load serum 1 7 10 14 day postinfection dpi HBVF infection caused enlargement hepatocytes mild lymphocytic infiltration interlobular connective tissue Thus virus damage hepatocytes drive infection progression HBV core antigen HBcAg accumulation observed AAV2WJ11Cas9 treated normal liver tissues AAV2WJ11Cas9 treatment reduced HBV DNA cccDNA liver tissues well serum level HBV surface antigen HBV corerelated antigen HBcrAg including HBcAg HBeAg 14 dpi AntiHBc antiHBs antiAAV Abs production also detected AAV2WJ11Cas9 treatment suppressed inflammatory cytokine TLR1 TLR2 TLR3 TLR4 TLR6 TLR7 TLR9 mRNA levels Thus WJ11Cas9 delivered AAV2 vector may provide new therapeutic approach inhibiting HBV infection immunocompetent animal models could developed use human translational research",
        "mesh_terms": [
            "Animals",
            "Hepatitis B virus",
            "Dependovirus",
            "CRISPR-Cas Systems",
            "Liver",
            "Disease Models, Animal",
            "Virus Replication",
            "Tupaiidae",
            "Hepatitis B",
            "Viral Load",
            "Hepatocytes",
            "Tupaia",
            "Humans",
            "Hepatitis B, Chronic",
            "Genetic Vectors",
            "Hepatitis B Core Antigens",
            "DNA, Viral"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39988206/"
    },
    {
        "pmid": "39961976",
        "title": "Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia.",
        "abstract": "Acuteonchronic liver failure ACLF condition associated high mortality absence liver transplantation various definition proposed worldwide first consensus report working party Asian Pacific Association Study Liver APASL set 2004 ACLF published 2009 APASL ACLF Research Consortium AARC formed 2012 AARC database prospectively collected nearly 10500 case ACLF various country AsiaPacific region database instrumental developing AARC score grade ACLF concept Golden Therapeutic Window transplant window plasmapheresis treatment modality Also data key identifying pediatric ACLF European Association Study LiverChronic Liver Failure EASL CLIF North American Association Study End Stage Liver Disease NACSELD West added concept organ failure infection precipitant development ACLF CLIFSequential Organ Failure Assessment SOFA NACSELD score prognostication Chinese Group Study Severe Hepatitis B COSSH added COSSHACLF criterion manage hepatitis b virusACLF without cirrhosis literature support definition equally effective respective cohort identifying patient high mortality overcome difference develop global consensus APASL took initiative invited global stakeholders including opinion leader Asia EASL AASLD researcher field ACLF identify key issue develop evidencebased consensus document consensus document presented hybrid format APASL annual meeting Kyoto March 2024 Kyoto APASL Consensus presented carry final recommendation along relevant background information area requiring future studies",
        "mesh_terms": [
            "Acute-On-Chronic Liver Failure",
            "Humans",
            "Asia",
            "Consensus",
            "Organ Dysfunction Scores",
            "Liver Transplantation"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39961976/"
    },
    {
        "pmid": "39940455",
        "title": "Thyroid Stimulatory Activity of <i>Houttuynia cordata</i> Thunb. Ethanolic Extract in 6-Propyl-Thiouracil-Induced Hypothyroid and STZ Induced Diabetes Rats: In Vivo and In Silico Studies.",
        "abstract": "iHouttuynia cordatai Thunb hold longstanding reputation traditional folk remedy East Asia employed treat variety inflammatory conditions nephritis hepatitis cancer Despite extensive use exists paucity research examining efficacy managing thyroid disorder diabetes Moreover bioactive component responsible modulating molecular pathway remain elusive research aimed determine key bioactive component ethanolic extract iH cordatai Thunb HCEE responsible thyroidmodifying property examine effect rat experimentally induced hypothyroidism diabetes Molecular docking performed investigate possible mechanism thyroid regulation HCEE constituents Researchers induced hypothyroidism rat adding 6propyl2thiouracil drinking water period four weeks induce diabetes rat received intraperitoneal injection streptozotocin animal given daily oral dos HCEE 500 mgkg bw levothyroxine 50 mgkg bw glibenclamide 5 mgkg bw 28 days Following treatment standard method employed measure biochemical parameter rats serum result demonstrate HCEE ameliorated hypothyroidism increasing serum T3 1438 T4 12596 level decreasing TSH ipi  001 4175 levels diabetic rat induced hypothyroidism HCEE significantly ipi  0001 increased T3 14951 T4 7354 level reduced TSH 6439 levels silico analysis demonstrated identified bioactive compound HCEE may enhance thyroid hormone function interaction thyroid hormone receptor protein TRβ1 PDB3GWS similar conventional pharmaceutical levothyroxine triiodothyronine T3 HCEE exhibit potential natural alternative synthetic medication prevention treatment thyroid dysfunctions",
        "mesh_terms": [
            "Animals",
            "Hypothyroidism",
            "Diabetes Mellitus, Experimental",
            "Thyroid Gland",
            "Molecular Docking Simulation",
            "Rats",
            "Houttuynia",
            "Male",
            "Propylthiouracil",
            "Plant Extracts",
            "Ethanol",
            "Streptozocin",
            "Computer Simulation",
            "Rats, Sprague-Dawley",
            "Thyroxine"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39940455/"
    },
    {
        "pmid": "39820842",
        "title": "Machine learning and spatio-temporal analysis of meteorological factors on waterborne diseases in Bangladesh.",
        "abstract": "Bangladesh facing formidable challenge mitigating waterborne disease risk exacerbated climate change However comprehensive understanding spatiotemporal dynamic disease district level remains elusive Therefore study aimed fill gap investigating spatiotemporal pattern identifying best treebased ML model determining meteorological factor associated waterborne disease Bangladesh study used districtlevel reported case waterborne disease cholera amoebiasis typhoid hepatitis A obtained Bangladesh Bureau Statistics BBS meteorological data temperature relative humidity wind speed precipitation sourced NASA period spanning 2017 2020 Exploratory spatial analysis spatial regression treebased machine learning model utilized analyze data 2017 2020 Bangladesh reported 73 606 cholera 38 472 typhoid 2 510 hepatitis 1 643 amoebiasis disease cases Among waterborne disease cholera showed higher incidence rate ChapaiNawabganj 45623 Brahmanbaria 41744 Faridpur 22507 Nilphamari 18862 Pirojpur 17162 districts spatial regression model identified mean temperature β  1216 se 391 significant risk factor waterborne diseases optimal XGBoost model highlighted mean minimum temperature relative humidity precipitation determinant associated waterborne disease Bangladesh 2017 2020 finding study incorporating One Health perspective provide insight planning early warning prevention control strategy combat waterborne disease Bangladesh similar endemic countries Precautionary measure intensified surveillance need implemented certain highrisk district waterborne disease across country",
        "mesh_terms": [
            "Bangladesh",
            "Humans",
            "Machine Learning",
            "Spatio-Temporal Analysis",
            "Meteorological Concepts",
            "Waterborne Diseases",
            "Cholera",
            "Typhoid Fever",
            "Incidence",
            "Temperature"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39820842/"
    },
    {
        "pmid": "39802853",
        "title": "HeberNasvac: Development and Application in the Context of Chronic Hepatitis B.",
        "abstract": "immune system play central role controlling acute hepatitis B infection patient resolving chronic hepatitis B CHB Given 221 million 75 CHB patient reside low middleincome countries development vaccine therapeutic property represents rational costeffective approach romantic endeavor review systematically analyzes key variable related safety efficacy effectiveness CHB treatments HeberNasvac experience revisited addressing challenge potentiality therapeutic vaccines well current roadblock research development registration largescale implementation Aguilar JC Akbar SMF AlMahtab M iet ali HeberNasvac Development Application Context Chronic Hepatitis B Euroasian J HepatoGastroenterol 2024142221237",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39802853/"
    },
    {
        "pmid": "39781299",
        "title": "Training of medical coordinators for noncommunicable diseases based on Japanese experience.",
        "abstract": "incidence noncommunicable disease NCDs increasing low middleincome country represents major public health challenge Herein present Japans experience training medical coordinator combat NCDs focus hepatitis earlyonset dementia child medical complexity Coordinators play important role bridging gap patient healthcare services examined training role coordinators Japanese model medical coordinators including medical nonmedical personnel successfully strengthened delivery healthcare service specific diseases However challenge persist including uneven distribution coordinators inconsistency training programs programs relatively recent establishment limited awareness coordinators role activities Training medical coordinator strengthen comprehensive patient support managing NCDs Despite limitations model provides valuable insight developing interventional strategy Asian country facing similar medical human resource shortages Collaboration among governments hospitals related organisation training coordinator hold promise addressing growing prevalence NCDs regions",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39781299/"
    },
    {
        "pmid": "39739489",
        "title": "Serum Vitamin D Status in Infants with Cholestatic Jaundice.",
        "abstract": "Cholestatic jaundice potentially serious condition requires early diagnosis proper management Fatsoluble vitamin FSV deficiency develops consequence cholestasis Vitamin deficiency common remains challenge patient cholestasis Objectives study evaluate serum 25hydroxyvitamin status infant cholestatic jaundice crosssectional analytical study conducted department Paediatric Gastroenterology Nutrition Bangabandhu Sheikh Mujib Medical University Dhaka Bangladesh January 2017 June 2018 purposively sampled infants Infants developed jaundice three month age direct bilirubin 200 total bilirubin total bilirubin ≥5 mgdl 10 mgdl total bilirubin 5 mgdl pale stool dark urine included case infant visited hospital diagnosis acute bronchiolitis reactive airway disease acute viral infection evidence liver gastrointestinal disease renal disease checked mean medical history physical examination review medical record included controls Blood collected patient cholestatic liver disease liver biochemistries prothrombin time 25hydroxyvitamin serum calcium Blood also collected control 25hydroxyvitamin serum calcium 25hydroxyvitamin level 15 15 20 20 ngml defined vitamin deficiency insufficiency sufficiency respectively Thirty patient 30 control evaluated Mean age case control 11343±7408 14550±8862 day respectively p0134 Biliary atresia found commonest cause 18600 followed idiopathic neonatal hepatitis INH 7233 choledochal cyst 4133 1 case neonatal hepatitis NH due CMV infection mean serum bilirubin total 1207±392 mgdl mean serum bilirubin direct 651±203 mgdl serum ALT 1307±6781 UL serum AST 13507±5254 UL prothrombin time 1736±1188 seconds serum gammaglutamyl transpeptidase GGT 7003±55589 UL alkaline phosphatase 56037±28312 UL serum albumin 36±04 gmdl Mean serum calcium 918±084 mgdl Mean 25hydroxyvitamin level cholestatic patient 147±575 ngml compared 2768±1044 ngml control p0001 Vitamin deficiency found 433 patients correlation age presentation serum 25hydroxyvitamin level significant r  0051 p  0784 Statistically significant negative correlation r  0389 p0034 found serum 25hydroxyvitamin serum gammaglutamyl transpeptidase Serum calcium found statistically significant positive correlation 25hydroxyvitamin r0692 p0001 Blood level 25hydroxyvitamin patient cholestasis lower controls So adequate vitamin supplementation monitoring population great importance",
        "mesh_terms": [
            "Humans",
            "Infant",
            "Vitamin D",
            "Male",
            "Female",
            "Cross-Sectional Studies",
            "Vitamin D Deficiency",
            "Jaundice, Obstructive",
            "Bangladesh",
            "Infant, Newborn",
            "Cholestasis",
            "Bilirubin"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39739489/"
    },
    {
        "pmid": "39585861",
        "title": "Knowledge, attitude, and practice towards Hepatitis B and vaccination status of pre-clinical medical students at Sylhet Women's Medical College, Bangladesh.",
        "abstract": "Hepatitis B global health problem high morbidity mortality risk transmission common among health care personnel medical student professional health trainings Vaccination effective mean prevention main objective study determine level knowledge attitude practice regarding Hepatitis B vaccination among preclinical student medical college webbased singlecenter descriptive crosssectional study conducted among preclinical medical student Bangladesh April 28 2024 May 4 2024 whole sampling technique method used taking entire population study Data collected using selfadministered questionnaire analyzed using JMP Pro V17 Statistical Software Sixtyone 34 student vaccinated Hepatitis B 18 received three dos booster dose common reason nonvaccination lack awareness ones vaccination status 43 median knowledge attitude practice KAP score 54 5060 19 1721 20 1923 respectively moderately positively correlated Fortysix 2598 student good overall KAP score ≥ 102 onethird student vaccinated commonest reason nonvaccination lack awareness ones vaccination status Nearly onefourth participant good knowledge attitude practice related Hepatitis B Therefore education regarding Hepatitis B infection risk factors importance vaccination must among preclinical medical student Bangladesh",
        "mesh_terms": [
            "Humans",
            "Students, Medical",
            "Bangladesh",
            "Female",
            "Hepatitis B",
            "Health Knowledge, Attitudes, Practice",
            "Vaccination",
            "Cross-Sectional Studies",
            "Young Adult",
            "Male",
            "Adult",
            "Surveys and Questionnaires",
            "Hepatitis B Vaccines",
            "Adolescent"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39585861/"
    },
    {
        "pmid": "39570557",
        "title": "APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024.",
        "abstract": "AsiaPacific region hepatocellular carcinoma serious health threat attributing 600000 death year account 70 global cases Clinically major unmet need recurrence curativeintent surgery liver transplantation local ablation disease progression hepatocellular carcinoma eligible resection failed locoregional therapy recent years new targeted therapy immunecheckpoint inhibitor registered systemic therapy address issues Notably new form systemic therapy either firstline secondline therapy unresectable hepatocellular eligible locoregional therapy available New data also emerging use systemic therapy prevent hepatocellular carcinoma recurrence curativeintent resection local ablation therapy retard disease progression locoregional therapy future implementation immunecheckpoint inhibitor form immunotherapy expected bring new paradigm management hepatocellular carcinoma New insight related immunerelated adverse event use immunotherapy allso enabled optimization therapeutic approach patient hepatocellular carcinoma purpose clinical practice guideline provide uptodate recommendation based clinical evidence experience expert AsiaPacific key opinion leader field hepatocellular carcinoma Three key question addressed namely 1 patient hepatocellular carcinoma considered systemic therapy 2 systemic therapy used 3 patient planned immune checkpointbased systemic therapy managed monitored",
        "mesh_terms": [
            "Humans",
            "Carcinoma, Hepatocellular",
            "Immune Checkpoint Inhibitors",
            "Immunotherapy",
            "Liver Neoplasms"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39570557/"
    },
    {
        "pmid": "39547254",
        "title": "It is time for World Hepatitis Testing Week.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39547254/"
    },
    {
        "pmid": "39543999",
        "title": "Addressing Public Health Risks: Strategies to Combat Infectious Diseases After the August 2024 Floods in Bangladesh.",
        "abstract": "August 2024 flood Bangladesh precipitated major public health crisis significantly elevating risk waterborne vectorborne disease exacerbating existing health vulnerabilities disaster impacted 5 million people causing widespread environmental disruption population displacement strained healthcare resources flooding latrines sewage systems agricultural land led contamination drinking water sources increasing risk cholera enterotoxigenic Escherichia coli diarrhoea shigellosis hepatitis Additionally stagnant floodwaters created breeding ground mosquitoes thereby increasing threat malaria dengue fever disruption healthcare service compounded crisis delaying emergency response impeding access care psychological impact affected community profound mental health issue anxiety depression posttraumatic stress disorder emerging significant concerns perspective provides analysis public health threats supported data impact flood discussion underlying risk factors underscore need immediate longterm public health interventions including restoring clean water access enhancing disease surveillance repairing healthcare infrastructure addressing mental health needs response disaster must rapid comprehensive lesson learned inform preparedness effort better manage similar event future",
        "mesh_terms": [
            "Humans",
            "Bangladesh",
            "Floods",
            "Public Health",
            "Risk Factors",
            "Communicable Diseases",
            "Disasters"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39543999/"
    },
    {
        "pmid": "39477629",
        "title": "Global multi-societies endorsement of the MAFLD definition.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39477629/"
    },
    {
        "pmid": "39472687",
        "title": "Clinical validation of peripheral blood mononuclear cell DNA methylation markers for accurate early detection of hepatocellular carcinoma in Asian patients.",
        "abstract": "Hepatocellular carcinoma HCC leading cause cancerrelated death globally pose significant challenge early detection Improved diagnostic accuracy drastically influence patient outcomes emphasizing need innovative noninvasive biomarkers study utilized cohort 402 participants including healthy controls chronic hepatitis patients HCC patient Bangladesh evaluate DNA methylation signature peripheral blood mononuclear cell PBMC performed targeted nextgeneration sequencing selected gene previously identified assess methylation dynamics development M8 M4 score based dynamics using Receiver Operating Characteristic ROC analysis determine effectiveness detecting earlystage HCC alongside existing marker epiLiver alphafetoprotein AFP Integration M8 M4 score epiLiver AFP significantly enhances diagnostic sensitivity earlystage HCC M4epiLiver score achieves sensitivity 794 Stage HCC combining M4 AFP increase sensitivity 882957 across stages indicating superior diagnostic performance compared marker used alone study confirms combining gene methylation profile established diagnostic marker substantially improves sensitivity detecting earlystage HCC integrated diagnostic approach hold promise advancing noninvasive cancer diagnostics potentially leading earlier treatment intervention improved survival rate highrisk patients",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39472687/"
    },
    {
        "pmid": "39424567",
        "title": "Hepatitis E vaccine and fetal loss: the potential pathophysiological basis - Authors' reply.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39424567/"
    },
    {
        "pmid": "39367477",
        "title": "Effective community-based interventions to prevent and control infectious diseases in urban informal settlements in low- and middle-income countries: a systematic review.",
        "abstract": "impact rapid urbanization taking place across world posing variegated challenges Especially term communicable disease risk concentrated urban poor area basic amenity inadequate systematic review synthesizes evidence effective communitybased intervention CBIs aimed preventing controlling infectious disease among urban poor low middleincome country LMICs systematic review conducted following PRISMA Preferred Reporting Items Systematic Reviews MetaAnalysis guidelines comprehensive search across five major database conducted capture literature CBIs published 2011 2021 Scientific article design reported type CBIs effective preventing controlling infectious disease tuberculosis diarrhea typhoid dengue hepatitis B C influenza COVID19 included Screening selection study done two pair independent researcher using predefined eligibility criteria risk bias included study assessed using modified checklist outlined Cochrane Handbook Systematic Reviews Interventions Effective Public Health Practice Project EPHPP Analysis effective CBIs guided conceptual framework integrated CBIs neglected tropical disease NTDs narrative synthesis carried out Geographical restriction limited LMICs paper published English 18260 identified papers 20 study met eligibility criterion included review Communitybased screening socioeconomic support communitybased vector control behavior change communication capacity building community health worker CHWs health education e mhealth intervention found effective CBIs Diversified CBIs found effective specific diseases including tuberculosis TB diarrhea dengue influenza ARI hepatitis B C Bundling intervention found effective specific diseases However difficult isolate effectiveness individual intervention within bundle sociocultural context considered designing implementing CBIs effectiveness intervention inextricably linked social context stakeholder dimensions broader societal issues System approach recommended emphasizing contextspecific multicomponent intervention address social determinant health Integrating intervention public health strategy community involvement crucial sustainable outcomes finding guide design future intervention better prevention control communicable disease urban poor areas PROSPERO CRD42021278689",
        "mesh_terms": [
            "Humans",
            "Developing Countries",
            "Communicable Disease Control",
            "COVID-19",
            "Community Health Services",
            "Communicable Diseases",
            "Urban Population",
            "SARS-CoV-2"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39367477/"
    },
    {
        "pmid": "39319277",
        "title": "Efficacy and Safety of Valganciclovir in Congenital Cytomegalovirus Infection with Isolated Intrahepatic Cholestasis: A Randomized Controlled Trial.",
        "abstract": "Cytomegalovirus CMV infection affect hepatic neurologic hematopoietic respiratory gastrointestinal organs resulting high mortality rate longterm sequelae may cause acute chronic hepatitis even lead hepatic cirrhosis Valganciclovir VGCV effective safe welltolerated treatment congenital CMV infection without serious adverse effects study conducted evaluate clinical biochemical virological profile infant CMV intrahepatic cholestasis determine outcome without treatment VGCV Twenty infant aged 6 month diagnosed congenital CMV infection evidence intrahepatic cholestasis included study Randomization used divide study participant 2 groups control group n10 treated supportive management intervention group n10 treated oral VGCV 16 mgkgdose 12 hour day 6 week plus supportive treatments Physical examination biochemical serological virological test performed time diagnosis end 6 week 6 months control intervention group compared term clinical laboratory parameter jaundice dark urine pale stool hepatomegaly total bilirubin aminotransferases gammaglutamyl transferase alkaline phosphatase CMV polymerase chain reaction load showed significant reduction treatment intervention group ipi005 oral VGCV side effects whereas control group showed significant changes Oral VGCV used effectively treat CMV infection intrahepatic cholestasis without notable side effects",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39319277/"
    },
    {
        "pmid": "39246409",
        "title": "Regulation of Hepatitis B Virus Replication by Modulating Endoplasmic Reticulum Stress (ER-Stress).",
        "abstract": "Hepatitis B virus HBV resistant several antiviral drug due viral genomic mutations reported aggravates chronic infection lead hepatocellular carcinoma Therefore host cellular factorssignaling modulation might alternative way treatment drugresistant HBV Here investigated viral protein expression replication virion production using endoplasmic reticulum ER stressmodulating chemicals tunicamycin an ERstress inducer salubrinal an ERstress inhibitor found ERstress could induced HBV replication transfected HepG2 cell well tunicamycin demonstrated dual luciferase assay HBV intracellular coreassociated DNA quantified qPCR significantly increased tunicamycin transfected HepG2 cells Inversely intracellular core associated extracellular particle DNA significantly decreased dosedependent manner salubrinaltreated HepG2 cell transfected HBVreplicating plasmid pHBI Similar result found stably HBVexpressing hepatoblastoma HB611 cell treated salubrinal However increased decreased ERstress tunicamycin salubrinal treatment respectively confirmed expression analysis grp78 using Western blot addition Western blot result demonstrated expression HBV core protein large HBsAg increased decreased tunicamycin salubrinal respectively conclusion salmediated inhibition HBV replication virion production might due simultaneous reduction core large HBsAg expression maintaining ER homeostasis result HBV replication regulation modulation ERstress dynamic would useful designingidentifying antiHBV drug targeting cellular signaling pathways",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39246409/"
    },
    {
        "pmid": "39186570",
        "title": "Prevalence and associated risk factors of current hepatitis C infection among U.S. general population and injection drug users aged 20-59 years: NHANES 2009-2018.",
        "abstract": "people inject drug PWID attributed highrisk group transmission Hepatitis C virus HCV study assessed prevalence associated factor current HCV infection CHI among US general population PWID age 20 59 year old study utilized crosssectional data 20092018 National Health Nutrition Examination Survey conducting separate analysis US general population including PWID nonPWID well specific analysis focusing solely PWID analytical method included estimation CHI prevalence RaoScott chisquare test compare CHIpositive CHInegative groups univariate multivariable logistic regression model evaluate associated risk factor CHI prevalence CHI among general population PWID 1 19 respectively Compared nonPWID odds CHI significantly higher among PWID OR  326 95 CI  177603 general population Among PWID male vs female OR  26 95 CI  1159 adult aged 4059 vs 2039 year old OR  29 95 CI  1273 NonHispanic Black vs White OR  46 95 CI  15136 high school diploma less educational attainment vs college degree OR  35 95 CI  1492 showed higher odds CHI prevalence CHI found higher among PWID especially male aged 4059 year old NonHispanic Black lower educational attainment Targeted intervention screening awareness program among PWID population recommended reduce burden new HCV infection US",
        "mesh_terms": [
            "Humans",
            "Adult",
            "Male",
            "Female",
            "Middle Aged",
            "Risk Factors",
            "United States",
            "Prevalence",
            "Substance Abuse, Intravenous",
            "Hepatitis C",
            "Cross-Sectional Studies",
            "Nutrition Surveys",
            "Young Adult",
            "Drug Users"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39186570/"
    },
    {
        "pmid": "39185365",
        "title": "miRNA-221: A Potential Biomarker of Progressive Liver Injury in Chronic Liver Disease (CLD) due to Hepatitis B Virus (HBV) and Nonalcoholic Fatty Liver Disease (NAFLD).",
        "abstract": "bBackgroundb Early detection progressive liver damage chronic liver disease CLD patient crucial better treatment response Several study shown association microRNA miRNA progression CLD regulating cell proliferation fibrosis apoptosis well carcinogenesis bObjectivesb study aimed determining expression miRNA221 among different stage fibrosis CLD patient due hepatitis B virus HBV nonalcoholic fatty liver disease NAFLD thus evaluate role early biomarker CLD bMethodsb total 100 participant 75 CLD patient 25 healthy control recruited crosssectional study divided four groups 25 healthy control 25 CLD without fibrosis 25 CLD fibrosis 25 CLD cirrhosis Total RNA extracted plasma followed cDNA synthesis finally expression miRNA221 analyzed diagnostic potential single biomarker using qRTPCR method bResultsb plasma level miRNA221 significantly upregulated different fibrosis stage CLD ipi  005 upregulation positively correlated progression fibrosis ipi  005 Significantly increased expression miRNA221 found NAFLD patient compared HBV patient CLD without fibrosis patient group ipi  005 expression miRNA221 significantly upregulated among HBV patient CLD fibrosis group miRNA221 showed high diagnostic accuracy discriminating different stage fibrosis healthy control ipi  005 bConclusionb miRNA221 may used potential plasma biomarker early prediction fibrosis progression CLD patients",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39185365/"
    },
    {
        "pmid": "39165251",
        "title": "Microbial infection among SARS-COV-2-infected patients in a COVID-19-dedicated tertiary care hospital of Bangladesh: a cross-sectional study.",
        "abstract": "bObjectivesb study aimed determine pattern respiratory bloodborne uropathogenic microbial pathogen among SARSCoV2infected patient COVID19coronavirus disease 2019 dedicated tertiary care hospital Dhaka Bangladesh bDesignbThis crosssectional study bSettingb COVID19dedicated tertiary care hospital Dhaka Bangladesh conducted March June 2021 bParticipantsb Hospitalized individual COVID19 infection regardless age sex bPrimary secondary outcome measuresb percentage coinfected COVID19 patient characterization microorganism responsible coinfection served primary outcome measures Finding association coinfection age coinfection sex coinfection comorbidity secondary outcome variable bInterventionsb applicable bResultsbOut 79 patients 61  male mean age 4953 years Coinfection seen 77  patients 51  isolates urine samples followed 26  blood Bacteria isolated urine iEnterococcusi 26  coagulasenegative iStaphylococcusi CONS 13  iEnterobacteri spp 13  iPseudomonasi spp organism isolated blood sample Mixed growth found nasopharyngeal throat swabs predominant specie Staphylococcus aureus Streptococcus spp time data collection 557  patient given antimicrobials 304  patient given single antimicrobial HBsAg positive 13  patient none antihepatitis C dengue NS1Ag positive bConclusionb Microbial infection seen associated SARSCoV2 infection great value prescribing antimicrobial reducing fatal outcome hospitalized patients",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39165251/"
    },
    {
        "pmid": "39146948",
        "title": "WHO global research priorities for antimicrobial resistance in human health.",
        "abstract": "research agenda antimicrobial resistance AMR human health identified 40 research priority addressed year 2030 priority focus bacterial fungal pathogen crucial importance addressing AMR including drugresistant pathogen causing tuberculosis research priority encompass entire peoplecentred journey covering prevention diagnosis treatment antimicrobialresistant infections addition addressing overarching knowledge gap AMR epidemiology burden drivers policy regulations awareness education research priority identified multistage process starting comprehensive scoping review knowledge gaps expert input gathered survey open call priority setting involved rigorous modified Child Health Nutrition Research Initiative approach ensuring global representation applicability findings ultimate goal research agenda encourage research investment generation evidence better understand AMR dynamic facilitate policy translation reducing burden consequence AMR",
        "mesh_terms": [
            "Humans",
            "World Health Organization",
            "Global Health",
            "Research",
            "Drug Resistance, Bacterial",
            "Anti-Bacterial Agents",
            "Drug Resistance, Microbial",
            "Bacterial Infections"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39146948/"
    },
    {
        "pmid": "39078795",
        "title": "An immunoinformatic investigation on Rift Valley fever virus protein reveals possible epitopes for vaccines.",
        "abstract": "immunoinformatic study identified potential epitope envelopment polyprotein GnGc Rift Valley fever virus RVFV pathogenic virus causing severe fever human livestock Effective vaccination crucial controlling RVFV outbreaks identification suitable epitope crucial development safe effective vaccines Protein sequence obtained UniProt database evaluated VaxiJen v20 predict B Tcell epitope within RVFV glycoprotein GnGc protein sequence analyzed bioinformatics tool algorithms predicted Tcell Bcell epitope evaluated antigenicity allergenicity toxicity VaxiJen v20 system AllerTop v20 ToxinPred server respectively employed computational method screen RVFV envelopment polyprotein encompassing Nterminal Cterminal glycoprotein segments discover antigenic T Bcell epitopes analysis unveiled multiple potential epitope within RVFV glycoprotein specifically within GnGc protein sequences Subsequently selected eleven cytotoxic Tlymphocytes CTL four helper Tlymphocytes HTL population coverage analysis collectively extended cover 9704 worlds population representing diverse ethnicity regions Notably CTL epitope VQADLTLMF exhibited binding affinity numerous human leukocyte antigen HLA alleles identification glycoprotein GnGc epitope immunoinformatic study bear significant implication advancing development effective RVFV vaccine finding provide valuable insight immunological aspect disease may contribute towards development broadspectrum antiviral therapy targeting RNA virus similar polymerase enzymes",
        "mesh_terms": [
            "Rift Valley fever virus",
            "Epitopes, T-Lymphocyte",
            "Epitopes, B-Lymphocyte",
            "Computational Biology",
            "Humans",
            "Viral Vaccines",
            "Rift Valley Fever",
            "Animals"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39078795/"
    },
    {
        "pmid": "39030061",
        "title": "Receipt of hepatitis E vaccine and fetal loss in rural Bangladesh: further analysis of a double-blind, cluster-randomised, controlled trial.",
        "abstract": "Vaccination constitutes attractive control measure hepatitis E virus HEV major cause maternal perinatal mortality globally Analysis pregnant participant effectiveness trial HEV vaccine HEV239 showed possible HEV239associated fetal losses aimed conduct detailed analysis safety signal doubleblind clusterrandomised trial 67 village Matlab Bangladesh randomly allocated 11 two vaccine groups nonpregnant woman aged 1639 year received either HEV239 HEV239 group HepaB a hepatitis B vaccine control group implemented weekly surveillance pregnancy detection followup pregnancy every 2 weeks using physicianconfirmed diagnosis evaluate fetal loss outcome miscarriage spontaneous abortion stillbirth elective termination Data parallel system reproductive health surveillance Matlab used clarify study diagnosis necessary Miscarriage assessed among participant whose first positive pregnancy test vaccination date for whichever dose closest date last menstrual period LMP 20 weeks gestation defined following analysis period interest 90 day LMP pregnancy outcome the proximal period LMP date pregnancy outcome the pregnancy period 90 day LMP LMP date 90 day preLMP period enrolment 90 day LMP the distal period Poisson Cox regression model used assess association receipt HEV239 fetal loss outcomes trial registered ClinicalTrialsgov NCT02759991 Among 19 460 nonpregnant participant enrolled trial 5011 identified pregnancy within 2 year following vaccination met criterion analysis 2407 HEV239 group 2604 control group Among participant vaccinated proximal period evaluated miscarriage miscarriage occurred 54 8·9 607 HEV239 group 32 4·5 719 control group adjusted relative risk aRR 2·0 95 CI 1·33·1 p0·0009 Similarly risk miscarriage increased HEV239 group versus control group among participant inadvertently vaccinated pregnancy 22 10·5 miscarriage among 209 participant HEV239 group v 14 5·3 266 control group aRR 2·1 95 CI 1·14·1 p0·036 among vaccinated within 90 day preLMP 32 8·0 398 v 18 4·0 453 1·9 1·13·2 p0·013 increased risk miscarriage observed received HEV239 distal period 93 5·6 1647 v 80 4·5 1773 1·3 0·81·9 p0·295 Stillbirth elective termination showed increased risk among woman administered HEV239 versus administered HepaB analysis periods HEV239 given shortly pregnancy associated elevated risk miscarriage association pose possible safety concern programmatic use HEV239 woman childbearing age Research Council Norway Innovax",
        "mesh_terms": [
            "Humans",
            "Female",
            "Bangladesh",
            "Pregnancy",
            "Adult",
            "Double-Blind Method",
            "Young Adult",
            "Viral Hepatitis Vaccines",
            "Adolescent",
            "Hepatitis E",
            "Abortion, Spontaneous",
            "Rural Population",
            "Hepatitis E virus",
            "Fetal Death"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39030061/"
    },
    {
        "pmid": "39030060",
        "title": "Safety and effectiveness of a recombinant hepatitis E vaccine in women of childbearing age in rural Bangladesh: a phase 4, double-blind, cluster-randomised, controlled trial.",
        "abstract": "Hepatitis E virus HEV lead high mortality pregnant woman lowincome countries aimed evaluate safety HEV vaccine effectiveness preventing hepatitis E pregnancy phase 4 doubleblind clusterrandomised trial 67 village Matlab Bangladesh randomised 11 receive HEV239 a recombinant HEV vaccine control vaccine HepaB hepatitis B vaccine using block randomisation random number table block size eight stratified cluster population size Eligible nonpregnant woman aged 1639 years vaccinated intramuscularly day 0 1 month 6 months followed 2 year last immunisation primary endpoint hepatitis E pregnant perprotocol population those received three dos within 2 day scheduled dates safety secondary endpoint assessed intentiontotreat ITT population participants received least one dose Solicited adverse event recorded first 7 day dose unsolicited event 2 year participants final dose Pregnancyrelated safety outcome assessed pregnant ITT population study registered ClinicalTrialsgov NCT02759991 Oct 2 2017 Feb 28 2019 19 460 participant enrolled received either HEV239 9478 48·7 participants 33 clusters HepaB 9982 51·3 participants 34 clusters 17 937 92·2 participant received three dos 17 613 90·5 vaccinated according protocol 8524 48·4 HEV239 group 9089 51·6 control group pregnant participant confirmed hepatitis E either treatment group HEV239 showed mild safety profile similar HepaB difference proportion solicited adverse event group severe solicited events Pain common local symptom 1215 12·8 HEV239 recipient 1218 12·2 HepaB recipients fever common systemic symptom 141 1·5 HEV239 recipient 145 1·5 HepaB recipients None serious adverse event death vaccine related Among pregnant participants HEV239 group higher risk miscarriage 136 5·7 2407 pregnant participants compared control group 102 3·9 2604 adjusted odds ratio 1·54 95 CI 1·152·08 effectiveness HEV239 pregnant woman remains uncertain HEV239 safe well tolerated nonpregnant women finding regarding miscarriage warrant investigation Research Council Norway Innovax",
        "mesh_terms": [
            "Humans",
            "Female",
            "Bangladesh",
            "Adult",
            "Double-Blind Method",
            "Hepatitis E",
            "Pregnancy",
            "Young Adult",
            "Adolescent",
            "Viral Hepatitis Vaccines",
            "Rural Population",
            "Vaccines, Synthetic",
            "Hepatitis E virus",
            "Pregnancy Complications, Infectious"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39030060/"
    },
    {
        "pmid": "39016385",
        "title": "Impact of Diabetes, Drug-Induced Liver Injury, and Sepsis on Outcomes in Metabolic Dysfunction Associated Fatty Liver Disease-Related Acute-on-Chronic Liver Failure.",
        "abstract": "prevalence metabolic dysfunctionassociated fatty liver disease MAFLD complication MAFLDrelated acuteonchronic liver failure MAFLDACLF rising Yet factor determining patient outcome MAFLDACLF remain understudied Patients MAFLDACLF recruited Asian Pacific Association Study LiverACLF Research Consortium AARC registry diagnosis MAFLDACLF made treating unit identified etiology chronic liver disease MAFLD or previous nomenclature nonalcoholic fatty liver disease nonalcoholic steatohepatitis nonalcoholic steatohepatitiscirrhosis Patients coexisting etiology chronic liver disease such alcohol hepatitis B virus hepatitis C virus etc excluded Data randomly split derivation n  258 validation n  111 cohort 7030 ratio primary outcome 90day mortality baseline clinical laboratory feature severity score considered derivation group 258 patients 60 male mean age 53 Diabetes noted 27 hypertension 29 dominant precipitant included viral hepatitis hepatitis virus hepatitis E virus 32 druginduced injury druginduced liver injury 29 sepsis 23 Model EndStage Liver DiseaseSodium MELDNa AARC score admission averaged 32 ± 6 104 ± 19 90 days 51 survived Nonviral precipitant diabetes bilirubin international normalized ratio encephalopathy independent factor influencing mortality Adding diabetes precipitant MELDNa AARC scores novel MAFLDMELDNa score 12 diabetes 12 nonviral precipitant MAFLDAARC score 5 each formed outperformed standard score cohorts Almost half patient MAFLDACLF die within 90 days Diabetes nonviral precipitant druginduced liver injury sepsis lead adverse outcomes new MAFLDMELDNa MAFLDAARC score provide reliable 90day mortality prediction patient MAFLDACLF",
        "mesh_terms": [
            "Humans",
            "Male",
            "Acute-On-Chronic Liver Failure",
            "Female",
            "Middle Aged",
            "Sepsis",
            "Chemical and Drug Induced Liver Injury",
            "Aged",
            "Non-alcoholic Fatty Liver Disease",
            "Diabetes Mellitus",
            "Severity of Illness Index",
            "Adult"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/39016385/"
    },
    {
        "pmid": "38995937",
        "title": "A qualitative study on the challenges of Afghan child labourers in Tehran.",
        "abstract": "Afghan refugee child labourer face many challenge labelled refugees attempt explore challenges present study conducted Tehran qualitative approach present qualitative research conducted using conventional content analysis approach 25 Afghan child labourer 2022 Tehran Child labourer selected purposive snowball sampling interviewed semiindepth interview data analysed based Granheim Lundmans criteria well Guba Lincoln enrich findings total 3 categories 13 subcategories 183 initial code extracted data analysis including psychological challenges history harassment abuse negative effects highrisk behaviours family detachment health challenges physical problems inappropriate accommodation medicaltherapeutic problems health threats social challenges neglected childhood dual identity educational limitations inadequate social support social isolation social humiliation individual level possible meet child labourers health need make aware hazard working street physical examination certain interval holding training workshop harassment prevention anger control prevention highrisk behaviours prevention infectious disease hepatitis strengthening selfconfidence improve health Also Afghan child labourers work could intervened social familial level providing accommodation suitable neighbourhoods providing health insurance child labourers creating chance studying schools preventing dropouts strengthening social relation order improve childrens health",
        "mesh_terms": [
            "Humans",
            "Iran",
            "Afghanistan",
            "Male",
            "Child",
            "Female",
            "Qualitative Research",
            "Refugees",
            "Child Labor",
            "Adolescent",
            "Social Support"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38995937/"
    },
    {
        "pmid": "38992660",
        "title": "The spectrum of health conditions in community-based cross-sectional surveys in Southeast Asia 2010-21: a scoping review.",
        "abstract": "Southeast Asia undergoing epidemiological transition noncommunicable illness becoming increasingly important yet infectious disease tuberculosis HIV hepatitis B malaria remain widely prevalent populations emerging zoonotic disease threaten also limited populationlevel estimate many important heath conditions restricts evidencebased decisionmaking disease control prevention priorities Crosssectional survey efficient epidemiological tool measure prevalence wide range diseases systematic assessment coverage different health condition produced region conducted systematic search Medline Embase Global Health CINAHL Scopus Web Science Core Collection Global Index Medicus additionally Google Scholar inclusion criterion crosssectional survey conducted communitybased recruitment Bangladesh Cambodia Laos Myanmar Thailand published January 1 2010 January 27 2021 reporting prevalence health condition 542 publication 337 survey included Noncommunicable condition n  205 reported survey infectious condition n  124 Disability n  49 selfreport history disease symptom n  35 selfperceived health status n  34 reflect holistic picture health studied many fewer surveys addition 45 survey studied symptomatic condition overlap noncommunicable infectious conditions surveyed condition undernutrition obesity hypertension diabetes intestinal parasites malaria anemia diarrhea fever acute respiratory infections condition overlap important cause death disability Global Burden Disease study However highburden condition eg hearing loss headache disorder low back pain chronic liver kidney diseases cancers rarely studied relatively recent survey estimate representative prevalence trend health condition beyond known high burden Expanding spectrum health condition crosssectional survey could improve understanding evolving disease pattern region",
        "mesh_terms": [
            "Humans",
            "Asia, Southeastern",
            "Communicable Diseases",
            "Cross-Sectional Studies",
            "Health Status",
            "Health Surveys",
            "Noncommunicable Diseases",
            "Prevalence"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38992660/"
    },
    {
        "pmid": "38944709",
        "title": "Comparative Study of Treatment Outcome with Tenofovir Alafenamide and Entecavir in Patients with HBV Related Acute on Chronic Liver Failure.",
        "abstract": "Major cause acute insult Hepatitis B virus related acute chronic liver failure Asian region reactivation Hepatitis B virus super infection hepatitis E virus ACLF Anti viral therapy started soon possible ACLF patient presentation waiting confirmation HBV DNA level randomized controlled trial carried Department Hepatology BSMMU Bangladesh September 2019 august 2020 Hepatitis B virus related ACLF patient trial conducted among twenty seven HBV acute chronic liver failure patient compare Child Turcotte pugh CTP score Model end stage liver disease MELD score Asia Pacific Association study Liver APASL ACLF Research consortium AARC score survival patient HBV DNA level 3 month antiviral therapy tenofovir alafenamide 25mg entecavir 05mg group CTP score MELD score AARC score significantly p005 decline baseline subsequent followup 1st at 7 days 2nd at 14 days 3rd at 30 days 4th at 90 days group non significant p005 difference occurred two group twenty seven patient detectable HBV DNA level pretreatment survived patient became undectable 4th 90 day followup Total 10 patient 3707 survived 90 day followup seven patient 700 tenofovir alafenamide group three patient 300 entecavir group statistically significant p005 two group Hepatic encephalopathy hepatorenal syndrome common cause death groups drug tenofovir alafenamide entecavir significantly improves liver function former one superior regarding survival",
        "mesh_terms": [
            "Humans",
            "Tenofovir",
            "Guanine",
            "Antiviral Agents",
            "Male",
            "Acute-On-Chronic Liver Failure",
            "Female",
            "Adult",
            "Middle Aged",
            "Treatment Outcome",
            "Alanine",
            "Hepatitis B",
            "Hepatitis B virus"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38944709/"
    },
    {
        "pmid": "38808441",
        "title": "Recent Insights into the Antimicrobial Properties of Phyllanthus emblica L.: A Comprehensive Review of Wonder Berry.",
        "abstract": "Phyllanthus emblica L Amla known therapeutic property used medicinal plant rich vitamin C bioactive phytochemical like polyphenols gallic acid chebulagic acid leutolin quercetin etc Different part plant used treat various viral bacterial fungal diseases review article summarizes recent literature relevant antiviral antibacterial antifungal effect P emblica variety bacteria Staphylococcus aureus Bacillus subtillus Enterococcus faecalis Salmonella typhi Escherichia etc fungi Alternaria alternate Botroyodiplodia theobromae Colletotrichum corcori Curvularia lunata Fusarium exquisite Fusarium solanii Aspergillus niger Candida albicans Colletotrichum gleosparoitis Macrophomina phaseolina viruses like Influenza virus strain H3N2 hepatitis B Human Immunodeficiency virus type1 HIV1 Simplex virus type 1 HSV1 type 2 HSV2 experimented Different technique used based way identification For example disc diffusion dilution methods sound diffusion Immunoperoxidase monolayer assay serum HBV HBsAg assay enzyme immunoassay etc present review analyzed summarized antimicrobial activity P emblica possible mechanism action provide future direction translating finding clinically",
        "mesh_terms": [
            "Humans",
            "Anti-Bacterial Agents",
            "Anti-Infective Agents",
            "Antifungal Agents",
            "Antiviral Agents",
            "Bacteria",
            "Fruit",
            "Fungi",
            "Microbial Sensitivity Tests",
            "Phyllanthus emblica",
            "Plant Extracts",
            "Viruses"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38808441/"
    },
    {
        "pmid": "38724531",
        "title": "Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis.",
        "abstract": "Sputum culture reversion conversion indicator tuberculosis TB treatment failure analyze data endTB multicountry prospective observational cohort NCT03259269 estimate frequency primary endpoint among individual receiving longer 18to20 month regimen multidrug rifampicinresistant MDRRR TB experienced culture conversion also conduct Cox proportional hazard regression analysis identify factor associated reversion including comorbidities previous treatment cavitary disease conversion low body mass index BMI conversion time conversion number likelyeffective drugs 1286 patients 54 42 experienced reversion median 173 day 97306 conversion Cavitary disease BMI  185 hepatitis C prior treatment secondline drugs longer time initial culture conversion positively associated reversion Reversion uncommon cavitary disease low BMI hepatitis C prior treatment secondline drugs culture conversion delayed may benefit close monitoring following conversion",
        "mesh_terms": [
            "Humans",
            "Antitubercular Agents",
            "Sputum",
            "Tuberculosis, Multidrug-Resistant",
            "Diarylquinolines",
            "Male",
            "Female",
            "Oxazoles",
            "Adult",
            "Nitroimidazoles",
            "Middle Aged",
            "Prospective Studies",
            "Mycobacterium tuberculosis",
            "Drug Repositioning"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38724531/"
    },
    {
        "pmid": "38679925",
        "title": "Crowdsourcing to increase hepatitis B and C testing and reduce hepatitis stigma among medical students in Bangladesh.",
        "abstract": "study address pervasive challenge low hepatitis B HBV hepatitis C HCV testing rate coupled stigma associated disease low middleincome country LMICs special focus Bangladesh study aim introduce innovative crowdsourcing intervention involves medical students crucial cohort potential shape healthcare attitudes structured crowdsourcing approach study design implement digital intervention counter stigma promote testing among medical student Dhaka Bangladesh Participants submitted brief video text aiming encourage hepatitis testing reduce stigma call advertised meetings emails social media welcomed entry English Bengali 3 weeks panel six judge evaluated entry based clarity impact potential innovation feasibility sustainability awarding prize student behind highestrated submissions Seventeen video four text message received average score 55 among 440 surveyed medical students predominantly 22 year old 16 fourth year 21 viewing 360 student underwent screening identifying two previously undiagnosed HBV case referred care HCV infection found Notably 41 expressed concern individual HBV working hospital doctor living HBV conclusion pilot showcase power medical student spearheading campaign counter hepatitis stigma encourage testing utilizing crowdsourcing study introduces innovative approach persistent issue LMICs specially Bangladesh offering model could potentially adapted region grappling similar challenges",
        "mesh_terms": [
            "Humans",
            "Students, Medical",
            "Bangladesh",
            "Social Stigma",
            "Hepatitis C",
            "Hepatitis B",
            "Male",
            "Female",
            "Crowdsourcing",
            "Young Adult",
            "Adult",
            "Mass Screening"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38679925/"
    },
    {
        "pmid": "38648414",
        "title": "Clinical and laboratory profile of Expanded Dengue Syndrome: experience of 2019 outbreak from Dhaka, Bangladesh.",
        "abstract": "Bangladesh afflicted periodic dengue outbreak every year one worst upsurge recorded 2019 increasing trend dengue unusual symptom common before study aim describe experience three tertiary care centre Dhaka regarding clinical laboratory hospital outcome management profile Expanded Dengue Syndrome EDS case admitted 2019 outbreak current work crosssectional observational study took place August 1 December 31 2019 three major tertiary care centre Dhaka Bangladesh total 2017 screened dengue cases 49 met inclusion criterion 39 enrolled taking informed written consent Data analysed using Microsoft Excel Graph pad prism 931 probability value p005 considered statistically significant 39 cases majority male 7949 median ±IQR age 33±9 years Hypertension 4 1026 commonly associated comorbidity Among systemic manifestations prevalent hepatitis 3849 followed encephalopathy 1282 Majority patient suffering primary infection 85 Case fatality rate 1538 Hepatitis meningoencephalitis predominant cause death study record known case report Acute respiratory dress syndrome ARDS complicating dengue Bangladesh None patient cohort managed steroids two 513 39 case received antibiotics year 2019 unusual rise EDS case 154 fatality observed study Hepatitis common presentation cause death Here report first ARDS case encountered Bangladesh Despite multifaceted presentation EDS indiscriminate use antibiotic steroid minimal Early recognition multifarious feature EDS important choosing targeted treatment option avert many deaths result study underline necessity indepth research risk factor contributing mortality EDS cases",
        "mesh_terms": [
            "Humans",
            "Bangladesh",
            "Male",
            "Female",
            "Adult",
            "Cross-Sectional Studies",
            "Dengue",
            "Disease Outbreaks",
            "Young Adult",
            "Tertiary Care Centers",
            "Middle Aged"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38648414/"
    },
    {
        "pmid": "38624203",
        "title": "Complete genome sequence of hepatitis B virus identified from a patient suffering from chronic kidney disease in Bangladesh.",
        "abstract": "Hepatitis B virus HBV infection reported risk factor chronic kidney disease CKD study sequenced complete genome HBV strain identified CKD patient Bangladesh followed genomic characterization mutational analyses",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38624203/"
    },
    {
        "pmid": "38515143",
        "title": "Assessment of preventive practices towards hepatitis B infection among nursing students in Bangladesh: role of knowledge, attitudes and sociodemographic factors.",
        "abstract": "Globally hepatitis B infection HBI pose substantial public health concern healthcare workers including nursing students higher risk contracting disease Thus study aimed assess knowledge attitudes sociodemographic factor associated HBI prevention among sample Bangladeshi nursing students crosssectional survey performed among 737 nursing student nursing institute Khulna Barishal division Bangladesh January April 2023 data collected providing questionnaire structured questionnaire classroom following stratified random sampling process model multinomial logistic regression used evaluate factor linked HBI prevention practices mean SD score 1142 ± 288 knowledge 433 ± 191 attitude 427 ± 2056 practice respectively Participants low knowledge adjusted odds ratio aOR  2562 95 CI 129507 poor attitude aOR  5730 95 CI 3191028 regarding HBI significantly associated higher likelihood poor practice towards HBI prevention Moreover 2nd year nursing student aOR  2147 95 CI 119386 aged 1920 year aOR  3038 95 CI 130709 married aOR  0320 95CI 013082 family history HBI aOR  0134 95CI 005036 significantly associated poor practice HBI prevention among study participants knowledge attitude practice score nursing student HBI prevention suboptimal advocate implementing regular HBI prevention education policies free subsidized services skill development proper HBI prevention enforcement strict professional ethic within nursing colleges effort predominantly focus secondyear aged 1920 unmarried nursing students",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38515143/"
    },
    {
        "pmid": "38497497",
        "title": "Annual risk of hepatitis E virus infection and seroreversion: Insights from a serological cohort in Sitakunda, Bangladesh.",
        "abstract": "Hepatitis E virus HEV major cause acute jaundice South Asia Gaps understanding transmission driven nonspecific symptom scarcity diagnostics impeding rational control strategies context serological data provide important proxy measure infection enrolled populationrepresentative serological cohort 2337 individual Sitakunda Bangladesh estimated annual risk HEV infection seroreversion using serostatus change paired serum sample collected 9 month apart fitting catalytic model agestratified crosssectional seroprevalence baseline 15 95 CI 1417 people seropositive seroprevalence highest relatively urban south study 27 individual seroreverted annual seroreversion risk 15 95 CI 1021 38 seroconverted annual infection risk 3 95CI 25 Relying crosssectional seroprevalence data alone ignoring seroreversion underestimated annual infection risk fivefold 06 95 CrI 0506 accounted observed seroreversion reversible catalytic model infection risk consistent measured seroincidence result quantify HEV infection risk Sitakunda highlight importance accounting seroreversion estimating infection incidence crosssectional seroprevalence data",
        "mesh_terms": [
            "Humans",
            "Hepatitis E virus",
            "Bangladesh",
            "Seroepidemiologic Studies",
            "Cross-Sectional Studies",
            "Hepatitis E",
            "Hepatitis Antibodies"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38497497/"
    },
    {
        "pmid": "38460060",
        "title": "Expert consensus on the diagnosis and treatment of end-stage liver disease complicated by infections.",
        "abstract": "Endstage liver disease ESLD lifethreatening clinical syndrome complicated infection mortality markedly increased patient ESLD bacterial fungal infection induce aggravate occurrence progression liver decompensation Consequently infection among common complication disease deterioration overwhelming need standardized protocol early diagnosis appropriate management patient ESLD complicated infections Asia Pacific region largest number ESLD patients due hepatitis B growing population alcohol NAFLD Concomitant infection add organ failure high mortality also financial healthcare burdens consensus document assembled uptodate knowledge experience colleague across AsiaPacific region providing data principle well evidencebased current working protocol practice diagnosis treatment patient ESLD complicated infections",
        "mesh_terms": [
            "Humans",
            "Bacterial Infections",
            "Consensus",
            "End Stage Liver Disease",
            "Mycoses"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38460060/"
    },
    {
        "pmid": "38367678",
        "title": "Comprehensive analysis of antigenic variations and genomic properties of hepatitis B virus in clinical samples in the mid-north east region of Bangladesh.",
        "abstract": "investigation delineates exhaustive analysis clinical immunological genomic landscape hepatitis B virus HBV infection across cohort 22 verified patients demographic analysis unveiled pronounced male bias 7727 patient age spanning 20 85 year duration illness ranging 10 day 4 years Predominant clinical manifestation included fever fatigue anorexia abdominal discomfort arthralgia alongside observed comorbidities chronic renal disorder hepatocellular carcinoma Antigenic profiling HBV envelope protein elucidated significant heterogeneity among infected subjects particularly highlighted discordance detection capability small large HBsAg assays suggesting antigenic diversity Quantitative assessment viral load unveiled broad spectrum accompanied atypical HBeAg reactivity patterns challenging reliability existing serological markers Correlative study viral burden antigenicity envelope protein unearthed phenomenon indicative diagnostic evasion Notably sample demonstrating robust viral replication paradoxically undetectable large HBsAg ELISA kit advocating sophisticated diagnostic methodologies Genotypic examination three HBV isolates classified genotype D2 phylogenetic alignment strain various global origins Mutational profiling identified pivotal mutation within basic core promoter preS2S1 regions associated augmented risk hepatocellular carcinoma Further mutation discerned small HBsAg RToverlap region recognized contributor vaccine andor diagnostic escape mechanisms summation scholarly discourse elucidates intricate interplay clinical presentations antigenic diversity genomic attribute HBV infection accentuating imperative ongoing investigative endeavor refine diagnostic therapeutic modalities",
        "mesh_terms": [
            "Humans",
            "Male",
            "Hepatitis B virus",
            "Hepatitis B Surface Antigens",
            "Carcinoma, Hepatocellular",
            "Bangladesh",
            "Phylogeny",
            "Reproducibility of Results",
            "Hepatitis B",
            "Mutation",
            "Genotype",
            "Liver Neoplasms",
            "Antigenic Variation",
            "Genomics",
            "DNA, Viral",
            "Hepatitis B, Chronic"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38367678/"
    },
    {
        "pmid": "38367629",
        "title": "Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update.",
        "abstract": "top 20 highest burdened country in disabilityadjusted life years account 75 global burden viral hepatitis effective response 20 country crucial global elimination target achieved update Lancet Gastroenterology  Hepatology Commission accelerating elimination viral hepatitis convene national expert top 20 highest burdened country provide update progress Although global burden disease falling progress towards elimination varies greatly country use hepatitis elimination policy index conceived part 2019 Commission measure countries progress towards elimination Progress elimination policy made 14 20 country highest burden since 2018 substantial gain observed Bangladesh India Indonesia Japan Russia improvement attributable publication formalised national action plan elimination viral hepatitis provision publicly funded screening programmes government subsidisation antiviral treatments Key theme emerged discussion national commissioner highest burdened country build original recommendation accelerate global elimination viral hepatitis theme include need simplified model care improved access appropriate diagnostics financing initiatives rapid implementation lesson COVID19 pandemic",
        "mesh_terms": [
            "Humans",
            "Gastroenterology",
            "Pandemics",
            "Hepatitis",
            "Hepatitis A",
            "India"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38367629/"
    },
    {
        "pmid": "38361592",
        "title": "Monitoring and evaluation practices and operational research during public health emergencies in southeast Asia region (2012-2022) - a systematic review.",
        "abstract": "systematic review aimed explore monitoring evaluation ME operational research OR practice public health emergency PHE southeast Asian region SEAR last decade searched electronic database grey literature source study published 2012 2022 study written English included narrative synthesis undertaken total 29 study included review Among 25 study documented ME four study documented practices majority study India Bangladesh evidence found Sri Lanka Bhutan Myanmar TimorLeste ME surveillance program identified among PHE due COVID19 prevalent ME conducted response COVID19 cholera Nipah Ebola iCandida aurisi hepatitis A practice minimal reported India Indonesia India conducted COVID19 malaria whereas Indonesia focused COVID19 influenza SEAR country mechanism conducting ME noticeable limitation practices compelling need develop standard framework ME Additionally enhancing private sector engagement crucial strengthening preparedness PHE Furthermore necessity increase awareness importance conducting ME PHE",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38361592/"
    },
    {
        "pmid": "38344624",
        "title": "A Systematic Review of Pediatric Dialysis in Asia: Unveiling Demographic Trends, Clinical Representation, and Outcomes.",
        "abstract": "Dialysis pediatric group complicated wide range factor affect longterm prognosis purpose metaanalysis systematic review better understand demographic clinical factor affect dialysis success children searched variety database relevant article included 14 report dealt case study pediatric patient undergoing dialysis wide range renal diseases Patients demographics clinical presentations laboratory findings treatment outcome primary area data collection get better sense overall prevalence certain outcome spot noteworthy trend pattern disease process conducted metaanalysis Variations dialysis efficacy outcome highlighted throughout wide range age pediatric dialysis cohort neonate teenagers Acute kidney injury AKI tended impact boys chronic kidney disease CKD lupus nephritis disproportionately afflicted girls Many different ethnic group represented evidence disease hereditary component common area others However potential longterm consequence remained concern Hemodialysis found effective controlling endstage renal disease ESRD AKI patient going kidney transplant time peritoneal dialysis associated increased risk infection comprehensive analysis highlight importance demographic clinical parameter determining pediatric dialysis outcomes 1447 mortality rate gender disparity revealed metaanalysis pediatric renal diseases included cohort 235 patient condition like lupus nephritis hepatitis C infection finding stress necessity individualized treatment technique suggest demographic characteristic addressed prognostic models better patient outcomes study also suggests standardized reporting pediatric dialysis studies",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38344624/"
    },
    {
        "pmid": "38236834",
        "title": "Social and structural determinants associated with the prevalence of sexually transmitted infections among female commercial sex workers in Dhaka City, Bangladesh.",
        "abstract": "Female commercial sex worker FCSWs bear higher rate sexually transmitted infection STIs among key populations association structural determinant STIs among FCSWs forefront research earlier Bangladesh study examined structural factor correlate prevalence STIs physicalsocialeconomicpolicy level among FCSWs Dhaka city 495 FCSWs screened HIV hepatitis B syphilis Structural variable Individual risks highrisk sexual behaviors work environments extracted previous multilevel study FCSWs analyzed 2020 determine whether macromicrostructural factor associated STIs prevalence STIs 436 95 CI 39148 n  207495 FCSWs infected Syphilis Hepatitis B 18 coinfection none positive HIV Multiple logistic regression revealed Individual risk factor like age ≤18 years adjusted odds ratio  AOR  28 181299 years AOR  57 year sex industry 1 year AOR  15 15 years AOR  39 condom contraceptive AOR  27 significantly associated STIs Considering Highrisk behaviors like monthly coitus regular client AOR  33 performing anal sex ever AOR  03 consistent condom use AOR  13 less likely associated STIs P005 association ever group sex STIs reported double AOR  21 Work environment like sex roadsparksshrinesmarkets AOR  26 ever HIVtesting AOR  25 significantly linked STIs However microlevel factor like experiencing forced sex past year AOR  179 condom collected hotel boy AOR  34 significantly associated STIs Hierarchical model increasing modelpower Microstructural determinant predominated Macropolicylevel factors profoundly influenced STIs FCSWs need comprehensive integrated intervention promote accurate condom use perception eliminate risky sexual behaviors provide quality reproductive health care Necessary step policy level urgently needed decriminalize commercial sex work",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38236834/"
    },
    {
        "pmid": "38223570",
        "title": "Prevalence of hepatitis B and C, and syphilis among aspirant migrant workers of Bangladesh.",
        "abstract": "Bangladesh labour migration source employment workers remittance critical poverty mitigation aim study assess prevalence hepatitis B C HIV tuberculosis syphilis kidney liver disease along presence infection among aspirant migrant worker Bangladesh study carried SeptemberDecember 2019 analysed data collected screening test specific disease aspirant workers test prevalence computed 95 confidence interval Association categorical data determined Chisquare test total 2385 aspirants 1988 8335 males aged 18 65 year 2976±6578 studied Positive result screening test HBsAg 38 16 antiHCV 2 008 TPHA 25 105 VDRL 5 021 though individual positive HIV TB Elevated level SGOT n99 42 SGPT n322 135 RBS n57 24 bilirubin n46 192 creatinine n7 03 ESR n19 08 found workers Diagnosis disease worker obligatory going abroad safeguard health worker resident destination country Consequently contribute reducing global burden infectious diseases",
        "mesh_terms": [
            "Male",
            "Humans",
            "Adolescent",
            "Young Adult",
            "Adult",
            "Middle Aged",
            "Aged",
            "Female",
            "Syphilis",
            "HIV Infections",
            "Transients and Migrants",
            "Prevalence",
            "Bangladesh",
            "Hepatitis B",
            "Hepatitis B Surface Antigens"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38223570/"
    },
    {
        "pmid": "38222956",
        "title": "A Narrative Review on the Specific Pattern of HBV Genotype in Bangladesh: Clinical Implications for Management.",
        "abstract": "Bangladeshs unique epidemiological landscape present intriguing puzzle South Asian nation complex sociodemographic environmental factors home diverse array hepatitisB virus HBV genotypes identified Genotype C Genotypes also making significant contribution viral landscape Reviewing insight necessary underscore countrys regional diversity HBV strain also bring focus clinical implication genetic variation may disease progression management thorough database search covered various source using relevant keywords like Hepatitis B virus genotypes HBV genotype Bangladesh HBV clinical implications review synthesized finding analyzed HBV genotype prevalence clinical implication Bangladesh Genotypes C collectively represent 82 chronic hepatitisB infection CHB case Bangladesh underscoring regional prevalence geographic context pivotal understanding HBV infection dynamic disease progression area Notably genotype C presence A1762TG1764A mutation appear distinct impact disease development potentially affecting immune response CHB patients highlight need tailored management approach specific region research vital confirm elaborate findings particularly relation mutation influence hosts immune response summary study HBV genotype Bangladesh stress need genotypespecific clinical consideration research improve diagnostics therapies Raihan R Akbar SMF Narrative Review Specific Pattern HBV Genotype Bangladesh Clinical Implications Management Euroasian J HepatoGastroenterol 2023132152158",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38222956/"
    },
    {
        "pmid": "38222954",
        "title": "Depression among Patients with Chronic Hepatitis B: A Cross-sectional Study in a Tertiary Hospital of Bangladesh.",
        "abstract": "Patients chronic hepatitis B suffer physical illness Rather often present mental health consequence chronic disease major objective assess level depression among patient chronic hepatitis B Department Hepatology Bangabandhu Sheikh Mujib Medical University directed study comparative crosssectional study time duration September 2021 September 2022 Incidence grading depression patient chronic hepatitis B HBsAg negative healthy volunteer assessed compared study association different variable depression among chronic hepatitis B CHB patient also measured 90 patient chronic hepatitis B 52 578 found degree depression whereas among 90 HBsAgnegative healthy controls 32 356 found various degree depression dissimilarity two group significantly determined ipivalue  005 majority depressed population group mild degree depression however variance top notch ipivalue  005 prevalence moderate depression moderately severe depression statistically significant among CHB patient compared counterpart controls Depression among CHB patient found femalepredominant study shown higher prevalence depression among patient chronic hepatitis B compared HBsAgnegative healthy controls Rahman M NoorEAlam SM Rahim MA iet ali Depression among Patients Chronic Hepatitis B Crosssectional Study Tertiary Hospital Bangladesh Euroasian J HepatoGastroenterol 20231327983",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38222954/"
    },
    {
        "pmid": "38222949",
        "title": "Impact of the Route and Schedule of Immunization on the Serological and Virological Response of Chronic Hepatitis B Patients Treated with HeberNasvac.",
        "abstract": "HeberNasvac recently developed therapeutic vaccine chronic hepatitis B CHB administered intranasal IN subcutaneous SC route 14 days10 dos schedule compare different schedule route immunizations group patient received four different vaccination regimen placebocontrolled factorial study Subsequently patient followed minimum time 48 weeks Samples collected end followup compared initial samples Groups II received product INSC routes every 14 7 days respectively Groups III IV treated SC route alone following 14 7 day schedule group 21 CHB patient received vaccine four different schedule eight patient received placebo total 29 patient enrolled 619 vaccinee reduced VL ≥2Log compared baseline level 25 placebo group 476 vaccine reduced HBV level undetectable 25 placebo HBeAg loss seroconversion antiHBeAg achieved vaccinees 4 9 444 40 8 20 developed antiHBs response none placebo group Reduction HBsAg level ≥1Log achieved 350 vaccinee none placebotreated patients Considering individual factorial analysis significant HBV DNA reduction detected group II immunized INSC routes significantly higher proportion patient reducing VL ≥2Log also detected grouping patient treated INSC route G  II grouping inoculated every 14 day G  III 727 636 respectively compared placebo group 250 patient immunized every 14 day G  G III also reduced HBsAg level compared baseline conclusion 48 week treatmentfree followup HeberNasvactreated patient demonstrated superior response compared placebo group term antiviral serological responses factorial analysis evidenced schedule combining route immunization frequency 14 day resulted stronger antiviral serological responses Present result support study INonly immunization schedule future consistent previous results Longlasting followup done explore histological variable progression serological variable order detect late responders Freyre FM Aguiar JA Cinza Z iet ali Impact Route Schedule Immunization Serological Virological Response Chronic Hepatitis B Patients Treated HeberNasvac Euroasian J HepatoGastroenterol 20231327378",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38222949/"
    },
    {
        "pmid": "38179453",
        "title": "TLR agonists as vaccine adjuvants in the prevention of viral infections: an overview.",
        "abstract": "Tollike receptor TLR agonists potent adjuvants gained attention vaccine research ability enhance immune responses study focus application improving vaccine efficacy key viral infections including hepatitis B virus HBV hepatitis C virus HCV human immunodeficiency virus HIV SARSCoV2 influenza virus flaviviruses including West Nile virus dengue virus chikungunya virus Vaccines crucial preventing microbial infections including viruses adjuvant play vital role modulating immune responses However still many disease effective vaccine lacking limited immune response posing significant threat human health use TLR agonist adjuvant viral vaccine formulation hold promise improving vaccine effectiveness tailoring adjuvant specific pathogens HBV HCV HIV SARSCoV2 influenza virus flavivirus protective immunity chronic emerging infectious disease elicited",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38179453/"
    },
    {
        "pmid": "38081982",
        "title": "Effects of neddylation on viral infection: an overview.",
        "abstract": "Neddylation posttranslational modification play important role cancer development also regulating viral infection replication Upregulation neddylation occurs viral infections inhibition neddylation suppress viral replication Neddylation thought enhance viral protein stability replication Neddylation reported enhance stability regulatory hepatitis B virus HBV X protein modulate viral replication enhance hepatocarcinogenesis Inhibition neddylation using NEDD8activating enzyme E1 inhibitor MLN4924 inhibits viral replication including HBV Understanding role neddylation viral infection critical developing new therapeutic target potential treatment strategies review discus recent progress understanding effect neddylation viral infection particularly HBV infection strategy curing viral infection targeting neddylation pathway",
        "mesh_terms": [
            "Humans",
            "NEDD8 Protein",
            "Ubiquitins",
            "Neoplasms",
            "Protein Processing, Post-Translational",
            "Virus Diseases"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38081982/"
    },
    {
        "pmid": "38064471",
        "title": "HBV prevalence in Sub-continental countries: A systematic review and meta-analysis.",
        "abstract": "Hepatitis B virus HBV major source disease burden worldwide estimated 296 million individual living infection worldwide Although vaccine program exist control infections certain subpopulations around world continue high prevalence HBV infection systematic search study HBV published 2010 conducted India Pakistan Bangladesh Nepal Sri Lanka Bhutan paper independently screened risk bias inclusion Data extracted included study analysed estimate pooled prevalence conduct subgroup analyses Randomeffects model used estimating summary prevalence due high level heterogeneity studies funnel plot combined Eggers test assess publication bias Metaregression conducted investigate source betweenstudy heterogeneity pooled prevalence HBV across study 3 95 CI 002 005 country multiple studies pooled prevalence India 3 95 CI 002 004 Pakistan 6 95 CI 003 009 Bangladesh 5 95 CI 002 012 Nepal 1 95 CI 000 008 evidence publication bias high level heterogeneity across studies Risk bias analysis found study fair moderate quality prevalence HBV among country subcontinent higher global average high regions Countries greater number displaced person higher prevalence HBV wide range prevalence subpopulation likely reflecting differential uptake implementation vaccination programs",
        "mesh_terms": [
            "Humans",
            "Hepatitis B virus",
            "Prevalence",
            "Hepatitis B",
            "India",
            "Pakistan"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38064471/"
    },
    {
        "pmid": "38031080",
        "title": "The burden of HEV-related acute liver failure in Bangladesh, China and India: a systematic review and meta-analysis.",
        "abstract": "Hepatitis E potentially progress HEVrelated acute liver failure HEVALF East South Asia bear substantial burden HEV infection Bangladesh China India facing severe threat region Therefore conducted systematic review metaanalysis evaluate burden HEVALF three highrisk countries systematic literature search performed utilizing PubMed Cochrane Library Medline Embase Web Science databases Studies English Chinese reported data burden HEVALF Bangladesh China India included Outcomes pooled metaanalysis utilizing R software Estimates calculated randomeffects models subgroup analysis sensitivity analysis conducted address heterogeneity Eggers test Beggs test performed assess publication bias total 20 eligible study included study pooled HEVattributable proportion viralrelated acute liver failure estimated 400 95 CI 028052 300 95 CI 018044 610 95 CI 049072 among nonpregnant individual India China Bangladesh Indian pregnant females 710 95 CI 062079 combined prevalence among nonpregnant HEVinfected participant 280 95 CI 020037 100 95 CI 001028 India China 340 95 CI 027042 Indian pregnant female HEV infection overall mortality HEVALF estimated 320 95 CI 023042 640 95 CI 050077 among nonpregnant pregnant participant India 230 95 CI 014034 Chinese nonpregnant participants burden HEVALF Bangladesh China India nonnegligible despite geographic population heterogeneity prevention HEV infection early recognition HEVALF great significance especially highrisk country populations PROSPERO registration ID CRD42022382101",
        "mesh_terms": [
            "Pregnancy",
            "Female",
            "Humans",
            "Bangladesh",
            "Hepatitis E virus",
            "Liver Failure, Acute",
            "India",
            "China"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38031080/"
    },
    {
        "pmid": "38027884",
        "title": "Seroprevalence of hepatitis E virus (HEV) among male craft and manual workers in Qatar (2020-2021).",
        "abstract": "rapid growth Qatar last two decade attracted large influx immigrant craft manual worker CMWs seeking employment job associated food handling domestic service construction Nearly 60  Qatars population expatriate CMWs including many hyperendemic country HEV Thus estimating seroprevalence HEV Qatar understanding epidemiology essential public health effort control HEV transmission Qatar Blood sample 2670 CMWs collected 2020 2021 sample tested HEVIgG antibodies Positive HEVIgG sample tested HEVIgM antibodies positive also tested viral antigen using HEVAg ELISA kit HEVRNA RTPCR confirm current HEV infections seroprevalence HEVIgG 273  7292670 95  CI 256290 HEVIgG positive 823  60729 95  CI 630105 HEVIgM positive IgMpositive samples 2 HEVRNA positive 339  95  CI 040117 1 HEVAg positive 169  95  CI 004909 addition HEVIgG seroprevalence associated age nationality highest seroprevalence participant Egypt IgG 600  IgM 556  Pakistan IgG 590  IgM 224  Nepal IgG 293  IgM 270  Bangladesh IgG 278  IgM 245  India IgG 239  IgM 243  study showed seroprevalence HEV among CMWs slightly higher previously reported among urban population Qatar 20132016",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/38027884/"
    },
    {
        "pmid": "37974105",
        "title": "Public healthcare system utilization for chronic hepatitis C infection in Vietnam.",
        "abstract": "Healthcare utilization typically adversely affected treatment expensive requires multiple visits examined determinant healthcareseeking Hepatitis C virus HCV infection asymptomatic chronic requires costly treatment urban tertiary care referral hospital Vietnam conducted secondary analysis hospital data patient attending Hospital Tropical Diseases Ho Chi Minh City Vietnam 2017 2020 specifically HCV infection treatment Poisson regression used determine effect personal factor age sex comorbidities structural factor health insurance proximity facility seasonality year visit number hospital visits 2017 2020 total 22052 eligible patient sought treatment hospital Among patients 504 male 587  50 year age mean number visit per person 217 multivariate analysis compared 2017 number hospital visit increased 4 2018 significantly decreased 2019 2020 Visit number significantly lower 6 among South East region resident compared Central Highlands lived away hospital visit number significantly higher among older age group 511 health insurance 6 comorbidities 5 compared others Although number hospital visit female higher 7 male 2017 significantly decreased subsequent years study indicated structural individual factor affecting number visit HCV treatment meet global strategy elimination HCV Vietnam Government need address structural personal barrier healthcare seeking special focus women",
        "mesh_terms": [
            "Male",
            "Humans",
            "Female",
            "Aged",
            "Hepatitis C, Chronic",
            "Vietnam",
            "Hepatitis C",
            "Hepacivirus",
            "Patient Acceptance of Health Care"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37974105/"
    },
    {
        "pmid": "37973326",
        "title": "People who inject drugs: testing and treatment of HIV and HCV.",
        "abstract": "",
        "mesh_terms": [
            "Humans",
            "Drug Users",
            "HIV Infections",
            "Substance Abuse, Intravenous",
            "Hepatitis C",
            "Hepacivirus"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37973326/"
    },
    {
        "pmid": "37915649",
        "title": "Hepatitis is still a major health concern in Pakistan: short communication.",
        "abstract": "Hepatitis often called silent killer patient remain asymptomatic hence remain unaware illness either diagnosed incidentally get symptomatic illness advance year getting infection Pakistan transmission increased due ignorance sterilization techniques sharing personal items unsafe healthcare practice burden liver cancer transplant risen threefold past 20 years Chronic hepatitis often go undetected leading rise liver cancer transplants Pakistan bear secondlargest burden hepatitis C globally nationwide prevalence 48 2015 2019 5 increase hepatitis Crelated death 8 increase hepatitis Brelated deaths last 4 years 110 million population 281 578 individual screened hepatitis B C 1 634 614 individual registered various hepatitis clinics However 278 308 patient treated Despite national vaccination strategy coverage fall short regular screening neglected burden hepatitisrelated morbidity considerable challenge Pakistani government healthcare system lowincome country limited health resource limited access treatment Increased awareness education emphasizing preventive measures hepatitis B vaccination crucial Careful supervision healthcare worker promotion safe practice essential Pakistan learn implement Egypt model combat hepatitis effectively article aim discus barrier challenge provides possible recommendations",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37915649/"
    },
    {
        "pmid": "37872525",
        "title": "The impact of COVID-19 on hepatitis B and C virus prevention, diagnosis, and treatment in Bangladesh compared with Japan and the global perspective.",
        "abstract": "study aimed assess effect COVID19 hepatitisrelated service Bangladesh compared situation study conducted Japan globally conducted online crosssectional questionnaire survey among clinician four society associated liver disease Bangladesh October December 2022 questionnaire included question survey conducted Japan globally total 83 clinician 8 division Bangladesh participated 663 head departmentsinstitutions Except HCV treatment initiation 30 clinician reported 7699 decline services Compared Japan global survey significantly higher decline HBV HCV service Bangladesh resume service back preCOVID19 levels Patient anxiety fear Bangladesh Survey 807 v Japan Survey 674 v Global Survey 379 p  00001 loss space due COVID19 Bangladesh Survey 639 v Japan Survey 347 v Global Survey 194 p  00001 main challenges part mitigation strategy usage telemedicine Bangladesh Survey 831 vs Japan Survey 673 v Global Survey 786 p  00001 COVID19 benefits increased laboratory testing platform Bangladesh Survey 771 v Japan Survey 179 v Global Survey 418 p  00001 reported significantly higher Bangladesh Japan global survey servicesrelated HBV HCV highly affected greatest impact month COVID19 Bangladesh decline level higher Japan global survey Repeated countermeasure COVID19 constrained healthcaresystem probable reason Bangladesh Positive impact resulting COVID19 countermeasure utilized national hepatitis program Bangladesh",
        "mesh_terms": [
            "Humans",
            "Japan",
            "Bangladesh",
            "Cross-Sectional Studies",
            "COVID-19",
            "Hepatitis B",
            "Hepatitis C",
            "COVID-19 Testing"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37872525/"
    },
    {
        "pmid": "37868514",
        "title": "A Case of Disseminated Histoplasmosis Presenting As Adrenal Insufficiency With Granulomatous Hepatitis.",
        "abstract": "Histoplasmosis fungal infection caused iHistoplasma capsulatumi United States histoplasmosis endemic Mississippi River Valley Ohio Histoplasmosis often asymptomatic immunocompetent individuals severe disseminated case often seen immunosuppressed patients Disseminated histoplasmosis often affect reticuloendothelial system invading specific visceral organ liver spleen pancreas current study present unique case disseminated histoplasmosis 64yearold immunocompetent male patients presentation included 40lb weight loss year bilateral adrenal nodules abnormal liver enzymes granulomatous hepatitis initially raised suspicion malignant etiology adrenal mass biopsy showed fungal morphology confirmed iH capsulatumi infection history showed patient recently traveled Bangladesh thought region endemic histoplasmosis case noteworthy disseminated histoplasmosis rarely affect immunocompetent individuals infectious etiology adrenal insufficiency exceedingly rare especially United States treatment regimen included 14day induction therapy IV amphotericin B followed outpatient itraconazole leading symptom resolution case highlight need consider infectious etiology adrenal insufficiency especially among immunocompetent individual may risk traveling endemic areas",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37868514/"
    },
    {
        "pmid": "37760732",
        "title": "Antiviral Activity of Anthranilamide Peptidomimetics against Herpes Simplex Virus 1 and a Coronavirus.",
        "abstract": "development potent antiviral agent utmost importance combat global burden viral infections Traditional antiviral drug development involves targeting specific viral proteins may lead emergence resistant strains explore alternative strategies investigated antiviral potential antimicrobial peptidomimetic compounds study evaluated antiviral potential 17 short anthranilamidebased peptidomimetic compound two viruses Murine hepatitis virus 1 MHV1 surrogate human coronaviruses herpes simplex virus 1 HSV1 halfmaximal inhibitory concentration ICsub50sub value compound determined vitro assess potency antiviral agents Compounds b11b b14b displayed potent inhibitory effect ICsub50sub value 238 μM 63 μM MHV1 compound b9b b14b showed ICsub50sub value 148 μM 13 μM HSV1 Multiple antiviral assessment microscopic image obtained transmission electron microscopy TEM collectively demonstrated compound exert direct influence viral envelope Based outcome concluded peptidomimetic compound could offer new approach development potent antiviral agents",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37760732/"
    },
    {
        "pmid": "37703339",
        "title": "The Role of Nonprofit and Nongovernmental Organizations and People With Viral Hepatitis on the Path Toward Hepatitis C Virus Elimination.",
        "abstract": "Nonprofit nongovernmental organization driven continue drive hepatitis C elimination putting people viral hepatitis affected community center hepatitis elimination efforts key driving decentralization service communitybased delivery hepatitis care pathway improve health wellbeing population affected hepatitis C article explores formation World Hepatitis Alliance WHA international network community organization 100 countries led powerful advocacy community leader people hepatitis resulting establishment World Hepatitis Day Since then World Health Organization WHO recognized importance viral hepatitis setting 2030 global elimination targets WHA collaborated 3 World Hepatitis Summits built momentum across many sector help elevate hepatitis global health agenda article discusses paradigmshifting campaign also present civil society organizations hepatitis elimination effort Egypt Mongolia Bangladesh United Kingdom significant impact local resource mobilization engagement national governments",
        "mesh_terms": [
            "Humans",
            "Hepacivirus",
            "Organizations, Nonprofit",
            "Hepatitis C",
            "Hepatitis A",
            "Bangladesh"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37703339/"
    },
    {
        "pmid": "37700968",
        "title": "Assessing Thrombocytopenia and Chronic Liver Disease in Southeast Asia: A Multicentric Cross-Sectional Study.",
        "abstract": "Background multicentric crosssectional study aimed examine prevalence thrombocytopenia TCP investigate various cause chronic liver disease CLD across 15 Southeast Asian India Pakistan Bangladesh tertiary care center threemonth period study focused assessing fibrosis index FI Model EndStage Liver Disease MELDsodium Na scores capacity grade predict progression outcome patient already diagnosed CLD Methods crosssectional study enrolled 377 CLD patients study utilized admission registry 15 tertiary care hospital Southeast Asia spanning April 2023 June 2023 Various descriptive variable collected including gender tobacco use specifically chewed tobacco underlying etiology presence anemia leukopenia pancytopenia infectious state liver cirrhosis diagnosed via traditional ultrasonography study examined liver failure indicators including alanine transaminase levels compensation status TCP liver transplant LT listing MELDNa score focus frequency percentage analysis MELDNa FI median standard deviation provided Results study 377 patient CLD found TCP present 4 patient leukopenia present 12 patients risk TCP significantly higher leukopenic patient 895 nonleukopenic patient 525 p  0003 common CLD cause undiagnosable 31 followed autoimmune 26 hepatitis C virus 21 hepatitis B virus 14 schistosomiasis 8 majority patient 98 decompensated liver disease patients 64 TCP 36 not illness severity indicator MELD score FI mean ± SD value 1689 ± 642 41 ± 106 respectively Similarly prevalence LT need among traditional ultrasonographydiagnosed cirrhotic patient 831 compared 596 among noncirrhotic patient p  0001 Conclusion Leukopenia TCP may linked may affect CLD treatment prognosis population Noninvasive indicator like FI MELDNa score detect liver fibrosis severity without invasive procedures enhancing patient management finding highlight need improve early diagnosis method CLD Southeast Asia raise awareness among clinician effective diagnostic strategy noninfectious cause CLD",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37700968/"
    },
    {
        "pmid": "37697804",
        "title": "Global diversity and antimicrobial resistance of typhoid fever pathogens: Insights from a meta-analysis of 13,000 <i>Salmonella</i> Typhi genomes.",
        "abstract": "Global Typhoid Genomics Consortium established bring together typhoid research community aggregate analyse iSalmonella entericai serovar Typhi Typhi genomic data inform public health action analysis mark 22 year since publication first Typhi genome represents largest Typhi genome sequence collection date n13000 metaanalysis global genotype antimicrobial resistance AMR determinant extracted previously sequenced genome data analysed using consistent method implemented open analysis platform GenoTyphi Pathogenwatch Compared previous global snapshots data highlight genotype 431 H58 spread beyond Asia EasternSouthern Africa regions distinct genotype dominate independently evolved AMR Data gap remain many part world show potential travelassociated sequence provide informal sentinel surveillance locations data indicate ciprofloxacin nonsusceptibility 1 resistance determinant widespread across geography genotypes highlevel ciprofloxacin resistance ≥3 determinants reaching 20 prevalence South Asia Extensively drugresistant XDR typhoid become dominant Pakistan 70 2020 yet become established elsewhere Ceftriaxone resistance emerged eight nonXDR genotypes including ciprofloxacinresistant lineage 43121 India Azithromycin resistance mutation detected low prevalence South Asia including two common ciprofloxacinresistant genotypes consortiums aim encourage continued data sharing collaboration monitor emergence global spread AMR Typhi inform decisionmaking around introduction typhoid conjugate vaccine TCVs prevention control strategies specific funding awarded metaanalysis Coordinators supported fellowship European Union ZAD received funding European Unions Horizon 2020 research innovation programme Marie SklodowskaCurie grant agreement 845681 Wellcome Trust SB Wellcome Trust Senior Fellowship National Health Medical Research Council DJI supported NHMRC Investigator Grant GNT1195210",
        "mesh_terms": [
            "Humans",
            "Salmonella typhi",
            "Typhoid Fever",
            "Anti-Bacterial Agents",
            "Travel",
            "Drug Resistance, Bacterial",
            "Ciprofloxacin"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37697804/"
    },
    {
        "pmid": "37601374",
        "title": "Corrigendum: Insights into the coinfections of human immunodeficiency virus-hepatitis B virus, human immunodeficiency virus-hepatitis C virus, and hepatitis B virus-hepatitis C virus: prevalence, risk factors, pathogenesis, diagnosis, and treatment.",
        "abstract": "This corrects article DOI 103389fmicb2021780887",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37601374/"
    },
    {
        "pmid": "37565062",
        "title": "Molecular Epidemiology of HCV RNA Genotype-3 in Dhaka City, Bangladesh.",
        "abstract": "Hepatitis C virus HCV causative agent cause chronic liver disease worldwide little enclosed singlestranded ribonucleic acid RNA virus recognition pathogenic HCV genotype critical remedy sufferers aim study identify HCV RNA genotype decide correct treatment hepatitis C positive sufferer Bangladesh Blood sample collected 390 individual isolated RNA 60 µg blood plasma Extracted RNA used quantitative HCV RNA complementary DNA cDNA prepared polymerase chain reaction PCR conducted reverse transcriptase enzyme cDNA amplified multiplex RTPCR performed specific set primers HCV RNA genotype detected 297 390 patients 390 test samples 200 5128 sample male 190 4871 females age ranging 5 78 years all 166 200 male sample 131190 female sample found positive HCV 390 participant included study 213 5461 identified genotype 3 positive 78 20 genotype 1 positive 6 153 genotype 6 positive remaining 93 2385 sample unclassified due lowundetected viral load study detected highest percentage 3089 genotype 3 HCV patient aged 51 60 years result suggested genotype 3 HCV frequently present Bangladesh usually response better interferon therapy However genotype 1 6 HCV also found circulating country demand longer treatment effective control measures",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37565062/"
    },
    {
        "pmid": "37525798",
        "title": "Evaluation and Determination of Quantitative Hepatitis B Surface Antigen Diagnostic Performance in Chronic Hepatitis B Virus-Infected Patients.",
        "abstract": "Background Hepatitis B virus DNA HBVDNA assessment recommended diagnosing monitoring chronic hepatitis B CHB patients Quantitative hepatitis B surface antigen qHBsAg estimation adjunct HBVDNA vital assessing HBV chronicity therapeutic prognosis study aimed estimate qHBsAg compare diagnostic performance HBVDNA level CHB patient Bangladesh Methodology total 148 CHB patient enrolled study qHBsAg hepatitis B eantigen HBeAg estimated using chemiluminescent enzyme immunoassays respectively HBVDNA quantified using realtime polymerase chain reaction parameter diagnostic performance analyzed receiver operating characteristic ROC curve analysis Results overall level mean ± SD qHBsAg HBVDNA alanine aminotransferase ALT among total population n  148 345 ± 080 logsub10sub IUmL 440 ± 244 logsub10sub IUmL 8617 ± 3906 IUL respectively Significant difference observed level qHBsAg p  0004 HBVDNA p  00001 case HBeAg positivity qHBsAg level showed weak positive correlation level HBVDNA ALT HBeAgpositive CHB patients relationship observed HBeAgnegative CHB patients ROC curve analysis showed area curve qHBsAg level distinguish high HBVDNA level 5 logsub10sub IUmL 0653 p  0002 indicated acceptable diagnostic performance best cutoff qHBsAg predicting high HBVDNA level 3469 logsub10sub IUmL Conclusions result indicated qHBsAg might useful marker monitoring HBVDNA CHB patient throughout treatment followup",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37525798/"
    },
    {
        "pmid": "37509583",
        "title": "Development of Therapy Based on the Exploration of Biological Events Underlying the Pathogenetic Mechanisms of Chronic Hepatitis B Infection.",
        "abstract": "According World Health Organization WHO estimated 296 million people chronically infected hepatitis B virus HBV Approximately 1525 people develop complication advanced chronic liver disease ACLDs Mortality due HBVrelated complication accounted estimated 882000 death 2019 Potent preventive vaccine already restricted new HBV infections several drug available treat chronic HBV infections However positive impact drug recorded patient chronic HBV infection drug show longterm efficacy cannot halt progression complications Thus effective evidencebased therapeutic strategy need urgently developed patient chronic HBV infection CHB pathological entity induced HBV progress due impaired host immunity indicates inherent limitation antiviraldrugbased monotherapy treating patient chronic HBV infection Additionally commercially available antiviral drug available patient developing resourceconstrained countries posing challenge achieving following goal Elimination Hepatitis 2030 such review aimed provide insight regarding evidencebased effective management strategy chronic HBV infection",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37509583/"
    },
    {
        "pmid": "40636909",
        "title": "Efficiency and safety of sofosbuvir in Bangladeshi children with chronic hepatitis C virus infection.",
        "abstract": "Currently treatment oral directacting antiviral recommended hepatitis C virus HCVinfected pediatric patients aim study evaluate efficacy safety sofosbuvir ribavirin combination therapy child adolescent Bangladesh living chronic HCV infection experimental study performed January 2021 December 2022 HCV polymerase chain reaction PCRpositive thalassemic children 618 year age enrolled consecutive nonprobability sampling Clinical feature recorded investigation performed patient initially treated sofosbuvir 200 mg 6 11yearolds 400 mg 12 18yearolds ribavirin 1015 mgkgday assessed clinically fourweekly basis along liverfunction testing total duration therapy 24 weeks HCV PCR done end treatment 12 week completion treatment see sustained virological response 26 case total mean age 926 ± 282 years 14 male 538 12 female 462 Twentyfive 9615 patient achieved sustained virological response endoftreatment PCR negative One patient 385 nonresponder even 24 week treatment medication well received four patient 153 reporting headache reported untreated combination sofosbuvir ribavirin effective treating chronic HCV infection accompanied major negative side effects",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40636909/"
    },
    {
        "pmid": "37454777",
        "title": "The role of bixin as antioxidant, anti-inflammatory, anticancer, and skin protecting natural product extracted from Bixa orellana L.",
        "abstract": "Since long medicinal plant herb used different traditional treatment system therapeutic agent treat variety illnesses Bixa orellana L medicinal plant family Bixaceae Ayurvedic herb used treat dyslipidemia diarrhoea hepatitis since ancient times B orellana L seed contain orangered coloured component known bixin Csub25subHsub30subOsub4sub constitutes 80 extractChemically bixin natural apocarotenoid biosynthesized oxidative degradation C40 carotenoids Bixin help regulate Nrf2MyD88TLR4 TGF1PPARSmad3 pathways give antifibrosis antioxidant antiinflammatory properties current review article present comprehensive review bixin antiinflammatory antioxidant anticancerand skin protecting natural product addition biosynthesis molecular target bixin along bixin extraction techniques also presented",
        "mesh_terms": [
            "Antioxidants",
            "Bixaceae",
            "Biological Products",
            "Molecular Structure",
            "Carotenoids",
            "Anti-Inflammatory Agents",
            "Plants, Medicinal",
            "Plant Extracts"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37454777/"
    },
    {
        "pmid": "37427238",
        "title": "Liver injury: the therapeutic dilemma of homeopathy - a case report from Bangladesh.",
        "abstract": "Despite lack scientific evidence supporting effectiveness homeopathic treatment increasingly used form alternative medicine many people taking homeopathic remedy instead drug therapies based principle like cure like meaning remedy similar illness used treat it However several report suggesting risk homeopathic remedies among homeopathyinduced liver injury widely discussed Here report case 35yearold welloriented male patient typical clinical presentation liver injury presented yellowish discoloration sclera skin along generalized body itching following use homeopathic medicine musculoskeletal pain Laboratory report increased liver marker along bilirubin also suggestive Excluding differential like viral hepatitis alcoholic hepatitis hemochromatosis Wilson disease standard drug toxininduced hepatitis recent use homeopathic remedy contributing factor leading diagnosis homeopathyinduced liver injury treated discontinuation homeopathic medicine supportive care case highlight need public awareness possible complication headache tiredness skin eruption dizziness bowel dysfunction allergic reaction acute pancreatitis renal failure neurological dysfunction possible liver injury even mortality patient pursue homeopathic treatment health care professional take account making differential diagnosis patient liver injury",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37427238/"
    },
    {
        "pmid": "37425840",
        "title": "Targeting hepatitis B vaccine escape using immunogenetics in Bangladeshi infants.",
        "abstract": "Hepatitis B virus HBV vaccine escape mutant VEM increasingly described threatening progress control virus worldwide studied relationship host genetic variation vaccine immunogenicity viral sequence implicating VEM emergence cohort 1096 Bangladeshi children identified human leukocyte antigen HLA variant associated response vaccine antigens Using HLA imputation panel 9448 south Asian individual iDPB10401i associated higher HBV antibody response p45×10sup30sup underlying mechanism result higher affinity binding HBV surface antigen epitope DPB10401 dimers likely result evolutionary pressure HBV surface antigen adeterminant segment incurring VEM specific HBV Prioritizing preS isoform HBV vaccine may tackle rise HBV vaccine evasion",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37425840/"
    },
    {
        "pmid": "37391960",
        "title": "Comparison of Serum Zinc in Children of Wilson Disease and Non-Wilsonian Volunteers in Bangladesh.",
        "abstract": "Wilson disease WD autosomal recessive disorder copper metabolism diverse clinical manifestations Zinc Zn used treatment WD Recent study showed low serum zinc level patient suffering WD normal crosssectional analytical study designed compare serum zinc level paediatric patient suffering WD yet started treatment child normal ALT level study carried Department Pediatric Gastroenterology Nutrition BSMMU Dhaka Bangladesh July 2018 June 2019 Total 51 child included study Among 27 diagnosed case WD aged three eighteen year 24 child age suffering liver disease normal ALT included volunteers patient WD divided four group according presentation acute hepatitis chronic liver disease CLD acute liver failure  neuropsychiatric manifestation Informed written consent obtained patient volunteer participation study Along physical finding laboratory investigation 3 ml venous blood collected estimation serum zinc level estimation serum zinc level result analyzed statistically difference serum zinc level compared groups Serum zinc level significantly lower Wilson disease patient 438±197μgdl range 1383 compared volunteer group 678±118μgdl range 4797 p0001 Among diseased group serum zinc level significantly lower 18 CLD 384±174μgdl 4 acute liver failure 331±37μgdl compared 4 acute hepatitis 718±43μgdl p0001 p0001 respectively Mean serum zinc level low 4 Wilsonian acute liver failure 331±37μgdl significant compared 23 presented Wilson disease non acute liver failure 457±208μgdl p0013 Serum zinc level significantly lower Wilson disease child compared volunteers Zinc level also found significantly low Wilson disease presented CLD acute liver failure comparison Wilson disease presented acute hepatitis",
        "mesh_terms": [
            "Humans",
            "Child",
            "Child, Preschool",
            "Adolescent",
            "Hepatolenticular Degeneration",
            "Bangladesh",
            "Cross-Sectional Studies",
            "Liver Failure, Acute",
            "Volunteers"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37391960/"
    },
    {
        "pmid": "37375532",
        "title": "Discovery of Terpenes as Novel HCV NS5B Polymerase Inhibitors via Molecular Docking.",
        "abstract": "Hepatitis C virus HCV dangerous virus responsible large number infection death worldwide treatment HCV important drug effective additional hepatotoxic effects aim study test silico activity 1893 terpene HCV NS5B polymerase PDBID 3FQK Two drugs sofosbuvir dasabuvir used controls GOLD software CCDC InstaDock used docking using result obtained PLPFitness GOLD pKi binding free energy InstaDock nine terpene finally selected based scores druglikeness property calculated using Lipinskis rule five ADMET value studied using SwissADME pkCSM servers Ultimately shown nine terpene better docking result sofosbuvir dasabuvir gniditrin mulberrofuran G cochlearine A ingenol dibenzoate mulberrofuran G isogemichalcone C pawhuskin B 3cinnamyl4oxoretinoic acid DTXSID501019279 mezerein docked complex submitted 150 nslong molecular dynamic simulation ascertain binding stability result show mulberrofuran G cochlearine A stereoisomers pawhuskin B form stable interaction active site region reaction product form are therefore good candidate use effective competitive inhibitors compound identified docking screen either afford extremely weak or even hardly any binding such ingenol dibenzoate gniditrin mezerein must first undergo preliminary movement active site attaining stable binding conformations process may take 60 80 n for DTXSID501019279 3cinnamyl4oxoretinoic acid isogemichalcone C",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37375532/"
    },
    {
        "pmid": "37363565",
        "title": "Dreadful infectious disease outbreaks threaten flood-ravaged pakistan: short communication.",
        "abstract": "rise incidence waterborne communicable illnesses viral outbreak Pakistan follows period heavy rainfall Due climate change flood drought devastating effect human health facilitating spread infectious illness including cholera malaria typhoid dengue fever viral hepatitis A Food instability starvation malnutrition lack potable water indirect effect flooding health Recently one worst flood history devastated Pakistan affecting 333 million people along significant portion nation submerged Malaria dengue fever ailment rise Pakistan threatening overwhelm countrys healthcare infrastructure urgent need preventative measure Pakistan cope dreadful outbreaks",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37363565/"
    },
    {
        "pmid": "37346467",
        "title": "Study of kaempferol in the treatment of COVID-19 combined with Chikungunya co-infection by network pharmacology and molecular docking technology.",
        "abstract": "Chikungunya CHIK patient may vulnerable coronavirus disease COVID19 However presently antiCOVID19CHIK therapeutic alternative available purpose research determine pharmacological mechanism kaempferol function treatment COVID19associated CHIK coinfection used series network pharmacology computational analysisbased technique decipher define binding capacity biological functions pharmacological targets treatment process COVID19mediated CHIK coinfection identified key therapeutic target COVID19CHIK including TP53 MAPK1 MAPK3 MAPK8 TNF IL6 NFKB1 Gene ontology molecular upstream pathway analysis kaempferol COVID19 CHIK showed DEGs confined mainly cytokinemediated signalling pathway MAP kinase activity negative regulation apoptotic process lipid atherosclerosis TNF signalling pathway hepatitis B tolllike receptor signaling IL17 IL18 signaling pathways study gene regulatory network revealed several significant TFs including KLF16 GATA2 YY1 FOXC1 miRNAs let7b5p mir165p mir34a5p mir1555p target differentialexpressed gene DEG According molecular coupling results kaempferol exhibited high affinity 5 receptor protein TP53 MAPK1 MAPK3 MAPK8 TNF compared control inhibitors combination result identified significant target pharmacological mechanism kaempferol treatment COVID19CHIK recommended core target used potential biomarkers COVID19CHIK viruses conducting clinical study intervention COVID19 CHIK kaempferol might evaluated wet lab test molecular level",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37346467/"
    },
    {
        "pmid": "37298575",
        "title": "Toll-like Receptor Response to Human Immunodeficiency Virus Type 1 or Co-Infection with Hepatitis B or C Virus: An Overview.",
        "abstract": "Tolllike receptor TLRs evolutionarily conserved pattern recognition receptor play important role early detection pathogenassociated molecular pattern shaping innate adaptive immune responses may influence consequence infection Similarly viral infections human immunodeficiency virus type 1 HIV1 also modulates host TLR response therefore proper understanding response induced human HIV1 coinfection hepatitis B virus HBV hepatitis C virus HCV due common mode transmission viruses essential understanding HIV1 pathogenesis mono coinfection HBV HCV well HIV1 cure strategies review discus host TLR response HIV1 infection innate immune evasion mechanism adopted HIV1 infection establishment also examine change host TLR response HIV1 coinfection HBV HCV however type study extremely scarce Moreover discus study investigating TLR agonist latencyreverting agent immune stimulators towards new strategy curing HIV understanding help develop new strategy curing HIV1 monoinfection coinfection HBV HCV",
        "mesh_terms": [
            "Humans",
            "HIV-1",
            "Coinfection",
            "Hepatitis B",
            "Hepatitis B virus",
            "Toll-Like Receptors",
            "Hepatitis C",
            "Hepacivirus",
            "HIV Infections"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37298575/"
    },
    {
        "pmid": "37286539",
        "title": "A high-throughput test enables specific detection of hepatocellular carcinoma.",
        "abstract": "Highthroughput test early cancer detection revolutionize public health reduce cancer morbidity mortality show DNA methylation signature hepatocellular carcinoma HCC detection liquid biopsies distinct normal tissue blood profiles developed classifier using four CpG sites validated TCGA HCC data single F12 gene CpG site effectively differentiates HCC sample blood samples normal tissues nonHCC tumor TCGA GEO data repositories marker validated separate plasma sample dataset HCC patient controls designed highthroughput assay using nextgeneration sequencing multiplexing techniques analyzing plasma sample 554 clinical study participants including HCC patients nonHCC cancers chronic hepatitis B healthy controls HCC detection sensitivity 845 95 specificity 094 AUC Implementing assay highrisk individual could significantly decrease HCC morbidity mortality",
        "mesh_terms": [
            "Carcinoma, Hepatocellular",
            "Liver Neoplasms",
            "Liver",
            "DNA Methylation",
            "Humans"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37286539/"
    },
    {
        "pmid": "37243066",
        "title": "Antiviral Response across Genotypes after Treatment of Chronic Hepatitis B Patients with the Therapeutic Vaccine NASVAC or Pegylated Interferon.",
        "abstract": "openlevel randomized treatmentcontrolled clinical trial shown therapeutic vaccine containing hepatitis B surface antigen HBsAg hepatitis B core antigen HBcAg NASVAC endowed antiviral liver protecting capacity safer pegylated interferon PegIFN patient chronic hepatitis B CHB present study provides information role hepatitis B virus HBV genotype phase III clinical trial total 160 patient enrolled trial HBV genotype 133 patient characterized NASVAC induced stronger antiviral effect HBV DNA reduction 250 copy per mL PegIFN antiviral effect alanine aminotransferase level significantly different among different HBV genotype NASVACtreated patients However significantly higher proportion genotypeD patient receiving NASVAC showed better therapeutic effects compared genotypeD patient receiving PegIFN marked difference 44 conclusion NASVAC seems better alternative PegIFN especially patient HBV genotypeD patients reflects attractiveness NASVAC country genotype highly prevalent mechanism underlying effect HBV genotype studied new clinical trial",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37243066/"
    },
    {
        "pmid": "37007026",
        "title": "Emerging mechanistic insights of selective autophagy in hepatic diseases.",
        "abstract": "Macroautophagy hereafter referred autophagy highly conserved metabolic process regulates cellular homeostasis degrading dysfunctional cytosolic constituent invading pathogen iviai lysosomal system addition autophagy selectively recycles specific organelle damaged mitochondrion iviai mitophagy lipid droplet LDs iviai lipophagy eliminates specialized intracellular pathogenic microorganism hepatitis B virus HBV coronaviruses iviai virophagy Selective autophagy particularly mitophagy play key role preservation healthy liver physiology dysfunction connected pathogenesis wide variety liver diseases example lipophagy emerged defensive mechanism chronic liver diseases prominent role mitophagy lipophagy hepatic pathology including nonalcoholic fatty liver disease NAFLD hepatocellular carcinoma HCC druginduced liver injury Moreover selective autophagy pathway including virophagy investigated context viral hepatitis and recently coronavirus disease 2019 COVID19associated hepatic pathologies interplay diverse type selective autophagy impact liver disease briefly addressed Thus modulating selective autophagy eg mitophagy would seem effective improving liver diseases Considering prominence selective autophagy liver physiology review summarizes current understanding molecular mechanism function selective autophagy mainly mitophagy lipophagy liver physiology pathophysiology may help finding therapeutic intervention targeting hepatic disease iviai manipulation selective autophagy",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/37007026/"
    },
    {
        "pmid": "40823853",
        "title": "Circulating Cell-Free Mitochondrial DNA as a Prognostic Biomarker in Patients With HBV-Related Acute-on-Chronic Liver Failure.",
        "abstract": "Acuteonchronic liver failure ACLF particularly hepatitis B virusrelated ACLF HBVACLF severe condition high shortterm mortality study aimed evaluate prognostic value circulating cellfree mitochondrial DNA cfmtDNA predicting shortterm mortality HBVACLF patients total 320 HBVACLF patient included study population 192 patient derivation cohort 128 validation cohort Plasma cfmtDNA level quantified using qPCR Plasma cfmtDNA level significantly elevated HBVACLF patient 395 logsub10sub copiesμL compared healthy control 299 logsub10sub copiesμL patient chronic liver disease 303 logsub10sub copiesμL p  0001 Plasma cfmtDNA level progressively increased disease severity associated multiorgan failure Sequential measurement cfmtDNA showed significant decrease survivor 400 vs 378 logsub10sub copiesμL p  0019 nonsurvivors maintained persistently elevated level minimal change 419 vs 415 logsub10sub copiesμL p  0359 cutoff value 39 logsub10sub copiesμL cfmtDNA effectively stratified patient high lowrisk groups significantly lower survival rate highrisk group 28day 462 vs 860 p  0001 90day 377 vs 721 p  0001 Using cfmtDNA combination key clinical parameters developed novel prognostic score exhibited superior predictive accuracy 28 90day mortality AUROCs 0907 0906 respectively outperforming established prognostic score all p  005 finding validated independent cohort CfmtDNA superior biomarker predicting shortterm mortality HBVACLF association multiorgan failure disease severity highlight potential utility early risk assessment treatment optimization",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40823853/"
    },
    {
        "pmid": "40823441",
        "title": "Fatal Herpes Simplex Hepatitis in a Live Liver Donor.",
        "abstract": "present case report living liver donor death Herpes simplex hepatitis highlighting need vigilance regarding rare treatable cause acute liver failure donor hepatectomy Early consideration HSV hepatitis prompt initiation antiviral therapy may improve outcomes",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40823441/"
    },
    {
        "pmid": "40823266",
        "title": "Assessing Vaccination Coverage Among Healthcare Workers in Primary Healthcare Facility in Najran City, Saudi Arabia.",
        "abstract": "Insufficient vaccination coverage among healthcare worker HCWs contributes nosocomial outbreak avoidable deaths study assesses vaccine hesitancy among HCWs primary healthcare facility identifies contributing factor Najran City Saudi Arabia crosssectional study conducted August 2023 among healthcare worker HCWs various healthcare facility providing primary care study utilized questionnaire developed accordance World Health Organization WHO Centers Disease Control Prevention CDC guidelines covering sociodemographic medical characteristics vaccination profile 19 items evidence vaccination status multistage sampling technique employed obtain representative sample involving random selection HCWs various category physicians pharmacists dentists nurses laboratory technicians radiology technicians paramedics clustering willing participant facility type Among 591 healthcare worker HCWs 577 male 458 aged 3140 years Vaccination compliance rate varied highest rate observed third COVID19 dose 863 hepatitis B 812 influenza 783 lowest rate Tdap pregnancy 277 Immunization documentation primarily evidenced vaccine record 675 lab test 518 disease confirmation 369 study 709 partially 191 fully vaccinated 10 unvaccinated Regarding immunization documentation 57 partial 157 complete 272 incomplete Significant predictor unvaccinated included male sex p0001 Saudi nationality p0030 technicianparamedic profession p0001 Additionally HCWs experiencing burnout likely unvaccinated p0006 Multivariate analysis revealed techniciansparamedics 274 time likely unvaccinated physician AOR2743 95 CI11406600 p0024 study highlight significant gap vaccination coverage among HCWs working primary healthcare facility 191 fully vaccinated Factors male gender burnout contribute vaccine hesitancy address gaps future direction targeted educational interventions burnout mitigation mobile vaccination units awareness campaign recommended Additionally supportive measure manage burnout crucial improving vaccination rate protecting public health",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40823266/"
    },
    {
        "pmid": "40823178",
        "title": "Comparative risk of osteoporosis and fractures in chronic hepatitis B patients: Tenofovir disoproxil fumarate vs. entecavir in a Korean nationwide cohort.",
        "abstract": "optimal antiviral agent patient chronic hepatitis B CHB risk osteoporosis remains debated aim study compare incidence osteoporosis osteoporotic fracture patient treated tenofovir disoproxil fumarate TDF entecavir ETV using nationwide cohort South Korea analyzed 40404 patient CHB treated either TDF n  23779 ETV n  16625 risk osteoporosis osteoporotic fracture evaluated using Cox proportional hazard models incidence rate ratio IRRs KaplanMeier survival analysis adjust baseline differences inverse probability treatment weighting applied mean followup 508 months osteoporosis occurred 1712 TDF user 1094 ET V users incidence rate osteoporosis significantly higher TDF group IRR 130 95 CI 123137 ip i0001 Multivariate Cox regression also confirmed increased osteoporosis risk TDF hazard ratio HR 1328 95 CI 12581401 ip i0001 fracture incidence significantly different HR 1027 95 CI 09391122 ipi  0569 patient aged ≥60 years TDF group significantly higher risk osteoporosis HR 1347 95 CI 12241484 ip i0001 fracture HR 1213 95 CI 10511403 ipi  0009 divergence KaplanMeier curve evident 1 3 year treatment respectively Longterm use TDF associated significantly increased risk osteoporosis fractures especially patient aged ≥60 years finding support need proactive bone health surveillance patient CHB receiving longterm TDF therapy study highlight need careful antiviral selection patient chronic hepatitis B aged ≥60 due increased risk osteoporosis fracture longterm tenofovir disoproxil fumarate use recommend using entecavir tenofovir alafenamide fumarate preferred therapy patient high risk fractures Early intervention essential fracture incidence tends rise 23 year tenofovir disoproxil fumarate therapy making regular bone mineral density monitoring critical patients",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40823178/"
    },
    {
        "pmid": "40823171",
        "title": "Recompensation in patients with autoimmune hepatitis-related decompensated cirrhosis following immunosuppressive therapy.",
        "abstract": "study aimed evaluate incidence predictors prognostic significance recompensation autoimmune hepatitis AIHrelated decompensated cirrhosis following immunosuppressive therapy IST retrospectively analyzed patient AIH first decompensation Recompensation defined using modified Baveno VII criteria required clinical resolution ≥12 month without ascites variceal bleeding hepatic encephalopathy liver function restored ChildPugh A along aetiological suppression complete biochemical response IST Predictors recompensation identified using multivariate regression survival outcome compared among compensated recompensated nonrecompensated groups total 258 patient AIHrelated decompensated cirrhosis included median followup 47 months IQR 2875 Clinical resolution achieved 124 patient 481 68 patient 309 220 treated IST met criterion recompensation Predictors recompensation included ascites complication hazard ratio HR 1440 95 CI 4174964 ip i0001 lower IgG level HR 090 95 CI 089096 ip i0001 higher bilirubin level HR 104 95 CI 100108 ipi  0030 higher platelet count HR 101 95 CI 100101 ipi  0039 Patients achieving recompensation experienced significantly reduced risk liver transplantation death HR 007 95 CI 001050 ipi  0009 survival outcome comparable compensated patients Recompensation achieved approximately onethird patient AIHrelated decompensated cirrhosis undergoing IST leading markedly improved transplantfree survival Predictors recompensation included ascites sole complication lower IgG levels higher bilirubin levels higher platelet counts predictor longterm prognostic implication recompensation patient autoimmune hepatitis AIHrelated decompensated cirrhosis remain unclear study demonstrates recompensation achievable patient AIHrelated decompensated cirrhosis associated significant longterm benefits including improved survival reduced transplantation needs identified ascites as sole decompensating event lower IgG levels higher bilirubin level higher platelet count independent predictor recompensation finding used clinician identify patient likely benefit immunosuppressive therapy",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40823171/"
    },
    {
        "pmid": "40822997",
        "title": "Neoadjuvant Immunotherapy in Bladder Cancer: Ushering in a New Era of Treatment-A Systematic Review of Current Evidence.",
        "abstract": "Immune checkpoint inhibitor ICIs alone platinumbased chemotherapy increasingly studied neoadjuvant therapy muscleinvasive bladder cancer BC sought evaluate current evidence neoadjuvant immunotherapy BC systematic review conducted October 2024 prospective study neoadjuvant immunotherapy BC included Extracted variable encompassed study design clinicalpathological characteristics perioperative outcomes pathological complete response pCR rates overall survival OS eventfree survival immunerelated irAEs treatmentrelated TRAEs adverse events 726 records 35 study met inclusion criteria highest pCR rate observed 54 utilizing durvalumab Perioperative chemoimmunotherapy durvalumab plus cisplatingemcitabine showed greater OS chemotherapy alone NIAGARA trial NEMIO trial achieved highest 12mo OS rate 97 using durvalumab combination tremelimumab dosedense methotrexate vinblastine doxorubicin cisplatin followed AURA trial 95 LCCC1520 trial 91 24 mo NEBULA trial reported 100 OS rate three dos atezolizumab PrECOG PrE0807 reached OS rate 89 nivolumab lirilumab highest rate grade 3 4 irAEs reported nivolumab combined ipilimumab 54 durvalumab combined tremelimumab 64 common grade 34 irAEs hepatitis 227 kidney injury 2100 skin rash 1141 Grade 34 TRAEs comparable ICI chemotherapy groups Neoadjuvant immunotherapy BC shown promising efficacy manageable adverse event profile However financial toxicity absence predictive biomarkers risk significant irAEs remain challenges study reviewed recent clinical trial tested immunotherapy surgery patient bladder cancer result suggest combination immunotherapy chemotherapy may improve outcome reduce risk cancer returning finding could help shape future treatment option patient muscleinvasive bladder cancer",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40822997/"
    },
    {
        "pmid": "40822493",
        "title": "<i>Isodon lophanthoides</i> alleviates liver fibrosis via modulation of purine metabolism and NF-κB signaling pathway: insights from multi-omics analysis.",
        "abstract": "iIsodon lophanthoidesi core botanical drug Yao ethnomedicine traditionally used treat jaundicetype hepatitis cholecystitis However therapeutic potential mechanism liver fibrosis remain largely unexplored metabolite iI lophanthoidesi water extract ILW characterized ultraperformance liquid chromatography UPLC UPLC coupled quadrupole timeofflight mass spectrometry QTOFMS carbon tetrachloride CClsub4subinduced liver fibrosis mouse model employed evaluate antifibrotic effect ILW integrated multiomics approach encompassing transcriptomics proteomics metabolomics used elucidate underlying mechanisms supported Western blotting targeted metabolite quantification enzymelinked immunosorbent assay ELISA Thirtytwo metabolite identified ILW Among them concentration caffeic acid rosmarinic acid schaftoside isoschaftoside determined 110 513 012 018 mg·gsup1sup respectively ILW treatment significantly reduced serum level alanine aminotransferase ALT aspartate aminotransferase AST procollagen type III PCIII collagen type IV COLIV laminin LN hyaluronic acid HA liver fibrotic mice Histopathological analysis showed ILW significantly alleviated liver inflammation collagen deposition fibrosis Multiomics analysis revealed ILWs antifibrotic effect linked modulation purine metabolism inhibition nuclear factor kappaB NFκB signaling pathway Highdose ILW lowered hepatic level adenine adenosine monophosphate AMP inosine monophosphate IMP increasing adenosine hypoxanthine Nsup6supmethyladenosine m6A Furthermore highdose mediumdose ILW downregulated key NFκBrelated proteins including tolllike receptor 4 TLR4 myeloid differentiation primary response 88 MyD88 phosphorylated NFκB transforming growth factor beta 1 TGFβ1 tumor necrosis factoralpha TNFα interleukin6 IL6 interleukin1 beta IL1β ILW exerts protective effect liver fibrosis attenuating inflammation fibrosis liver damage modulation metabolism modulation NFκB pathway inhibition finding provide scientific basis traditional use iI lophanthoidesi liverrelated disorders",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40822493/"
    },
    {
        "pmid": "40822084",
        "title": "Transarterial Chemoembolization Following Curative Resection May Not Improve Survival for Hepatitis B Virus Associated Intrahepatic Cholangiocarcinoma: Propensity Score Weighting Analysis.",
        "abstract": "hepatocellular carcinoma HCC adjuvant transarterial chemoembolization TACE show advantageous response prognosis recurrent patient resection consideration similar pathogenesis clinicopathological characteristics study conducted ascertain whether hepatitis B virus HBVassociated intrahepatic cholangiocarcinoma ICC successfully treated method used treat HCC role adjuvant TACE following liver resection HBVassociated ICC remains controversial study aim evaluate efficacy adjuvant TACE recurrence survival liver resection propensity score weighting PSW analysis total 356 patient categorized two groups i 77 patient received adjuvant TACE ii 279 patient underwent R0 resection alone Staging conducted according 8th edition American Joint Committee Cancer AJCC TumorNodeMetastasis TNM staging system Univariate multivariate analysis utilized assess independent prognostic factors Recurrencefree survival RFS overall survival OS rate compared using KaplanMeier method Among 356 enrolled patients 77 received adjuvant TACE median followup period 453 months Adjuvant TACE significantly affect OS P0629 PSW Subgroup analysis indicated TACE associated OS across different TNM stages propensity score weighting Cox regression model indicated significantly increased recurrence risk TACE HR153 95 CI 102228 P00071 Stagespecific risk visually summarized Supplementary Figure 1 Additionally TACE significantly impact RFS TNM stage P01720 stage II P07905 subgroups Conversely TACE positively associated increased recurrence risk TNM stage III P00014 stage IV P00051 patients finding suggest adjuvant TACE following radical surgery prolong OS patient HBVassociated ICC Furthermore adjuvant TACE associated increased recurrence risk TNM Stage III IV subgroups though observation requires validation due sample size limitation advanced stages",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40822084/"
    },
    {
        "pmid": "40821759",
        "title": "MiR-122-5p modulates ferroptosis via SLC7A11: A potential therapeutic target in autoimmune hepatitis.",
        "abstract": "Autoimmune hepatitis AIH relatively rare cause liver disease poor prognosis without intervention Ferroptosis classical form cell death play crucial role various diseases role AIH remains unclear Therefore investigated role ferroptosis AIH mechanism Here performed extensive bioinformatic analysis using online public database tools including Gene Ontology Kyoto Encyclopedia Genes Genomes Gene Set Enrichment Analysis Ferroptosisrelated assay kits quantitative realtime polymerase chain reaction Western blot analysis used validate result using clinical tissue cell samples obtained 449 differentially expressed microRNAs DEmiRNAs control AIH groups Among these hsamiR1225p hsamiR1433p screened potential key miRNAs evaluating diagnostic value expression levels number target genes Enrichment analysis revealed significant association hsamiR1225p ferroptosisrelated pathways confirmed vitro assay hsamiR1225p inhibited SLC7A11 expression thereby promoting ferroptosis AIH summarize study demonstrated hsamiR1225p potential therapeutic target promotes ferroptosis inhibiting expression SLC7A11 provides new insight pathogenesis AIH pave way innovative treatment strategies",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40821759/"
    },
    {
        "pmid": "40821684",
        "title": "Using linezolid as a substitute for the injectable in case of ototoxicity is safer and as effective as all-oral treatment for rifampicin-resistant TB.",
        "abstract": "recommends alloral bedaquiline BDQ linezolid LZDcontaining regimen rifampicinresistant TB RRTB Niger high cure rate achieved using adaptive short treatment regimen aSTR secondline injectable drug SLID LZD LZD replaced SLID case ototoxicity detected monthly audiometry 2020 recommended short oral BDQLZD regimen oSTR However success reported oSTR lower aSTR Niger SHOrt ORal Treatment trial therefore compared safety efficacy aSTR oSTR Niger pragmatic clinical trial patient fluoroquinolonesusceptible RRTB assigned alternate month aSTR oSTR Regression model estimated association regimen safety grade 34 adverse event AEs efficacy excluding loss followup 20212022 158 RRTB patient included 80 oSTR 78 aSTR Overall 34 patient experienced 43 grade 34 AEs anaemia 15 neurotoxicity 11 vomiting 8 hepatitis 7 arthralgia 1 QTc prolongation 1 Grade 34 AEs occurred 2680 325  oSTR versus 878 103 aSTR anaemia neurotoxicity arthralgia significantly higher oSTR group Ototoxicity nephrotoxicity appeared frequently aSTR none evolved grade 3 Patients treated oSTR 3fold increase grade 34 AE aHR 30495 CI136680 Endoftreatment success similar oSTR compared aSTR aSTR safer oSTR approach similar treatment efficacy",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40821684/"
    },
    {
        "pmid": "40821631",
        "title": "Serum TNF-a and biomarkers levels after tenofovir therapy in patients with serum HBeAg-positive chronic hepatitis B.",
        "abstract": "Chronic hepatitis B CHB remains widespread serious infectious disease pathogenesis still fully understood Tenofovir Amibufenamide prodrug tenofovir belongs class nucleoside reverse transcriptase inhibitor used treatment CHB study aimed evaluate efficacy safety Tenofovir Amibufenamide treating HBeAgpositive CHB total 60 patient diagnosed HBeAgpositive CHB randomly assigned two groups entecavir ETV group 05 mg Tenofovir Amibufenamide TMF group 025 mg 30 patient each 24 month treatment renal function serum creatinine glomerular filtration rate liver function ALT  AST  total bilirubin inflammatory marker TNFa levels measured assess antiviral efficacy safety profile two treatments Patients TMF group exhibited smaller change serum creatinine glomerular filtration rate indicating less renal impairment compared ETV group Furthermore TMF group demonstrated greater reduction alanine aminotransferase ALT total bilirubin TBIL levels indicating superior improvement liver function P005 TNFa level significantly elevated ETV group reflecting greater inflammatory activity TMF group showed controlled inflammation Additionally TMF group experienced significantly lower hepatitis B surface antigen HBsAg hepatitis B e antigen HBeAg HBV DNA levels showing superior antiviral efficacy incidence adverse reaction lower TMF group 33 compared ETV group 133 although difference statistically significant P005 Tenofovir Amibufenamide demonstrated superior efficacy improving liver function reducing viral load patient HBeAgpositive CHB Moreover minimal impact renal function presented higher safety profile compared entecavir finding suggest Tenofovir Amibufenamide promising alternative treatment HBeAgpositive CHB",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40821631/"
    },
    {
        "pmid": "40821263",
        "title": "Severe Perinuclear Antineutrophil Cytoplasmic Antibody (p-ANCA)-Positive Granulomatosis With Polyangiitis.",
        "abstract": "case report describes 50yearold Caucasian male history heroin use hepatitis C presented upper respiratory tract lower respiratory tract renal involvement ultimately diagnosed perinuclear antineutrophil cytoplasmic antibody pANCApositive granulomatosis polyangiitis GPA patient initially presented emergency department epigastric pain leg pain dyspnea hemoptysis accompanied recent ear infection olfactory disturbances skin manifestations Despite initial empiric treatment suspected pneumonia condition rapidly deteriorated investigation revealed elevated inflammatory markers positive pANCA characteristic imaging finding including pulmonary nodule cavitary lesions Renal involvement evident hematuria proteinuria ear nose throat ENT examination showed chronic sinusitis nasal crusting Renal biopsy revealed pauciimmune necrotizing crescentic glomerulonephritis evidence granulomatous inflammation serologic testing revealed pANCA positivity negative renal immunofluorescence microscopy results Treatment initiated highdose glucocorticoid rituximab considering patients hepatitis C history case emphasizes importance considering GPA patient multisystem involvement even pANCA positivity highlight complexity managing patient significant comorbidities",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40821263/"
    },
    {
        "pmid": "40821097",
        "title": "Case report: surgery combined with a SOX adjuvant chemotherapy regimen for patients with gastric adenocarcinoma and hepatocellular carcinoma.",
        "abstract": "Advances early tumor detection led increase reported incidence multiple primary cancers However concurrent occurrence gastric adenocarcinoma hepatocellular carcinoma remains rare present case 68yearold male patient chronic hepatitis B diagnosed stage Ib liver cancer T1bN0M0 Gastroscopy revealed mucosal lesion posterior wall gastric body biopsy confirmed moderately poorly differentiated adenocarcinoma patient underwent laparoscopic gastrectomy combined partial liver resection followed three cycle S1 plus oxaliplatin SOX chemotherapy Given lack standardized treatment protocol managing multiple primary cancers developing treatment plan two synchronous cancer challenging case underscore importance early screening multiple primary cancer need multidisciplinary approach formulate optimal treatment strategy Furthermore conducted literature review report simultaneous occurrence gastric hepatic cancer recent decades Unlike previous studies also examined postoperative adjuvant chemotherapy regimen suitable gastric adenocarcinoma hepatocellular carcinoma patients",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40821097/"
    },
    {
        "pmid": "40821029",
        "title": "Anesthetic management of diabetic foot amputation in a patient with renal failure and maintenance hemodialysis: case report and short communication.",
        "abstract": "Chronic kidney disease CKD progress advanced stage eventually developing endstage renal disease ESRD Currently effective treatment ESRD renal replacement therapy maintenance hemodialysis MHD widely used modality accounting approximately 90 dialysis patients However perioperative risk surgery anesthesia patient remains extremely high Therefore careful selection surgical timing appropriate anesthetic agents suitable anesthetic technique crucial report describes anesthetic management 62yearold female patient hospitalized orthopedic ward nine month due left toe necrosis secondary diabetic foot setting CKD requiring MHD later admitted Xingtai Central Hospital progressive necrosis involving left second third toe extending dorsum plantar aspect foot patient diagnosed leftsided diabetic foot necrosis stage 5 CKD type 2 diabetes mellitus multiple complications grade 3 hypertension high risk chronic hepatitis B infection elective transtibial belowknee amputation left lower limb planned Anesthesia provided using color Doppler ultrasoundguided left iliac fascia block left lateral femoral cutaneous nerve block left sciatic nerve block Intravenous isoproterenol infusion dexmedetomidine dizocine injection administered intraoperative sedation analgesia patients intraoperative vital sign remained stable Postoperatively patient awake good general condition transferred ward regular monitoring",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40821029/"
    },
    {
        "pmid": "40820903",
        "title": "The evolving landscape of pediatric hepatology: key updates and future directions.",
        "abstract": "provide update recent advancement pediatric hepatology highlighting new diagnostic criteria emerging therapeutic options molecular insight liver disease reshaping clinical practice guiding future research Nonalcoholic fatty liver disease NAFLD redefned metabolic dysfunctionassociated steatotic liver disease MASLD reflecting improved understanding underlying pathophysiology Advances immunophenotyping identified activated Tcell hepatitis significant contributor indeterminate pediatric acute liver failure Additionally introduction ileal bile acid transporter IBAT inhibitor mark transformative shift management pediatric cholestatic disease including Alagille syndrome progressive familial intrahepatic cholestasis PFIC offering improved growth quality life native liver survival Recent development pediatric hepatology changing liver disease approached clinical practice Evolving disease classifications expanded use genetic immunologic profiling introduction novel therapy mark shift toward individualized care Ongoing research needed evaluate longterm outcome ensure advance translate durable improvement child liver disease",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40820903/"
    },
    {
        "pmid": "40820805",
        "title": "Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with hematological malignancies.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40820805/"
    },
    {
        "pmid": "40819988",
        "title": "Autoimmune hepatitis and immune dysregulation: A case series.",
        "abstract": "assess presence inborn error immunity IEI pediatric autoimmune hepatitis AIH cohort retrospective study included patient aged 018 diagnosed AIH center 1995 2023 followed immunology department clinical andor molecular IEI diagnosis Among 83 AIH patients five 6 displayed sign associated IEI Two patient genetic confirmation IEI SP110 AIRE homozygous mutations IEIrelated sign recurrent infection n3 immunemediated cytopenia n4 skin disease n2 autoimmune polyendocrinopathy n1 four patient diagnosed seronegative AIH responded immunosuppressive therapy AIH type 2 patient underwent emergent liver transplantation fulminant liver failure diagnosis small case series highlight need look sign immune dysregulation AIH patients Conversely AIH atypical IEI threshold low perform diagnostic liver biopsy IEI patient suffering chronic cytolysis believe systematic genetic testing immune phenotyping AIH patient display sign immune dysregulation crucial better understand close link AIH IEI",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819988/"
    },
    {
        "pmid": "40819651",
        "title": "Service delivery models and care cascade outcomes for people living with chronic hepatitis B: a global systematic review and meta-analysis.",
        "abstract": "Chronic hepatitis B leading cause cirrhosis hepatocellular carcinoma globally 2022 13 254 million people chronic hepatitis B diagnosed 3 treated highlighting major gap care provision aimed comprehensively review service delivery model outcome across hepatitis B care cascade systematic review metaanalysis searched PubMed Embase Scopus observational interventional study chronic hepatitis B service delivery model reported care outcomes published May 1 2013 July 15 2024 language restrictions Care cascade outcome proportion people diagnosed hepatitis B assessed treatment eligibility proportion eligible people started antiviral therapy proportion retained care proportion therapy HBV DNA viral suppression evaluated pooled outcome across hospitalbased specialist care comanaged care primary specialist care community screening linkage specialist care community screening passive linkage care community test treat clinics primary care integrated care antenatal noncommunicable disease HIV prison health substance misuse service clinics using generalised linear mixed model logit link study random effects withinstudy comparison different models used inverse variance weighting estimate pooled risk ratio RR Heterogeneity assessed Isup2sup study registered PROSPERO CRD42023410009 4883 study identified search included 106 study comprising 110 cohort 50 country metaanalysis 45 41 110 cohort lowincome middleincome country 65 59 highincome countries 76 72 106 study observational 23 22 nonrandomised interventional studies seven 7 randomised trials Treatment eligibility assessment occurred 73·9 95 CI 65·880·6 Isup2sup98·5 patient hospitalbased specialist care 20 cohorts 63·1 53·072·2 Isup2sup99·9 comanaged care 23 cohorts 50·4 25·974·8 Isup2sup99·7 primary care four cohorts 82·3 58·793·8 Isup2sup96·1 community screening linkage specialist care ten cohorts 33·2 23·145·1 Isup2sup98·6 community screening passive linkage care three cohorts 56·9 40·272·1 Isup2sup98·8 diagnosis antenatal clinic postdelivery linkage specialist care five cohorts 75·0 37·793·7 Isup2sup0·0 integrated care harm reduction service two cohorts 85·4 78·090·6 Isup2sup0·0 integrated care prison health service two cohorts Initiation antiviral therapy eligible 78·1 95 CI 68·185·7 Isup2sup99·2 hospitalbased specialist care 25 cohorts 67·2 55·577·1 Isup2sup95·8 comanaged care 11 cohorts 49·3 32·466·4 Isup2sup87·9 primary care four cohorts 97·7 80·699·8 Isup2sup39·2 community screening linkage specialist care seven cohorts 49·4 22·177·0 Isup2sup84·0 integrated care noncommunicable disease clinic two cohorts Higher rate treatment eligibility assessment RR 2·07 95 CI 1·652·59 p0·0001 Isup2sup97·1 three cohorts initiation antiviral therapy 1·45 1·131·85 p0·0031 Isup2sup0·0 three cohorts observed hospitalbased specialist versus primary care models Retention care assessed 12 48 months 87·7 95 CI 79·992·8 Isup2sup 96·7 patient antiviral therapy hospitalbased specialist care 13 cohorts 47·2 95 CI 22·273·6 Isup2sup99·5 patient receiving antiviral therapy two cohorts Overall retention higher patient versus without antiviral therapy RR 1·72 95 CI 1·162·54 p0·019 HBV DNA viral suppression patient antiviral therapy specialist care nine cohorts 73·1 95 CI 64·380·4 Isup2sup92·0 median 12 month antiviral therapy IQR 1233 Considerable attrition seen across chronic hepatitis B care cascade low rate retention especially patient antiviral therapy Assessment treatment eligibility initiation antiviral therapy lower primary versus hospitalbased specialist care models Chronic hepatitis B service need adopt strategy optimise linkage care diagnosis initiation antiviral therapy eligible adherence antiviral therapy retention care promoted 2024 hepatitis B guidelines research also needed explore simplified care model integrated existing service promote access World Health Organization",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819651/"
    },
    {
        "pmid": "40819282",
        "title": "Coexistence of hepatitis B e antigen and antibody during antiviral treatment predicts better clinical outcomes in children.",
        "abstract": "coexistence hepatitis B e antigen HBeAg hepatitis B e antibody HBeAb antiviral therapy considered atypical patient chronic hepatitis B CHB clinical implication remain inadequately understood particularly pediatric patients study aimed investigate clinical characteristic coexistence pattern impact outcome combined antiviral therapy child CHB total 254 treatmentnaïve child diagnosed HBeAgpositive CHB retrospectively enrolled patient received combination therapy entecavir interferonalphapegylatedinterferonalpha Participants categorized coexistence group control group based whether HBeAg HBeAb coexisted treatment period Clinical characteristic treatment outcome compared Cox regression analysis used evaluate factor influencing coexistence pattern association antiviral responses incidence HBeAg HBeAb coexistence antiviral therapy 3543 90254 pattern associated higher HBV DNA level hazard ratio HR  125 p  0009 baseline Notably child coexistence group demonstrated greater likelihood achieving HBsAg loss HR  258 p  0001 HBeAg loss HR  223 p  0001 HBVDNA undetectability HR  142 p  0034 HBeAgHBeAb coexistence pattern relatively common antiviral therapy child associated significantly improved treatment outcomes finding highlight importance monitoring HBeAgHBeAb dynamic continuing treatment critical phase",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819282/"
    },
    {
        "pmid": "40819081",
        "title": "Roles of inflammatory cytokines in the pathogenesis of hepatitis B virus-related acute-on-chronic liver failure and CAR-T therapy.",
        "abstract": "investigate association inflammatory cytokine liver function index hepatitis B virusrelated acuteonchronic liver failure HBVACLF patient chimeric antigen receptor CAR therapy recipients aim identifying prognostic biomarkers elucidating pathophysiological role inflammatory cytokine HBVACLF retrospective cohort study analyzed clinical data three groups 68 patient confirmed HBVACLF 30 patient preHBVACLF 372 hematologic malignancy patient receiving CART therapy preserved liver function First Affiliated Hospital Soochow University Serum interleukin IL10 level demonstrated progressive increase across group healthy controls 015 010218 pgmL preHBVACLF 380 2381183 pgmL HBVACLF 595 3901475 pgmL p  0001 Patients clinical improvement exhibited significantly lower IL10 concentration higher IL6IL10 ratio compared disease progression p  005 Notably IL6 level remained stable across clinical stages HBVACLF patient without secondary infection showing lower IL6 level preHBVACLF patient p  005 Following CART therapy hematologic patient displayed significantly elevated IL6 levels accompanied increase AST INR prolongation whereas TBIL ALT remained stable p  005 Consistent HBVACLF observations improved CART recipient demonstrated significantly lower IL6IL10 ratio progression patient p  005 IL10 exhibit stagedependent dynamic HBVACLF pathogenesis progression closely mirroring hepatic functional deterioration IL6IL10 ratio serf prognostic biomarker HBVACLF CART therapyrelated liver injury lower ratio indicating better clinical outcomes applicable",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819081/"
    },
    {
        "pmid": "40819053",
        "title": "Sterile syringe availability in Georgia pharmacies remained rare, despite policy change permitting sales.",
        "abstract": "Numerous states including Georgia April 2019 advanced policy designed increase availability sterile syrinx pharmacy people inject drug PWID however extent pharmacy willing sell syrinx PWID unclear examine sterile syrinx sale practice Georgia pharmacy PWID following recent policy change pharmacists cited reason practices conducted telephone survey October 2020 May 2021 one pharmacist staff manager per pharmacy sample Georgia retail pharmacy stratified urbanicity 15question survey queried respondent pharmacys current practice regarding nonprescription sterile syringe sale respondents perception syringe sale counseling practice purchasing syringes Pharmacy pharmacist demographic collected correlation characteristic estimated using unadjusted logistic regression models obtained response 119 pharmacy response rate  34 surveyed pharmacy 81 reported sell syrinx patient without prescription nonmedical uses including intravenous drug use difference whether pharmacy less likely sell syrinx level urbanicity local poverty rate local racialethnic composition pharmacy type ie chain vs independently owned common reason cited selling syrinx security concerns syringe sale encourage drug use corporate policy Among pharmacist pharmacy currently selling syringes 54 aware state law change allowing sale syrinx without medical reason Despite important policy change advancing harm reduction sterile syringe access availability sterile syrinx PWID Georgia pharmacy likely still hampered lack dispensing pharmacies Implementation effort following important policy changesincluding building awareness new policy encouraging support harm reduction efforts continuing education around substance use disordersare essential achieving intended outcome policy",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40819053/"
    },
    {
        "pmid": "40818720",
        "title": "A novel ionizable lipid with comprehensive improvements in transfection potency, immune profile and safety of lipid nanoparticle.",
        "abstract": "Ionizable cationic lipid critical construction lipid nanoparticles LNPs mRNA delivery Here reported rational design evaluation FS01 novel ionizable cationic lipid incorporating orthobutylphenylmodified hydrophobic tail squaramidebased lipid headgroup architecture Molecular dynamic simulation revealed FS01 enhances mRNA stability ππ stacking interaction aromatic tail nucleobases aromatic rings alongside hydrogen bonding via squaramide headgroup FS01LNPs demonstrated smaller particle size  70 nm high encapsulation efficiency  90  superior mRNA delivery performance across intramuscular subcutaneous intravenous route mouse compared FDAapproved lipid DlinMC3DMA SM102 ALC0315 prophylactic vaccine model Varicellazoster virus Hepatitis B virus FS01LNP formulation elicited robust antigenspecific antibodies memory B cells Th1biased cell responses outperforming benchmark LNPs Further transcriptomic profiling safety assessment demonstrated FS01LNP induced wellbalanced innate immune activation minimal inflammation liver toxicity contrasting pronounced reactogenicity DlinMC3DMA ALC0315 LNPs finding highlighted FS01 promising ionizable lipid candidate mRNA therapeutics offering enhanced delivery efficiency immunogenicity safety potential application extending beyond vaccine gene editing protein replacement therapies",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818720/"
    },
    {
        "pmid": "40815495",
        "title": "Hepatitis B virus reactivation in patients with hematologic malignancies treated with Bruton tyrosine kinase inhibitors.",
        "abstract": "Bruton tyrosine kinase inhibitor BTKis effective welltolerated treatment chronic lymphocytic leukemia CLL mantle cell lymphoma MCL Here describe clinical characteristic hepatitis B virus HBV reactivation patient hematological malignancy treated BTKis Patients required pathologically confirmed diagnosis CLL MCL receive least one cycle ibrutinib zanubrutinib either positive hepatitis B surface antigen hepatitis B core antibody diagnosis Patients excluded received rituximab obinutuzumab within previous 12 months identified five patient CLL one MCL resolved HBV infection received BTKis study period None patient received antiHBV prophylaxis CLL diagnosis patient MCL received zanubrutinib confirmed HBV reactivation even prophylactic entecavir administration followed tenofovir five patient CLL received ibrutinib secondline therapy 62yearold man died hepatorenal syndrome associated HBV reactivation despite entecavir treatment best knowledge first description HBVrelated death patient receiving BTKis HBVendemic areas first case HBV reactivation associated zanubrutinib despite previous entecavir prophylaxis prospective study warranted develop useful guideline monitoring HBV DNA antiviral prophylaxis prevent HBV reactivation BTKi therapy",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40815495/"
    },
    {
        "pmid": "40815463",
        "title": "Network controllability analysis reveals the antiviral potential of Etravirine against hepatitis E virus infection.",
        "abstract": "Hepatitis E virus HEV major cause acute viral hepatitis lower middleincome countries HEV infection may lead acute liver failure chronic liver disease high mortality pregnant women Antiviral therapy standard treatment HEV patients Computational biology tool promise revolutionize antiviral drug discovery Here analyzed transcriptome data HEVinfected primary human hepatocyte cell connectivity map database applied control theory functional network identify antiviral target HEV analysis predicted PKCβ PKBAKT CK1ε potential antiviral target HEV antiviral function PKBAKT CK1ε experimentally validated using respective biochemical inhibitor g3 genotype 3HEV replicon Huh7 cellbased model g3 g1HEV infection Furthermore knockdown CK1ε showed similar effect data confirmed CK1ε antiviral target HEV present Food Drug Administration FDAapproved drug targeting CK1ε Etravirine FDAapproved nonnucleoside reverse transcriptase inhibitor drug used treatment AIDS patients iin silicoi study predicted Etravirine potent inhibitor CK1ε experiment revealed potent antiviral activity Etravirine HEV mediated via ability inhibit activity CK1ε Taken together current study demonstrates PKBAKT CK1ε bona fide antiviral target HEV pave way repurposing Etravirine treatment HEVinfected patientsIMPORTANCEAntiviral treatment standard care acute viral hepatitis E patients Unbiased identification antiviral target largescale screening antiviral compound hepatitis E virus HEV reported Here computational biology approach followed unbiasedly identify antiviral target HEV Transcriptome data HEVinfected primary human hepatocyte cell analyzed identify modulators network generate directional networks Network controllability analysis identified PKCβ PKBAKT CK1ε potential antiviral target HEV Antiviral function PKBAKT CK1ε confirmed using cellbased model genotype 1 g1 g3HEV infection experiment demonstrated antiviral activity Etravirine HEV mediated via ability inhibit CK1ε activity Etravirine Food Drug Administrationapproved nonnucleoside reverse transcriptase inhibitor used treatment AIDS patients study reveals potential repurposing Etravirine treatment HEV patient illustrates importance computational biology antiviral drug discovery",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40815463/"
    },
    {
        "pmid": "40814512",
        "title": "Clinical spectrum and outcomes of adult varicella (chickenpox) in India.",
        "abstract": "Despite recent rise incidence varicella adult remains underrecognized particularly tropical regions prevalence high study aim delineate clinical spectrum evaluate organ involvement assess outcome adult Indian patient varicella hospitalbased retrospective study conducted Postgraduate Institute Medical Education Research PGIMER Chandigarh India March 2016 February 2020 Adult patient aged ≥15 year diagnosed varicella included Diagnosis based presence characteristic vesicular rash epidemiological history recent exposure exclusion alternative etiologies Fifty patient mean age 32 years 31 males included Organ dysfunction seen 34 68 patients commonly pneumonia ini  17 hepatitis ini  12 hemorrhagic complication ini  12 acute meningoencephalitis myelitis ini  10 Multiorgan involvement present 12 24 Inhospital mortality 18 ini  9 highest among patient pneumonia 412 hemorrhagic complication 417 Advanced age independent predictor mortality OR 1144 iPi value 0034 Twentythree 46 patient underlying predisposing conditions commonly immunosuppressive therapy ini  9 hematological malignancy ini  5 However organ complication outcome comparable regardless immune status one case breakthrough varicella detected Admissions peaked March April ini  15 although case seen throughout year Varicella adult frequently associated severe organ complications particularly pneumonia substantial inhospital mortality adverse outcome occur even previously healthy individuals underscoring need heightened clinical vigilance timely antiviral therapy strengthened preventive strategy adult population",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40814512/"
    },
    {
        "pmid": "40814503",
        "title": "Clinico immunological profile of immune-mediated disorders in South Indian children- A prospective observational study.",
        "abstract": "Immunemediated disease affect part body genetically susceptible individuals disease predominantly affect single organ others present multisystemic manifestations collected data clinical demographic immunological detail child immunemediated disease presenting period three year January 2020 December 2022 retrospectively child enrolled Pediatric immunology clinic tertiary care hospital South India prevalence immunemediated disease among child visiting hospital various illness 5 per 1000 children percentage positive autoantibody child connective tissue disorder singleorgan autoimmune disorder 413 407 respectively common connective tissue disorder study juvenile idiopathic arthritis 21 patients among 9  21 428 autoantibody positive ANA common antibody group 475 34 rheumatoid factor positivity connective tissue group common singleorgan autoimmune disorder child autoimmune thyroid disorder 25 followed autoimmune hematological disorder 18 autoantibody common patient thyroid disorder 18  25 autoimmune hepatitis 7  8 Early clinical suspicion prompt diagnosis child prolonged illness atypical presentation essential ensure remission prevent complications morbidity mortality research needed identify early biomarkers immunemediated pediatric disorder help confirm diagnosis guide physician start immunosuppressive therapy right time",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40814503/"
    },
    {
        "pmid": "40813841",
        "title": "Investigation of Serum Nitric Oxide, Zinc, Copper, and C-Reactive Protein Levels in Acute Hepatitis B Patients.",
        "abstract": "Acute hepatitis B AHB infection impact million globally causing severe liver disease study aimed assess serum nitric oxide NO Creactive protein CRP copper Cu zinc Zn level interrelationship AHB pathogenesis investigated biomarkers 58 patient AHB 30 healthy controls Results showed patient AHB significantly higher serum level metabolites CRP Cu Zn concentration significantly lower compared control group p  0001 all distinct biomarker profile emerged correlation analysis strong positive correlation found among proinflammatory markers CRP level showing significant positive association Cu rho  0677 total metabolite rho  0631 Conversely serum Zn level exhibited consistent significant negative correlation measured markers notably CRP rho   0649 Cu rho   0520 finding highlight coordinated inflammatory response AHB characterized elevated proinflammatory mediator concurrent depletion essential trace element zinc interconnected biomarker panel underscore significant pathophysiological network hold potential composite tool diagnosis management AHB",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40813841/"
    },
    {
        "pmid": "40813740",
        "title": "Deep learning radiomics of elastography for diagnosing compensated advanced chronic liver disease: an international multicenter study.",
        "abstract": "Accurate noninvasive diagnosis compensated advanced chronic liver disease cACLD essential effective clinical management remains challenging study aimed develop deep learningbased radiomics model using international multicenter data evaluate performance comparing twodimensional shear wave elastography 2DSWE cutoff method covering multiple country regions etiologies ultrasound device manufacturers retrospective study included 1937 adult patient chronic liver disease due hepatitis B hepatitis C metabolic dysfunctionassociated steatotic liver disease patient underwent 2DSWE imaging liver biopsy 17 center across China Japan Europe using device three manufacturer SuperSonic Imagine General Electric Mindray proposed generalized deep learning radiomics elastography model integrated elastographic image liver stiffness measurement trained tested stratified internal external datasets total 1937 patient 9472 2DSWE image included statistical analysis Compared 2DSWE model achieved higher area receiver operating characteristic curve AUC 089 v 083 P  0025 also achieved highly consistent diagnosis across subanalyses P values 021091 whereas 2DSWE exhibited different AUCs country region P  0001 etiology P  0005 subanalyses manufacturer subanalysis P  024 model demonstrated accurate robust performance noninvasive cACLD diagnosis 2DSWE across different country regions etiologies manufacturers",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40813740/"
    },
    {
        "pmid": "40813475",
        "title": "Segmental Yttrium-90 Radioembolization with Day-of-Calibration Resin Microspheres: Durable Transarterial Ablation for Solitary Hepatocellular Carcinoma.",
        "abstract": "Several recent study report safety efficacy resin yttrium90 radiation segmentectomy localized hepatocellular carcinoma Data informing tumor dose angiosome dose spheresmL required ablativeintent resin radioembolization incomplete safety efficacy dosimetry explant pathology radiation segmentectomy dayof calibration DOC sphere reported Patients identified tertiary care institution received radiation segmentectomy DOC resin 10year period PostY90 dosimetry performed Medical Image Merge MIM Software Imaging response 30day toxicities explant pathology duration response overall survival analyzed Associations dosimetric variable durable response tested receiver operator characteristic Wilcoxon odds ratio analyses Twenty tumor 20 patient treated median size 26 range 1463 cm Fifteen patient 75 male median age 68 range 4888 years Seventeen patient 85 Child cirrhosis 12 hepatitis C 1520 AlBi grade 2 Sixteen singlevessel four doublevessel split dose treatment reached stasis 1724 71 infusions Median tumor angiosome dose 263 range 83649 139 31392 Median lowest dose portion treated tumor 147 29299 Gy Median tumor sphere concentration 79 k 23206 k spheresmL Local modified REsponse Evaluation Criteria Solid Tumors mRECIST response rate 18 90 complete 16 durable one partial response one stable disease Two patient experienced adverse events one grade 3 grade 2 Median followup 20 range 4126 months Median duration response 47 months Median overall survival    94 month without censoring patient transplant six explants demonstrated complete pathologic necrosis Smaller tumor volume associated durable complete response AUC 096 infusion stasis OR 18 95 CI 119 271 Smaller tumor volume lower angiosome dose associated stasis p  0013 0035 Dayof calibration resin segmentectomy treating stasis safe may yield highly durable ablative outcome HCC 3 cm diameter lower dos recommended glass precalibrated resin Y90 Use sphere higher dose target likely warranted larger tumors",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40813475/"
    },
    {
        "pmid": "40812556",
        "title": "Fufang Epimedium formula alleviates acute liver injury through dual modulation of PI3K/AKT/Bcl-2 anti-apoptotic signaling pathway and cGAS-STING-IRF3 anti-inflammatory signaling pathway.",
        "abstract": "Fufang Epimedium formula FEF empirical formulation utilized Traditional Chinese Medicine treatment hepatitis B acute liver injury ALI clinical settings far hepatoprotective property underlying mechanism action FEF remain inadequately understood explore effect mechanism FEF treatment ALI Firstly acute oral toxicity FEF extract evaluated using maximum single dose Following 7day pretreatment optimized dos FEF intraperitoneal injection lipopolysaccharide combined  galactosamine administered induce ALI mice component FEF extract well absorbed serum ALI mouse identified using UHPLCQTOFMSMS Subsequently potential active components key target signaling pathway associated FEFs treatment ALI uncovered utilizing network pharmacology conjunction molecular docking effect FEF ALI mice including reduction aminotransferase levels inflammation oxidative stress liver pathology assessed using biochemical assays ELISA kits hematoxylin eosin staining Furthermore mechanism action including inhibiting apoptosis modulating key protein associated PI3KAKTBcl2 cGASSTINGIRF3 pathways confirmed TUNNEL Western blot immunohistochemical assays single oral administration FEF maximum dose 176 gkg result acute toxicity mouse 14day period 479 component FEF extract 138 prototype component ALI mouse serum identified primary component showed binding energy lower 44 kcalmol interacting key target proteins Importantly FEF treatment improved pathological structure damaged liver markedly reduced ALT AST MDA levels increased GSH SOD CAT levels decreasing TNFα IL1β IL6 level ALI mice Furthermore FEF treatment markedly suppressed hepatocyte apoptosis characterized fewer TUNELpositive cells inhibited expression caspase3 PARP enhanced phosphorylation PI3K AKT well increased Bcl2Bax ratio Notably FEF treatment also significantly downregulated cGAS STING expressions suppressed phosphorylation TBK1 IRF3 result confirm FEF exerts hepatoprotective effect reducing aminotransferase levels countering oxidative stress suppressing inflammation preventing apoptosis effect mechanistically linked dual modulation PI3KAKTBcl2 antiapoptotic cGASSTINGIRF3 antiinflammatory pathways finding provide scientific foundation clinical translation FEF future development targeted therapy ALI",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40812556/"
    },
    {
        "pmid": "40811846",
        "title": "Updated hepatitis C modelling in Aotearoa New Zealand: a lower burden, but clearer elimination targets.",
        "abstract": "Aotearoa New Zealand progress toward elimination hepatitis C HCV public health threat 2030 updated national modelling provides clearer understanding remaining disease burden treatment targets Using Centre Disease Analysis Foundations Bright model revised earlier estimate reflect declining incidence among people inject drugs treatment uptake new seroprevalence data model estimate approximately 18000 people living viraemic HCV 2023 significantly fewer prior estimates still representing substantial public health challenge Current treatment rate around 450 people per year fall short needed meet World Health Organization target 2030 model suggests treating 1300 people annually required innovative approach expanded access priority groups broader general population strategy may necessary recalibrated model highlight urgency scaling testing improving diagnosis establishing operational target achieve elimination",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40811846/"
    },
    {
        "pmid": "40810901",
        "title": "The characteristics of drug users in rehabilitation centers in the West Bank, Palestine: A retrospective descriptive study.",
        "abstract": "Drug abuse pressing global public health issue West Bank Palestine societal stigma around substance use obstructs open conversation precise evaluations underscoring importance thorough assessment drug user rehabilitation facilities study aimed explore epidemiology drug abuse among Palestinian patient rehabilitation center treatment modality employed study examined 1141 medical file patient aged 1473 year two rehabilitation centers covering period 2014 2023 majority 7367 young adult 1839 years tobacco smoker 973 alcohol user 443 Additionally 82 patient diagnosed various infections primarily hepatitis C patient sought treatment voluntarily 782 entering center selfreferral commonly detected substance urine sample cannabis 352 morphine 388 benzodiazepine 328 ecstasy 21 Furthermore 3537 patient prescribed carbamazepine 3071 received methadone 613 struggling adhere prescribed regimens relapse rate high 825 62 patient experiencing three relapses key factor contributing relapse included peer influence withdrawal symptoms analysis treatment modality employed highlighted comprehensive integration pharmacotherapy psychotherapy social support systems emphasizing holistic approach recovery insight derived study aim inform policymakers healthcare provider specific need drug user rehabilitation ultimately contributing enhancement treatment strategy public health initiative region",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40810901/"
    },
    {
        "pmid": "40810215",
        "title": "Treatment Discontinuation and Adherence in Patients With Chronic Hepatitis B Infection Newly Initiating Nucleos(t)ide Analogues in Japan: A Retrospective Cohort Study.",
        "abstract": "Nucleostide analogue NA therapy current standard care chronic hepatitis B CHB virus infection rarely achieves functional cure necessitating longterm therapy often lead nonadherence increased treatment burden retrospective cohort study designed describe treatment discontinuation adherence secondgeneration NAs among patient CHB Japan used Japanese Medical Data Center Claims Database JMDC Inc identify adult CHB newly initiated singleagent secondgeneration NA January 2007 August 2023 Outcomes included treatment discontinuation adherence treatment restart discontinuation NA switching factor associated treatment discontinuationadherence 2473 patient included study mean age 499 years 656 male common index NAs entecavir 555 tenofovir alafenamide fumarate TAF 362 Treatment discontinuation observed 203 patients mean time discontinuation 204 months patient discontinued 507 restarted NAs Mean adherence proportion day covered PDC 087 812 participant PDC ≥ 80 Age group 3564 years index treatment TAF baseline hepatocellular carcinoma diagnosis significantly associated decreased probability treatment discontinuation nonadherence Although high proportion patient persistent adherent NA treatment subgroup patient whose need met receiving NA treatment particularly younger age groups result emphasise need alternative therapy shorter finite treatment duration improve patient persistence adherence outcomes",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40810215/"
    },
    {
        "pmid": "40810105",
        "title": "Navigating liver toxicity in the age of novel oncological agents.",
        "abstract": "advent novel oncological therapies including immune checkpoint inhibitors antibodydrug conjugates protein kinase inhibitors revolutionised cancer treatment significantly improving patient survival across range malignancies However advance accompanied emergence new often unpredictable adverse events among hepatotoxicity represents growing clinical challenge review provide comprehensive synthesis current knowledge liver injury associated three key class oncological agents particular focus mechanism action hepatotoxicity clinical presentation management strategies Given expanding use agents monotherapies combination regimens topic pressing relevance hepatologists oncologist alike combination therapy become increasingly common complexity drugliver interaction implication patient safety demand greater interdisciplinary awareness collaboration review advocate pragmatic approach management druginduced liver injury patient cancer underscoring critical need balance hepatic preservation imperative maintaining oncological efficacy uniquely vulnerable population addressing emerging area clinical importance aim stimulate research oncological hepatotoxicity phenomenon poised become increasingly prevalent routine clinical practice",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40810105/"
    },
    {
        "pmid": "40808966",
        "title": "Safety and efficacy of GST-HG141, a novel HBV capsid assembly modulator, for the treatment of chronic hepatitis B patients with low-level viremia: a randomized, double-blind, placebo-controlled, multicenter phase II study.",
        "abstract": "Chronic hepatitis B CHB remains major global health challenge curative therapies Approximately 1540 patient treated current standardofcare antiviral therapy nucleostide analog NUCs including entecavir ETV tenofovir TDFTAF fail fully suppress serum HBV DNA resulting persistent lowlevel viremia LLV associated increased risk cirrhosis liver failure hepatocellular carcinoma GSTHG141 novel HBV capsid assembly modulator previously demonstrated favorable safety antiviral activity Phase Ib study offering promising approach LLV management CHB patients Phase II randomized doubleblind placebocontrolled multicenter trial evaluated efficacy safety GSTHG141 CHB patient LLV registered ClinicalTrialsgov NCT05637541 Clinical Trial Registry GSTHG141II02 January 2023 July 2024 144 patient screened across ten research center China 90 eligible participant enrolled participant NUC therapy one year serum HBV DNA level 20 2000 IUmL ALT ≤5 × ULN Patients randomized 111 receive lowdose GSTHG141 50 mg BID ini  30 highdose GSTHG141 100 mg BID ini  30 placebo ini  30 administered orally 24 weeks primary endpoint proportion participant achieving serum HBV DNA level lower limit detection 20 IUmL Week 24 Secondary endpoint included change HBV DNA level virological marker baseline 4week followup phase assessed safety sustained virologic response total 89 patient received least one dose study medication enrolled Among them eighty patient completed treatment included perprotocol analysis 25 lowdose group 27 highdose group 28 placebo group GSTHG141 significantly reduced serum HBV DNA level CHB patient suboptimal response prior NUC therapy week 24 840 patient lowdose group 815 highdose group achieved HBV DNA 20 IUmL compared 321 placebo group ipi  005 treatment group vs placebo Mean HBV DNA reduction exceeded 1 logsub10sub IUmL GSTHG141groups Additionally pregenomic RNA pgRNA level also declined average 17 logsub10sub copiesmL 60 55 participant low highdose groups respectively achieving undetectable pgRNA compared 95 placebo group Safety profile favorable good tolerability comparable adverse event across groups GSTHG141 administered orally 50 100 mg BID safe welltolerated highly effective suppressing residual HBV DNA pgRNA level CHB patient LLV result support development GSTHG141 novel therapeutic option CHB patient inadequately responding conventional NUC treatment work supported Fujian Akeylink Biotechnology Co Ltd",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40808966/"
    },
    {
        "pmid": "40806558",
        "title": "Unravelling the Viral Hypothesis of Schizophrenia: A Comprehensive Review of Mechanisms and Evidence.",
        "abstract": "Schizophrenia challenging multifactorial neuropsychiatric disease involves interaction genetic susceptibility environmental insults Increasing evidence implicates viral infection significant environmental contributors particularly sensitive neurodevelopmental periods review synthesis current finding viral hypothesis schizophrenia encompassing wide array neurotropic viruses including influenza viruses herpesviruses HSV1 2 CMV VZV EBV HHV6 8 hepatitis B C viruses HIV HERVs HTLV Zika virus BoDV coronaviruses including SARSCoV2 others pathogen contribute schizophrenia mechanism direct microinvasion persistent central nervous system infection immunemediated neuroinflammation molecular mimicry disturbance bloodbrain barrier Prenatal exposure viral infection trigger maternal immune activation resulting cytokinemediated alteration neurological development foetus persist adulthood Genetic study highlight role immunerelated loci including major histocompatibility complex polymorphisms modulating susceptibility infection neurodevelopmental outcomes Clinical data also support mild encephalitis hypothesis suggesting subset schizophrenia case involve lowgrade chronic neuroinflammation Although antipsychotic immunomodulatory effects adjunctive antiinflammatory therapy show promise particularly treatmentresistant cases Despite compelling associations pathogenspecific link remain inconsistent emphasising need longitudinal study integrative approach viromics unravel causal relationships review support multihit model viral infection interfere hereditary immunological susceptibilities enhancing schizophrenia risk Elucidating virusimmunebrain interaction may facilitate discovery biomarkers targeted prevention novel therapeutic strategy schizophrenia",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40806558/"
    },
    {
        "pmid": "40806504",
        "title": "Real-Time PCR-Based Detection of Hepatitis E Virus in Groundwater: Primer Performance and Method Validation.",
        "abstract": "Hepatitis E virus HEV leading cause acute viral hepatitis primarily transmitted via contaminated water food Groundwater may also serve potential vector HEV transmission study aimed optimize realtime polymerase chain reaction rtPCR detection HEV employing TaqMan probe SYBR Greenbased methods total 12 primer set TaqMan probebased method 41 primer set SYBR Greenbased method evaluated order identify optimal combinations Primer set 4 TaqMan probebased 21 SYBR Greenbased demonstrated highest sensitivity specificity successfully detecting HEV artificially spiked sample 1 fgμL TaqMan probebased method facilitated rapid detection minimized nonspecific amplification whereas SYBR Greenbased method allowed broader primer exploration leveraging melting curve analysis Despite absence HEV detection 123 groundwater samples study underscore value realtime PCR environmental monitoring pave way enhanced diagnostic tool public health applications",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40806504/"
    },
    {
        "pmid": "40806358",
        "title": "Exploring Cirrhosis: Insights into Advances in Therapeutic Strategies.",
        "abstract": "Cirrhosis remains significant global health burden responsible nearly 4 annual death worldwide Despite progress antiviral therapy public health measures prevalence plateaued particularly region affected viral hepatitis alcohol misuse metabolic syndrome review present comprehensive synthesis multifactorial driver cirrhosis including hepatocyte injury liver stellate cell activation immunemediated inflammation emphasis central role metabolic dysfunction characterized mitochondrial impairment altered lipid glucose metabolism hormonal imbalance systemic inflammation exacerbating disease progression current therapy may slow progression earlystage disease often ineffective reversing established fibrosis Emerging molecular strategy offer promising alternative targeting key pathogenic pathways include AMPK activator eg metformin AICAR FGF21 analogs mitochondriatargeted agent eg MitoQ urolithin A NAD precursors restore bioenergetic balance reduce oxidative stress approaches mesenchymal stem cell therapy inflammasome inhibition hormonal modulation aim suppress fibrogenesis restore liver homeostasis integration system biology multiomics profiling support patient stratification precision medicine review highlight shift toward mechanismbased intervention potential alter cirrhosis outcome improve patient survival",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40806358/"
    },
    {
        "pmid": "40805232",
        "title": "The Exposome Perspective: Environmental and Infectious Agents as Drivers of Cancer Disparities in Low- and Middle-Income Countries.",
        "abstract": "Cancer disparity low middleincome country LMICs arise multifaceted interaction environmental exposures infectious agents systemic inequities limited access care exposome framework encompassing totality nongenetic exposure throughout life offer powerful lens understanding disparities LMICs population disproportionately affected air water pollution occupational hazards oncogenic infections including human papillomavirus HPV hepatitis B virus HBV iHelicobacter pylorii iH pylorii human immunodeficiency virus HIV neglected tropical diseases schistosomiasis infectious agent contribute increased cancer susceptibility poor outcomes particularly immunocompromised individuals Moreover climate change food insecurity barrier healthcare access exacerbate risks review adopts populationlevel exposome approach explore environmental infectious exposure intersect genetic epigenetic immune mechanism influence cancer incidence progression LMICs highlight critical pathway linking chronic exposure inflammation tumor development evaluate strategy HPV HBV vaccination antiretroviral therapy environmental regulation Special attention given tool exposomewide association study ExWASs offer promise exposure surveillance early detection public health policy integrating exposomic insight national health systems especially region subSaharan Africa SSA South Asia LMICs advance equitable cancer prevention control strategies holistic exposomeinformed strategy essential reducing global cancer disparity improving outcome vulnerable populations",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40805232/"
    },
    {
        "pmid": "40805161",
        "title": "Late-Onset Immune-Related Adverse Events in Patients with Advanced Melanoma: The LATENT Study.",
        "abstract": "Immune checkpoint inhibitor significantly transformed treatment paradigm advanced melanoma leading substantial improvement survival outcomes However therapeutic success accompanied spectrum treatmentrelated adverse events increasingly recognised enduring nonreversible Whilst earlyonset immunerelated toxicity well characterized lateonset toxicities often emerging patient longterm disease control remain understudied frequently overlooked address knowledge gap conducted retrospective multicentre study three UK tertiary referral centres exploring immunerelated adverse event 246 patient melanoma received immune checkpoint inhibitor advanced setting defined lateonset immunerelated adverse event occurring least 3 month last cycle immune checkpoint inhibitors Although patient experienced earlyonset toxicity almost 15 patient developed lateonset immunerelated adverse events including skin rash colitis hepatitis arthritis among others often challenging manage necessitated use systemic steroids 2 patient presented ultralateonset toxicities defined event occurring least 12 month treatment completion study provides valuable insight characteristic lateonset immunerelated adverse events advance understanding lateonset toxicities dedicated prospective study needed assess risk factor associated development impact quality life Additionally translational research focused finding predictive biomarkers essential identify patient higher risk developing delayed adverse event understand best manage them",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40805161/"
    },
    {
        "pmid": "40803751",
        "title": "Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial.",
        "abstract": "SCG101 autologous Tcell therapy specifically targeting hepatitis B virus HBV using natural highaffinity Tcell receptor stably expressed evaluated safety pharmacokinetics pharmacodynamics efficacy SCG101 patient HBVrelated hepatocellular carcinoma HCC investigatorinitiated trial Six human leucocyte antigen HLAA0201positive serum hepatitis B surface antigen HBsAgpositive hepatitis B e antigennegative patient advanced HBVHCC failed one three prior systemic therapies received SCG101 dos 5×10sup7sup 1×10sup8sup TCRTsupsup cellskg three day lymphodepletion Within 1 week patient experienced significant transient alanine aminotransferase elevation paralleled 76±57 fold expansion cell detected peripheral blood neurotoxicity cytokine release syndrome reaching grade 3 observed However side effect doselimiting could managed corticosteroids antiinterleukin6 andor vasopressor therapy Indicating ontarget activity SCG101 serum HBsAg level dropped 196 016384 logsub10sub within 2 weeks According modified Response Evaluation Criteria Solid Tumours three six patient achieved tumour shrinkage best percentage change target lesion size 195 746 100 One showed complete remission target lesion remaining progressionfree 27 month one achieved durable 6 months remission followup median 109 months three patient died one lost followup monotherapy patient HBVHCC SCG101 demonstrated pronounced antiviral antitumour activity safety profile manageable supportive care SCG101s Tcell expansion serum HBsAg drop tumour response collectively underscore ontarget activity NCT05339321",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40803751/"
    },
    {
        "pmid": "40803709",
        "title": "Cytomegalovirus hepatitis after treatment with dostarlimab for colorectal cancer.",
        "abstract": "man early 40 receiving treatment rectal cancer dostarlimab immune checkpoint inhibitor ICI developed fevers headache nausea hospitalised elevated liver enzyme infectious workup revealed acute cytomegalovirus CMV infection concern dostarlimab therapy could contributing inflammatory response ICIinduced hepatitis patient underwent liver biopsy Pathology instead consistent CMV hepatitis patient treated antiviral therapy complete resolution illness case illustrates importance monitoring immunerelated adverse effect patient taking ICIs still maintaining broad differential diagnosis causes",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40803709/"
    },
    {
        "pmid": "40803501",
        "title": "Targeting ferroptosis restores the antiviral activity of CD8<sup>+</sup> T cells during chronic HBV infection.",
        "abstract": "CD8supsup cell play crucial role antiviral immunity however hepatitis B virus HBVspecific CD8supsup cell become dysfunctional chronic HBV CHB infection Blocking inhibitory pathway partially restores efficient antiviral responses suggesting mechanism underlying CD8supsup Tcell dysfunction complicated study aimed investigate whether HBVspecific CD8supsup cell undergo ferroptosis examine correlation Tcell dysfunction elucidate underlying mechanism potential intervention strategies Analysis CD8 cell CHB patient revealed ferroptosis marker via flow cytometry electron microscopy scRNAseq HBVspecific CD8supsup cell identified using HBVcore antigen peptideloaded MHC tetramer Flow cytometry scRNAseq additional experimental approach employed investigate ferroptosisassociated mechanism CD8supsup Tcell dysfunction Ferroptosis observed CD8supsup cell CHB patients indicated increased lipid peroxidation Fesup2sup accumulation mitochondrial atrophy particular HBVspecific CD8supsup cells Downregulation GPX4 upregulation CD36 found CD8supsup cell high level lipid peroxidation Furthermore ferroptosis accompanied impaired antiviral ability Mechanistically palmitic acid PA upregulates CD36 expression leading lipid accumulation elevated serum TGFβ1 CHB patient reduces GPX4 expression impairs antioxidant capacity factor synergistically promote ferroptosis dysfunction CD8supsup cells Treatment selenium liproxstain1 enhanced cytotoxic cytokine production CD8supsup cells subsequently improved antiviral efficacy vivo study demonstrates ferroptosis drive CD8supsup Tcell dysfunction chronic HBV infection Targeting ferroptosis pathway may offer novel therapeutic strategy restore antiviral immunity",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40803501/"
    },
    {
        "pmid": "40802985",
        "title": "CROI 2025: The Challenges of Sustaining Viral Suppression, Addressing Advanced HIV Disease, and Ending the HIV Epidemic Targets.",
        "abstract": "Important new data presented 2025 Conference Retroviruses Opportunistic Infections Mathematic model predicted reversal progress toward Ending HIV Epidemic metric funding discontinued Interventions improved HIV care outcome included clinicbased personcentered care intervention lowbarrier care clinic service delivery model Several study demonstrated varying trend hepatitis B C incidence outcomes data one trial showed seroprotective durability adjuvanted hepatitis B vaccine people HIV Focus continued longacting antiretroviral therapy ART including data promising new agent formulations Integrase strand transfer inhibitor InSTIs may effective real world despite baseline reverse transcriptase resistance although 2 study highlighted emergence mutation outside integrase genome contribute InSTI resistance data HIV maternal pediatric health included study aimed HIV testing counseling also covered drug interaction implant injectable hormonal contraceptive dolutegravirbased ART along selected pharmacokinetics safety data ART infant children Various abstract addressed weight gain cardiometabolic dysfunction youth perinatally acquired HIV woman HIV well health outcome child exposed HIV ART utero",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40802985/"
    },
    {
        "pmid": "40802699",
        "title": "Hepatitis A beyond childhood causing diagnostic and therapeutic challenges in Addis Ababa, Ethiopia.",
        "abstract": "Hepatitis acute viral infection liver caused hepatitis virus HAV acquired fecooral route highest incidence among four major acute viral hepatitis type A B C E usually occurs early childhood However prevalence acute hepatitis recently increased among teenager young adults usually misdiagnosed study emphasizes significance awareness among healthcare worker increasing incidence acute hepatitis among group ensure accurate diagnosis appropriate management hospitalbased retrospective crosssectional study employed Fiftyeight confirmed acute HAV patient visited Adera Medical Surgical Center AMSC August 2023 January 2024 enrolled Sociodemographic clinical laboratory parameter documented management data including hospitalization trial antibiotic treatment considering HAV course illness collected data entered analyzed using SPSS SPSS Version 260 sex ratio similar slight male predominance MF  107 mean age ± SD patient 193± 88 years Thirtynine 672 patient students patient Addis Ababa Vomiting 828 anorexia 707 yellowish discoloration eye 621 common presenting symptoms icteric sclera 44 759 epigastric tenderness 17 293 common physical findings half patient 552 initially misdiagnosed typhoid fever TF 468 peptic ulcer disease PUD 312 urinary tract infection UTI 156 patient recovered fully liver function test LFTs normalized supportive care within 24 weeks study revealed shift age HAV susceptibility subsequent infection towards adolescent young adult mean ± SD age 1931 ± 88 years cohort half patient 552 initially misdiagnosed TF PUD UTI causing diagnostic treatment challenges necessitates heightened awareness among healthcare worker public Early HAV diagnosis targeted laboratory investigation avoiding unnecessary antibiotic crucial effective management prevention via hygienic immunization strategies",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40802699/"
    },
    {
        "pmid": "40802610",
        "title": "Molecular surveillance of hepatitis E virus in wastewater in Yaoundé, Cameroon.",
        "abstract": "Hepatitis E virus HEV zoonotic pathogen mainly transmitted contaminated food water subSaharan countries highlighting need environmental surveillance study aimed assess burden molecular characterization HEV environmental wastewater communitybased surveillance conducted Yaoundé Cameroon using untreated wastewater sample collected monthly January December 2023 hospitals residential sewage systems markets plant watering points Molecular phylogeny performed sequence Open Reading Frame 1 region HEV detected 264 1972 sites prevalence ranging 83 112 hospital 417 512 residential area p  00022 19 positives HEV detection highest specific residential area 263 plant watering point 158 Detection rate significantly higher short dry season 368 long dry season 316 compared shortwet season 2105 longwet season 1053 p  0034 Phylogenetic analysis sequenced sample revealed detected HEV strain closely related Orthohepevirus C genotype C1 previously associated rodent rather classical human HEV genotypes finding raise important question possible zoonotic transmission densely populated urban areas first study report HEV detection genetic analysis wastewater Mfoundi Division Yaoundé second report Cameroon presence HEV community wastewater especially residential irrigation sites suggests widespread circulation potential environmental foodborne risks identification HEVC1like strain highlight possible role rodent transmission finding emphasize importance integrating wastewater surveillance public health strategy call research zoonotic source One Health lens",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40802610/"
    },
    {
        "pmid": "40802556",
        "title": "Deep-Learning-Aided Quantification of Steatohepatitis-Associated Pathological Findings in Liver Specimens.",
        "abstract": "Although semiquantitative scoring common method quantifying histopathological findings semiquantitative evaluation may lead error objectivity reproducibility depending histological findings developed deep learning model quantify steatohepatitisassociated pathological finding liver specimens Eighteen liver specimen steatohepatitis eight liver specimen chronic hepatitis used train AI convolutional neural network construct AI quantify steatohepatitisassociated pathological findings AI model measured percentage steatosis area Steatosis ballooning area Ballooning fibrosis area Fibrosis liver biopsy specimens Subsequently 233 patient underwent ultrasonography liver biopsy used validation Histological finding liver specimen evaluated three evaluator expertise liver pathology Steatosis Ballooning Fibrosis measured liver specimens patients Steatosis strongly correlated histological steatosis grade R  078 p  0001 ultrasound controlled attenuation parameter R  051 p  0001 liver tissue 47 nonalcoholrelated steatotic liver disease NASLD patients Ballooning correlated histological ballooning grade R  04 p  001 NASLD patients Fibrosis strongly correlated histological fibrosis stage R  072 p  0001 ultrasound shear wave elastography R  07 p  0001 Deeplearningaided pathology quantify steatohepatitisassociated pathological finding liver tissue specimens AI model tool used quantify steatohepatitisassociated pathological finding algorithm diagnose steatohepatitis",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40802556/"
    },
    {
        "pmid": "40802226",
        "title": "Synbiotics: An Emerging Frontier in Infectious Diseases Control.",
        "abstract": "human gut microbiome critical promoting human health many aspects like facilitating nutrient absorption digestion immune system regulation protecting pathogens Gut microbiota dysbiosis associated pathogenesis several infectious diseases context combination prebiotics probiotic synbiotics emerging popular approach managing immune gastrointestinal health Synbiotics exhibited considerable potency restoring eubiosis via modulating gut microbiome dietary supplementation synbiotics shown promising result treating infectious disease like hepatitis gastroenteritis dental caries sepsis Synbiotics antagonise pathogen maintaining gut microbiota homeostasis competing pathogenic microorganism adhesion nutrition producing antimicrobial compounds stimulating immunomodulatory cell vivo present article conceptualised understand potential synbiotics alternative adjunct antibiotic managing infectious diseases Furthermore elaborates different formulation synbiotics available clinical use mode action Challenges associated recent approach improve efficacy therapeutic also addressed",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40802226/"
    },
    {
        "pmid": "40800185",
        "title": "Functional cure in a child with chronic hepatitis B with rtM204I mutation through an atypical serological response: a case report.",
        "abstract": "rtM204I mutation commonly associated resistance nucleostide analog NA therapy hepatitis B virus HBV often resulting virological breakthrough treatment failure Owing unique immunological virological characteristic HBV achieving functional cure pediatric patient easier adults case involving concurrent drugresistant mutation rare 4yearold boy infected HBV mothertochild transmission experienced virological rebound HBV DNA 466×107 IUmL 12 month lamivudine LAM monotherapy Resistance testing revealed rtM204I mutation treatment regimen adjusted tenofovir disoproxil fumarate TDF combined pegylated interferon α2a PegIFNα2a 12 week treatment significant decline hepatitis B surface antigen HBsAg level accompanied positive antibody hepatitis B surface antigen antiHBs thus presenting atypical serological pattern double positivity HBsAg antiHBs week 24 HBsAg negative hepatitis B e antigen HBeAg remained positive demonstrating atypical serological pattern response dissociation whereby HBsAg disappeared HBeAg TDF combined PegIFNα2a administered week 36 resulting persistent HBsAg negativity significant increase antiHBs levels PegIFNα2a discontinued TDF monotherapy continued 10 months period HBsAg negativity antiHBs positivity maintained HBeAg became negative alanine aminotransferase level remained normal result indicate achievement functional cure case indicated child rtM204I mutation optimizing antiviral therapy combined PegIFNα2a achieve functional cure despite atypical serological response patterns Longacting interferon significant therapeutic value pediatric patient drugresistant mutations",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40800185/"
    },
    {
        "pmid": "40800168",
        "title": "A retrospective study of clinical characteristics and steroid therapy in immune checkpoint inhibitor-mediated hepatitis.",
        "abstract": "widespread clinical application immune checkpoint inhibitor ICIs immunemediated hepatitis IMH become increasingly prevalent study aim analyze clinical characteristics steroid treatment prognosis IMH patients providing evidence enhance safety ICIs clinical practice retrospective cohort study included tumor patient received ICI therapy Comprehensive analysis conducted explore factor influencing occurrence clinical characteristics prognosis IMH Tumor patient treated PD1PDL1 inhibitor enrolled study Patients stratified based occurrence severity IMH well administration glucocorticoid therapy investigate risk factor IMH development critical factor influencing IMH progression treatmentspecific outcomes 744 patients 341 458 developed IMH IMH significantly frequent female ipi  0001 younger patient ipi  0001 receiving ICIs targeted therapy ipi  0009 patient hepatocellular carcinoma HCC ipi  0001 gastric cancer ipi  0001 Coexisting hepatitis B ipi  0001 cirrhosis ipi  0005 fatty liver disease ipi  0028 also associated higher IMH risk Independent risk factor included female gender age 45 years HCC gastric cancer Younger patient likely develop severe IMH ipi  0003 Hepatocellular injury common type IMH across grades similar risk severe progression among different IMH types Glucocorticoid therapy improved outcome ipi  0011 particularly grade 34 IMH although significant difference outcome observed group receiving sufficient versus insufficient recommended doses Female gender younger age 45 years HCC gastric cancer independent risk factor IMH Younger patient likely develop severe IMH Glucocorticoid therapy beneficial particularly grade 34 IMH Early detection prompt intervention tailored management strategy may help mitigate progression improve outcomes",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40800168/"
    },
    {
        "pmid": "40799938",
        "title": "Detecting early kidney injury due to host-virus interaction response in treatment-naive CHB-a pilot study.",
        "abstract": "Clinical evidence suggests patient chronic hepatitis B CHB increased risk renal impairment due inflammation induced virushost interaction aimed evaluate validate set protein biomarkers singularly combination early detection subclinical kidney injury patient CHB naive antiretroviral therapy work part prospective crosssectional study 69 HBsAgpositive treatmentnaive patient CHB equal number agematched healthy volunteer considered diagnosis serum creatinine sCr urea alanine transaminase aspartate transaminase serum cystatinC sCysC serum neutrophil gelatinaseassociated lipocalin sNGAL serum FetuinA sFetA urinary interleukin18 binding protein uIL18BP urinary kidney injury molecule1 uKIM1 level determined significant elevation concentration three protein CHB cohort sCysC sNGAL uIL18BP ipi  00001 sFetA downregulated ipi001 compared control group receiver operating characteristic curve analysis revealed Area curve 0935 sCysC 0811 sNGAL improved 0984 four indicator combined panel discriminate onset renal injury incited inflammatory response CHB 971 sensitivity 913 specificity Additionally sCysC sNGAL differed significantly among phase CHB infection ipi005 novel noninvasive diagnostic screen expedient detecting inflammation early kidney injury rise sCr aid predicting renal outcome patient CHB",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40799938/"
    },
    {
        "pmid": "40799791",
        "title": "Hepatitis C Treatment Outcomes for Patients With Infective Endocarditis Treated by an Interdisciplinary Team.",
        "abstract": "Patients endocarditis often comorbid injection substance use risk hepatitis C virus HCV infection population may encounter several significant barrier treatment improve access treatment developed interdisciplinary collaboration specialty pharmacy University Kentucky endocarditis team conducted retrospective study evaluating treatment outcomes Beginning September 2021 endocarditis team worked specialty pharmacy connect inpatient endocarditis HCV expedited treatment coordinated outpatient followup Study investigator retrospectively reviewed data consisting patient demographic treatment outcomes September 2021 April 2024 64 patient infective endocarditis HCV identified median age 37 years 41 female 97 history injection drug use Upon discharge 75 48 64 initiated treatment Treatment completed 69 33 48 patients main reason discontinuation included loss followup n  10 medication side effect n  3 Sustained virologic response 12 week achieved 42 n  20 patient initiated treatment 31 patients Among 22 patient available laboratory result 12 week posttreatment 91 n  20 HCV RNA negative Despite effort promoting expedited treatment interdisciplinary coordination care sustained virologic response rate patient endocarditis HCV infection remained 40 research required determine intervention starting therapy inpatient stay immediately upon discharge dispensing entire course medication improve treatment outcomes",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40799791/"
    },
    {
        "pmid": "40799641",
        "title": "The role of HLA-G in primary biliary cholangitis and response to therapy.",
        "abstract": "Primary biliary cholangitis PBC rare autoimmune liver disease involving bile duct damage fibrosis study explores role HLAG immunomodulatory molecule crucial immune tolerance PBC pathogenesis treatment cohort 166 PBC patient Sardinia compared 180 healthy control 205 autoimmune hepatitis type 1 AIH1 patients Plasma soluble HLAG sHLAG levels iHLAGi alleles i3UTRi haplotype analyzed alongside clinical data including therapy response ursodeoxycholic acid UTR1 haplotype significantly frequent PBC patient control 482 v 343 Pc 00018 extended haplotype iHLAG01010108UTR1i also strongly associated PBC 232 v 125 controls Pc  0008 232 v 66 AIH1 Pc 26×10sub9sub PBC patient exhibited lower sHLAG level compared control AIH1 91 UmL v 2403 UmL 139 UmL respectively Among iUTR1i carriers sHLAG level particularly reduced PBC patients iHLAG01010108UTR1i haplotype correlated lowest sHLAG level poorer therapy response 60 v 241 P  00001 finding suggest HLAG variants especially iHLAG01010108UTR1i potential biomarkers PBC prognosis treatment outcomes",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40799641/"
    },
    {
        "pmid": "40799509",
        "title": "MVA-HBVac-A novel vaccine vector that allows pan-genotypic targeting of hepatitis B virus by therapeutic vaccination.",
        "abstract": "Therapeutic vaccination hold promise cure chronic hepatitis B virus HBV infection hypothesize B cell CD4 CD8 cell response necessary overcome HBVspecific immune tolerance chronic infection accompany rare spontaneous resolution chronic HBV infection Therefore designed heterologous primeboost vaccine iTherVacBi viruslike particle vaccination stimulates B helper CD4 cell prime cytotoxic effector CD8 cell vector boost expands cell response Here report generation characterization novel modified vaccinia virus Ankara MVAbased vector MVAHBVac capable inducing strong multispecific cell response immunodominant epitope four different viral protein covering 95 HBV strain circulating worldwide MVAHBVac administered prime adjuvanted hepatitis B S coreantigens forming viruslike particles activated strong HBVspecific CD4 CD8 cell response major HBV antigen iin vivoi naive HBV carrier mice induced sustained antiviral effect different clinically relevant HBV genotypes data showed iTherVacBi regimen employing novel pangenotypic MVAHBVac vector could overcome HBVspecific immune tolerance lead initiation clinical trial evaluating therapeutic vaccine",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40799509/"
    },
    {
        "pmid": "40799443",
        "title": "Successful rechallenge of immune checkpoint inhibitors after severe immune-related hepatitis, thyroiditis and hypophysitis in TMB-high NSCLC: a case report.",
        "abstract": "Immune checkpoint inhibitor ICIs transformed cancer therapy frequently associated immunerelated adverse event irAEs complicate treatment decisions Patients experience severe irAEs often excluded immunotherapy due concern recurrence However rechallenging ICIs selected patient close monitoring may offer longterm benefits although evidence remains limited heterogeneous report case 65yearold man stage IVB pulmonary adenocarcinoma harboring iTP53i mutation high tumor mutational burden initially received pembrolizumabbased chemoimmunotherapy developed grade 4 hepatitis requiring immunosuppressive treatment discontinuation ICIs Subsequent tumor progression led rechallenge ICIs alongside prophylactic tocilizumab Although patient experienced grade 2 thyroiditis grade 2 hypophysitis toxicity manageable hormone replacement corticosteroids pacemaker implanted unrelated sick sinus syndrome Despite intermittent symptoms pembrolizumab monotherapy maintained prolonged period achieving durable tumor control progression noted 4year followup case highlight ICI rechallenge viable effective treatment strategy selected patient prior highgrade irAEs especially initial toxicity well controlled alternative cause symptom carefully excluded prophylactic use agent like tocilizumab may reduce risk irAE recurrence underscore need individualized riskbenefit assessment close clinical monitoring rechallenge scenarios",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40799443/"
    },
    {
        "pmid": "40797383",
        "title": "Immune deficiency due to SARS-CoV-2 infection in a child with GATA2-mutated AML: A case report.",
        "abstract": "Mutations guanineadeninethymineadenine 2 GATA2 gene lead immunodeficiency haematological diseases including acute myeloid leukaemia AML Severe acute respiratory syndrome coronavirus 2 SARSCoV2 infection reported impair immune function effect GATA2 mutation carrier remain unclear study report rare case persistent immunodeficiency child AML GATA2 mutation SARSCoV2 infection emphasizing role viral infection immune dysfunction patients 9yearold AML patient developed fever cough persistent immunodeficiency recurrent severe infection SARSCoV2 infection haematological remission patient diagnosed AMLM2 germline GATA2 mutation chemotherapy achieved haematological remission SARSCoV2 infection showed significant immunodeficiency manifestation recurrent infections patient received combined chemotherapy based CALSIIIAML18 achieved haematological remission SARSCoV2 infection comprehensive treatment  example antiviral Paxlovid antibacterial antifungal hormonal therapy  used support immune function patient completed HLA matching allogeneic hematopoietic stem cell transplantation scheduled undergo transplantation Despite various immune support treatment SARSCoV2 infection patient still persistent immune deficiency recurrent infection eg pneumonia hepatitis B patient currently stable waiting hematopoietic stem cell transplantation AML patient GATA2 mutation achieve remission SARSCoV2 infection may still trigger severe persistent immunodeficiency leading serious infection affecting prognosis Therefore early identification GATA2 mutation early implementation hematopoietic stem cell transplantation key improving prognoses",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40797383/"
    },
    {
        "pmid": "40795893",
        "title": "Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries with the Highest Adult HIV Prevalence.",
        "abstract": "Expanded access dolutegravir part fixeddose combination tenofovir disoproxil fumarate lamivudine TLD revolutionized global HIV treatment 25 million people prescribed regimen 2024 reviewed national clinical guideline management virologic failure firstline TLD 50 country highest prevalence HIV among adults recent guideline available online four Among remaining 46 country guidelines identified four distinct approaches 1 empiric switch protease inhibitor PIbased regimen without genotypic resistance testing GRT n28 61 2 GRT guide antiretroviral therapy selection n14 30 3 continuation TLD without GRT n3 7 4 empiric switch PIbased regimen concurrent GRT n1 2 diversity guidelineendorsed approach underscore critical need additional data inform policy regarding important clinical scenario",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40795893/"
    },
    {
        "pmid": "40795873",
        "title": "Sofosbuvir/Velpatasvir Concentrations in the Breastmilk of Postpartum Women with Opioid Use Disorder Receiving Treatment for Hepatitis C Virus: a pharmacokinetic study.",
        "abstract": "breastmilk pharmacokinetic study woman undergoing hepatitis C virus treatment sofosbuvirvelpatasvir sofosbuvir GS331007 sofosbuvir metabolite velpatasvir concentration breast milk 13 12 41 maternal plasma concentrations respectively estimated infant daily dose breastmilk 1 weightadjusted dose children",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40795873/"
    },
    {
        "pmid": "40794751",
        "title": "Non-negligible risk of HBV reactivation among rheumatoid arthritis patients receiving JAK inhibitors: bridging the evidence gap.",
        "abstract": "Hepatitis B virus HBV reactivation critical concern patient autoimmune disease undergoing immunosuppressive therapy Despite data HBV reactivation risk associated biologics impact new targeted immunosuppressive agentsJanus kinase inhibitor JAKi  remains unclear study aimed evaluate risk HBV reactivation among rheumatoid arthritis RA patient treated JAK inhibitors compared receiving TNF inhibitor rituximab conducted retrospective analysis RA patient treated National Taiwan University Hospital 2015 2023 Patients available baseline HBV status HBsAg antiHBc antiHBs HBV DNA received TNF inhibitors rituximab JAKi tofacitinib baricitinib upadacitinib included primary outcome hepatitis flare HBsAgpositive patient HBsAg seroreversion HBsAgnegativeantiHBcpositive patients included 35 HBsAgpositive patient 339 patient resolved HBV infection HBsAgnegativeantiHBcpositive Among resolved HBV infection reactivation risk low TNF inhibitor 09 281000 personyears higher rituximab 32 1511000 personyears JAKi overall 29 1031000 personyears Among individual JAK inhibitors upadacitinib highest incidence 65 4281000 personyears followed baricitinib 47 1921000 personyears tofacitinib 10 271000 personyears Among HBsAgpositive patients 50 JAKi user developed hepatitis flare emphasizing importance vigilant monitoring prophylaxis finding reveal nonnegligible risk HBV reactivation among RA patient receiving JAKi therapy particularly JAK1selective JAKi Larger registry prospective study needed validate findings",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40794751/"
    },
    {
        "pmid": "40793974",
        "title": "Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment.",
        "abstract": "Tenofovir alafenamide TAF shown noninferior efficacy tenofovir disoproxil fumarate TDF superior bone renal safety characterise 5year TAF efficacy safety patient East Asian ethnicity pivotal Phase 3 studies Patients randomised 21 receive TAF TDF 3 year doubleblind treatment followed openlabel TAF Patients either continued TAF switched TDF TAF Week 96 TDF → TAF 3 years Week 144 TDF → TAF 2 years treatment Efficacy endpoint virologic biochemical serologic safety assessed Among 591 patient East Asian ethnicity TAF n  401 TDF → TAF 3 years n  84 TDF → TAF 2 years n  106 high rate virologic control achieved 89 94 92 respectively Year 5 missing  failure analysis Year 5 rate alanine aminotransferase normalisation 85 90 78 hepatitis B e antigen loss 36 43 44 similar Following switch TDF TAF change fasting lipid parameter consistent removal known lipidlowering effect TDF However change total cholesterol highdensity lipoprotein ratio marker cardiovascular risk minimal comparable group Year 5 Renal bone parameter improved switching 5 years rate virologic suppression high East Asian patient treated TAF switched TDF TAF TAF TDF well tolerated improved renal bone safety observed patient switching TDF TAF",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40793974/"
    },
    {
        "pmid": "40793828",
        "title": "Regulation of viral hepatitis by N6-methyladenosine RNA methylation.",
        "abstract": "Recent study shown presence RNA modification N6methyladenosine msup6supA viral RNAs infection significantly impact outcome viral replication pathogenesis particular various function msup6supA elucidated hepatitis B virus HBV hepatitis C virus HCV hepatitis delta virus HDV viral infection msup6supA methylation directly affect replication virus also regulates diverse cellular RNAs control pathogenesis review aim explore function msup6supA modification infectious process pathogenesis HBV HCV HDV Understanding role msup6supA methylation viral life cycle essential elucidating pathogenesis developing novel therapeutic strategy HBV HCV HDV infections",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40793828/"
    },
    {
        "pmid": "40791485",
        "title": "Discovery of Inhibitors Targeting the RNA-Dependent RNA Polymerase of the Zika Virus.",
        "abstract": "Zika virus ZIKV Orthoflavivirus linked several neurological developmental diseases remains significant global health threat treatment vaccine currently available study optimized malachite green colorimetric assay previously used measure RNAdependent RNA polymerase RdRp activity hepatitis C foot andmouth disease viruses applied assay identify inhibitor ZIKV RdRp enzyme essential viral replication Inhibitor screening conducted using 204 compound Natural Product Set IV National Cancer Institute Developmental Therapeutics Program identified two compounds purpurogallin digallic acid inhibitor ZIKV RdRp Future study characterize potency elucidate mechanism action compounds",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40791485/"
    },
    {
        "pmid": "40790753",
        "title": "Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D.",
        "abstract": "Viral hepatitis pose considerable risk public health Among five hepatitis viruses hepatitis B C virus particular concern due high rate chronic infection significant global disease burden World Health Organizations Global Health Sector Strategy introduced 2016 seek eradicate viral hepatitis public health issue 2030 aiming 90 decrease new infection 65 drop fatality rates Currently several preventive therapeutic intervention effectively halt progression disease advanced stage Nevertheless forthcoming therapy must prioritize safety effectively manage viral progression timely manner Enhanced understanding molecular immunological mechanism underlying hepatitis viruses infection would facilitate formulation effective treatment strategies review summarizes pathogenesis viruses explores prevention strategy vaccination public health measures discusses current emerging treatments Emphasizing ongoing global effort future directions review highlight critical need sustained international collaboration achieve eradication chronic viral hepatitis",
        "mesh_terms": [
            "Humans",
            "Antiviral Agents",
            "Hepatitis B virus",
            "Hepatitis C",
            "Hepatitis B",
            "Hepatitis D",
            "Hepacivirus",
            "Global Health",
            "Hepatitis Delta Virus"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40790753/"
    },
    {
        "pmid": "40790556",
        "title": "Dynamic changes in liver stiffness measurement by 2D shear-wave elastography predict hepatocellular carcinoma in patients with chronic hepatitis B and well-controlled viremia: a retrospective study.",
        "abstract": "Antiviral treatment reduces eliminate risk hepatocellular carcinoma HCC patient chronic hepatitis B CHB Predicting HCC risk population remains challenging study aimed use dynamic change liver stiffness measurement LSM obtained using twodimensional 2D shearwave elastography SWE predict HCC patient noncirrhotic cirrhotic CHB wellcontrolled viremia retrospectively enrolled 303 patient CHB 45 patient cirrhosis wellcontrolled viremia hepatitis B virus DNA  100 IUmL ≥ 6 months antiviral treatment Patients followed every 36 month two twelve reliable LSMs using 2D SWE Clinical laboratory variables single LSM change two LSMs dynamic LSM change analyzed using least absolute shrinkage selection operator multivariable Cox regression analysis identify risk factor HCC Dynamic LSM change classified sustained low LSM all LSMs ≤ 81 kPa unstable LSM LSM ≤ 81 kPa least  81 kPa least once sustained high LSM all LSMs  81 kPa Among 303 patients 27 developed HCC multivariable analysis sustained high LSM dynamic LSM change HR  11624 95 CI 424131861 P  0001 compared sustained low LSM older age HR  1046 95 CI 10091084 P  0013 independently predicted HCC novel model combining age dynamic LSM change achieved Cindex 0845 internal validation demonstrating reliable agreement predicted observed probability HCC development novel model showed better performance noncirrhotic patient Cindex 0860 whereas Cindex 0634 cirrhotic patients Dynamic LSM change predict HCC patient CHB wellcontrolled viremia especially noncirrhotic patients",
        "mesh_terms": [
            "Humans",
            "Carcinoma, Hepatocellular",
            "Elasticity Imaging Techniques",
            "Hepatitis B, Chronic",
            "Liver Neoplasms",
            "Retrospective Studies",
            "Female",
            "Male",
            "Middle Aged",
            "Viremia",
            "Adult",
            "Liver Cirrhosis",
            "Liver",
            "Antiviral Agents",
            "Risk Factors",
            "Predictive Value of Tests",
            "Aged",
            "DNA, Viral",
            "Hepatitis B virus"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40790556/"
    },
    {
        "pmid": "40789459",
        "title": "Antihyperlipidaemic activity by flavonoids from the aerial part of Rhinacanthus nasutus.",
        "abstract": "Rhinacanthus nasutus known traditional medicine treatment fungal infections viral hepatitis skin disease Zhuang nationality Guangxi study eleven known flavonoid isolated aerial part R nasutus structure compound determined spectroscopic methods including 1D NMR ESIMS knowledge first instance documenting identification compound 111 plant isolated flavonoid evaluated antihyperlipidemic 16hydroxy2methoxy2″2″dimethylpyrano5″6″34234methylenedioxyphenyl12ethanedione 3 derrubone dimethyl ether 4 robustinmethylether 5 57dimethoxy63 methyl2butenyl 34methylenedioxy isoflavone 6 exhibited certain lipidlowering activity",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40789459/"
    },
    {
        "pmid": "40789194",
        "title": "Prevalence and severity of depression in patients with chronic viral hepatitis in Kazakhstan.",
        "abstract": "Depression common issue among patient chronic viral hepatitis Living chronic hepatitis create chronic stress known risk factor developing exacerbating depression stress related concern health effectiveness treatment social implication illness Neuropsychological scale assessment objectively measure severity depression mental health issue patients presence depression studied 233 patient chronic viral hepatitis treated Infectious Disease Hospital Shymkent Regional Hepatology Centre Shymkent period March 2021 January 2022 patient examined using Hamilton Depression Rating Scale HDRS identify presence depression 233 patient chronic viral hepatitis 383 mild depressive disorder 27 patient score indicating moderate depressive disorder 27 patient found major depressive disorder Multivariate analysis showed older age form chronic viral hepatitis higher viral load female gender strongly associated depression Depression common manifestation patient chronic viral hepatitis lead cognitive impairment difficulty concentration memory problems decreased executive function context chronic hepatitis may already affect liver function metabolic processes untreated depression exacerbate cognitive deficits",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40789194/"
    },
    {
        "pmid": "40789095",
        "title": "The Principle of Double Effect and Organ Donors with Hepatitis C.",
        "abstract": "AbstractSolid organ transplant save lives demand transplantable organ outpaces supply Traditionally organ patient infected Hepatitis C virus HCV ineligible donation recipient without HCV HCV DR transplants owing concern intentionally transmitting HCV organ recipients New directacting antiviral HCV increased HCV organ opioid epidemic promised solve organ shortage 2017 American Society Transplantation argued HCV DR transplant ethically permissible maximize transplantable organs utilitarian argument suffers flaw inherent utilitarianism could made obsolete resolving organ supplydemand mismatch better argument ethical HCV DR transplant arises principle double effect PDE good effect prolonging life transplantation outweighs evil effect infecting recipient HCV PDE provides ethical grounding HCV DR transplant creates better informed consent discussions",
        "mesh_terms": [
            "Humans",
            "Hepatitis C",
            "Tissue Donors",
            "Tissue and Organ Procurement",
            "Organ Transplantation",
            "Antiviral Agents",
            "Informed Consent",
            "Ethical Theory",
            "Hepacivirus",
            "United States"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40789095/"
    },
    {
        "pmid": "40788553",
        "title": "Therapeutic evaluation of bone marrow mesenchymal stem cells for hepatitis virus infection: immunoregulation, anti-inflammatory effects, and clinical potential - a systematic review.",
        "abstract": "One kind stem cell essential regenerative medicine mesenchymal stem cell MSCs common chronic viral infectious disease world viral hepatitis characterized potentially fatal liver inflammation brought hepatitis virus infection liver cells Hepatitis B virus HBV infection spread horizontally via contaminated blood vertically from mother child Hepatitis C Virus HCV main cause chronic liver disease mainly spread sharing needles receiving unsterilized blood transfusions intercourse contaminated blood study employ systematic review design using PRISMA method screening 19 journal based specific inclusion exclusion criteria Exosomes umbilical cord MSCs UCMSCs effectively suppressed interleukin 1β interleukin 6 transforming growth factor β1 vitro liver fibrosis model inhibited LX2 activation reducing extracellular matrix protein COL αSMA bone marrow MSC BMMSC group showed significantly higher 24week survival rate standard medical therapy SMT group MSCs secrete key antiinflammatory cytokine mediating immunomodulatory effect supporting regeneration differentiation potential Pretreating MSCs various stimulus enhances therapeutic efficacy liver transplantation BMMSCs improve liver function reduce infections increase survival due immunomodulatory antiinflammatory properties allogeneic autologous BMMSC UCMSC transplant cause secondary liver cirrhosis related chronic hepatitis B strict monitoring necessary prevent side effect like carcinogenesis viral transmission MSCs also influence angiogenesis tumor cell secreting growth factors Bone Marrow Mesenchymal Stem Cells BMMSCs Umbilical Cord Mesenchymal Stem Cells UCMSCs demonstrate promising therapeutic efficacy viral hepatitis infection various mechanisms including immunomodulation antiinflammatory effects regenerative potential Vigilant monitoring adverse effect necessary ensure safety clinical use",
        "mesh_terms": [
            "Humans",
            "Mesenchymal Stem Cells",
            "Mesenchymal Stem Cell Transplantation",
            "Immunomodulation",
            "Exosomes",
            "Hepatitis, Viral, Human",
            "Liver Cirrhosis",
            "Bone Marrow Cells",
            "Cell Differentiation",
            "Anti-Inflammatory Agents"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40788553/"
    },
    {
        "pmid": "40788479",
        "title": "The impact of anti-HBc positivity on clinical outcomes and treatment response in immune thrombocytopenia.",
        "abstract": "Immune thrombocytopenia ITP autoimmune disorder characterized low platelet count due destruction platelet autoantibodies presence hepatitis B core antibody antiHBc marker previous occult hepatitis B virus HBV infection may influence clinical course treatment outcome ITP patients retrospective study investigated impact antiHBc positivity clinical outcome response treatment ITP patients total 116 patient ITP divided 2 groups antiHBc positive n  31 antiHBc negative n  85 Clinical data including platelet count diagnosis followup response corticosteroid treatment remission rate analyzed result indicated antiHBc positive patient significantly lower platelet count diagnosis p  0009 longer hospital stay p  0042 Additionally patient demonstrated lower complete response rate initial corticosteroid treatment 1 month p  0001 6 month p  0021 compared antiHBc negative patients however significant difference overall response durable response rate group 12 months risk relapse higher antiHBc positive patient p  0041 finding suggest antiHBc positivity may associated severe disease course reduced treatment efficacy ITP highlighting importance assessing hepatitis B serological marker managing ITP patients",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40788479/"
    },
    {
        "pmid": "40788226",
        "title": "Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data.",
        "abstract": "phase 3 ALLIANCE study bictegraviremtricitabinetenofovir alafenamide BFTAF dolutegravir plus emtricitabinetenofovir disoproxil fumarate DTG  FTDF achieved high rate HIV1 RNA suppression week 96 adult HIV1 hepatitis B virus initiating treatment NCT03547908 study quantify preexisting HIV1 resistance evaluate effect HIV1 virologic suppression describe postbaseline HIV1 resistance week 96 Preexisting HIV1 resistance assessed historical andor screening genotyping HIV1 RNA suppression 50 copy cmL week 96 assessed preexisting resistance category Postbaseline resistance assessed participant HIV1 RNA ≥200 cmL week 96 Primary nucleosidenucleotide reverse transcriptase inhibitor nonnucleoside reverse transcriptase inhibitor protease inhibitor resistance substitution present baseline 4 17 19 79 5 21 241 participants respectively Virologic suppression rate high irrespective preexisting primary resistance substitutions including M184I Six participant 3 per group confirmed HIV1 RNA ≥200 cmL resuppress 50 cmL study drugs none 5 postbaseline resistance data treatmentemergent primary resistance substitutions One participant DTG  FTDF multiple virologic failure documented nonadherence pill count treatmentemergent K70E M184VI subsequently resuppressed people HIV1 hepatitis B virus treated firstline BFTAF DTG  FTDF preexisting HIV1 resistance uncommon affect virologic suppression treatmentemergent HIV1 resistance occurred BFTAF supporting high barrier resistance regimen",
        "mesh_terms": [
            "Adult",
            "Female",
            "Humans",
            "Male",
            "Middle Aged",
            "Adenine",
            "Alanine",
            "Anti-HIV Agents",
            "Dibenzocycloheptenes",
            "Drug Combinations",
            "Drug Resistance, Viral",
            "Drug Therapy, Combination",
            "Emtricitabine",
            "Hepatitis B",
            "Heterocyclic Compounds, 3-Ring",
            "Heterocyclic Compounds, 4 or More Rings",
            "HIV Infections",
            "HIV-1",
            "Oxazines",
            "Piperazines",
            "Pyridones",
            "Tenofovir",
            "Viral Load",
            "Amides"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40788226/"
    },
    {
        "pmid": "40788183",
        "title": "Clinical Evaluation of M1-c6v1 Oncolytic Virus Combined with Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma.",
        "abstract": "study evaluated safety tolerability preliminary efficacy M1c6v1 oncolytic virus combined immune checkpoint inhibitor ICIs camrelizumab vascular endothelial growth factor receptor 2 VEGFR2 inhibitor apatinib advanced hepatocellular carcinoma HCC singlearm investigatorinitiated openlabel clinical trial enrolled patient advanced HCC NCT04665362 Patients received M1c6v1 1×10⁹ CCID50 intravenously 5 day every 28 days camrelizumab 200 mg intravenously biweekly apatinib 250 mg orally daily Treatment continued 1 year disease progression intolerability withdrawal Primary endpoint safety tolerability secondary endpoint assessed efficacy based tumor response progressionfree survival PFS overall survival OS Thirteen patient enrolled 846 hepatitis B virus HBVrelated HCC 769 presenting tumor 10 cm treatment welltolerated 9215 adverse event AEs grade 1 2 common AEs included influenzalike symptom transient cytopenia viral shedding detected secretion excretion collected subjects 10 patient evaluable efficacy overall response rate ORR 70 710 7 partial response PR according mRECIST median OS PFS 154 89 month respectively combination M1c6v1 camrelizumab apatinib demonstrates acceptable safety profile promising efficacy advanced HCC",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40788183/"
    },
    {
        "pmid": "40787894",
        "title": "Author Response: Unpacking the 'Four-Support' Model: Towards Contextual Adaptation in HCV Care Cascade.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40787894/"
    },
    {
        "pmid": "40787473",
        "title": "Chronic viral hepatitis B: evaluation of the care of patients monitored at the SMIT in Tivaouane, Sénégal.",
        "abstract": "Chronic hepatitis B livertropic disease caused hepatitis B virus HBV hepatitis B surface antigen persisting beyond 6 months According 2024 report Pasteur Institute prevalence chronic HBV infection Senegal alarming ranking among highest world 10 17 Senegal currently standardized algorithm management chronic hepatitis B Since 2017 European Association Study Liver EASL proposed new classification chronic hepatitis B surveillance scheme objective evaluate management patient viral hepatitis B rural area according EASL criteria Retrospective prospective descriptive study analytical aim March 15 2022 December 7 2024 SMIT Mame Abdou Aziz Sy Dabakh hospital Tivaouane Included patient chronic hepatitis B benefited initial management assessment according criterion EASL Data captured using Kobocollect software encoded analyzed using R software V440 Ethical consideration respected collected 72 patients median age 34 year 2841 female predominance 569 Housewives 347 teacher 167 represented notion familial liver cancer 1667 reported 4167 first degree well second degree discovery HBV carriage made assessment initiated practitioner 639 prenatal assessment 19 blood donation 97 Nine patient 1251 symptomatic hepatitis B eantigen dosage negative 69 patient 9553 median alanine aminotransferase level 2310 IUl 163225 viral load 3795 IUml 371562 Two hepatitis virusHBV coinfections observed Fibrosis F0F1 found 825 cases F2F3 143 cirrhosis 32 Tenofovir disoproxil fumarate treatment initiated 10 patient 139 according 2017 EASL guidelines Ineligible patient 861 placed surveillance rate frequency depended initial phase Among patient lost followup 42 surveillance 6764 four treatment 40 Lack treatment high cost care main reason exclusion followup multivariate analysis factor significantly associated loss followup study highlight challenge managing chronic viral hepatitis B rural areas high cost monitoring lack treatment majority patient contribute loss followup",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40787473/"
    },
    {
        "pmid": "40787461",
        "title": "Immunological and clinical overlap between autoimmune gastritis and autoimmune liver diseases: a prospective cohort study.",
        "abstract": "Autoimmune gastritis AIG autoimmune liver disease AILDsincluding autoimmune hepatitis AIH primary biliary cholangitis PBC primary sclerosing cholangitis PSCare chronic organspecific immunemediated disorders condition frequently cooccur autoimmune diseases prevalence clinical overlap immunological association AIG AILDs remain underexplored investigate prevalence AIG patient AILD characterize clinical serological histopathological feature overlap improve early detection guide integrated management strategies conducted prospective study 104 patient confirmed diagnosis AILD participant screened antiparietal cell antibody APCA testing positive underwent upper gastrointestinal endoscopy gastric biopsies Histological assessment based updated Sydney System evaluation mucosal inflammation glandular atrophy intestinal metaplasia APCA positivity observed 221 AILD patients female predominance 783 median age AIG diagnosis APCApositive patient 58 years Among APCApositive individuals histological confirmation AIG achieved 913 high rate intestinal metaplasia 957 variable OLGA stage gastric atrophy Comorbid autoimmune condition common 435 APCApositive patient also presenting autoimmune thyroiditis Notably PBC disproportionately represented APCApositive subgroup 478 compared overall cohort 390 study highlight clinically significant association AIG AILDs particularly patient PBC concurrent autoimmune conditions Given elevated risk gastric mucosal atrophy potential neoplastic transformation targeted screening AIG AILD patientsespecially APCA positivity thyroid autoimmunityshould considered finding underscore importance crossspecialty surveillance open new avenue research shared immunopathogenic mechanisms study found significant number patient autoimmune liver diseases especially primary biliary cholangitis also show sign autoimmune gastritis result support consideration targeted screening gastric involvement selected patient improve early detection clinical management associated complications",
        "mesh_terms": [
            "Humans",
            "Female",
            "Male",
            "Middle Aged",
            "Prospective Studies",
            "Gastritis",
            "Autoimmune Diseases",
            "Aged",
            "Adult",
            "Hepatitis, Autoimmune",
            "Autoantibodies",
            "Cholangitis, Sclerosing",
            "Liver Cirrhosis, Biliary",
            "Parietal Cells, Gastric",
            "Prevalence"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40787461/"
    },
    {
        "pmid": "40786815",
        "title": "Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies.",
        "abstract": "contemporary epidemiology hepatocellular carcinoma HCC show shift main etiological risk factor less common highly virulent eg hepatitis C B common weak risk factor eg alcohol metabolic syndrome Therefore seemingly paradoxical state declining overall incidence rate HCCrelated improved prevention treatment viral hepatitis burgeoning number people elevated risk HCC Several geographic region reported increase HCC attributable alcoholic liver disease metabolic dysfunction associated steatotic liver disease MASLD importance risk stratification increasing allow targeted prevention early detection HCC risk factor predispose HCC formation cirrhosis served main risk stratifying factor However scheme showing crack end spectrum one hand risk developing HCC varies widely among patient contemporary advanced fibrosis cirrhosis hand onethird MASLDrelated HCC occurs among patient clear evidence cirrhosis use multidimensional eg clinical epidemiological biochemical predictive algorithm may improve risk stratification efforts shift HCC risk factor also heightened importance limitation current surveillance practice eg reduced performance ultrasound MASLD Therefore exploring advanced imaging methods new biomarkers also existing combination biomarkers augmented clinical factor HCC early detection crucial",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40786815/"
    },
    {
        "pmid": "40786326",
        "title": "Prevalence and Predictors of Occupational Exposure to Blood and Body Fluids Among Healthcare Workers in a Tertiary Care Hospital in Eastern India.",
        "abstract": "Background Healthcare worker HCWs increased risk occupational exposure blood body fluid BBFs leading transmission bloodborne infections Despite global data limited information available regarding prevalence predictor exposure Bihar India Methods hospitalbased crosssectional study conducted among 250 HCWs including resident doctors MBBS interns nursing staff paramedical staff India Institute Medical Sciences AIIMS Patna January October 2021 Stratified random sampling used Data collected using pretested semistructured questionnaire Descriptive statistics chisquare test Fishers exact test logistic regression employed analysis Statistical significance set pvalue less 005 Results mean age participant 27 years 52 female 22 reported least one occupational exposure BBFs duty AIIMS Patna 164 experienced exposure past year Needle stick injury 473 common mode exposure Twothirds participant fully vaccinated hepatitis B Following universal precaution significantly reduced odds exposure adjusted odds ratio AOR 019 95 CI 009040 Higher knowledge awareness score also protective AOR 008 95 CI 001058 Conclusion Occupational exposure BBFs remain considerable risk among HCWs Promoting universal precaution practices enhancing knowledge awareness ensuring complete hepatitis B vaccination coverage crucial minimizing risks",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40786326/"
    },
    {
        "pmid": "40786261",
        "title": "Fulminant Primary Biliary Cholangitis-Autoimmune Hepatitis (PBC-AIH) Overlap Syndrome in a 27-Year-Old Woman With Childhood-Onset AIH: Steroid-Refractory Decompensation Necessitating Urgent Transplant Evaluation.",
        "abstract": "Autoimmune hepatitis AIH primary biliary cholangitis PBC represent distinct autoimmune liver diseases characteristic clinical serological histological features Rarely patient may exhibit overlap syndrome presenting diagnostic therapeutic challenges describe 27yearold woman longstanding history childhoodonset AIH subsequently developed clinical serologic feature consistent PBC fulfilling Paris criterion AIHPBC overlap syndrome Despite aggressive treatment highdose corticosteroids experienced rapid clinical deterioration developing acute hepatic encephalopathy requiring intensive care unit admission liver biopsy confirmed coexistence interface hepatitis typical AIH florid bile duct lesion characteristic PBC Notably patient steroidrefractory course systemic autoimmune comorbidities including ulcerative colitis pyoderma gangrenosum exhibited atypical earlyonset disease progression Ultimately due severe refractory liver failure required urgent liver transplantation evaluation case highlight aggressive clinical course critical management complexity AIHPBC overlap syndrome emphasizing importance early recognition comprehensive histologic evaluation combined immunosuppressive cholestatic therapies expedited referral transplantation refractory cases",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40786261/"
    },
    {
        "pmid": "40785957",
        "title": "Epidemiology of reportable infectious diseases in the Najran Health Cluster.",
        "abstract": "control disease outbreak promote prevention disease monitoring burden infectious illness epidemiology essential Keeping track change disease rate and crucially effectiveness control measure like immunization campaign eradication certain infectious illness depends heavily national surveillance data study analyzed national surveillance data illustrate evolving epidemiology reportable infectious disease Najran Health Cluster 2022 2024 disease incidence rate per 100000 population 95 confidence interval calculated using population census data 2022 2024 year number case described sex nationality age Statistical analysis performed using SPSS Pearsons ChiSquare Fishers exact test assessed association disease incidence population demographics common bacterial disease brucellosis pulmonary tuberculosis salmonellosis 2024 outbreak pertussis cholera incidence rate 52 76100000 respectively common viral disease measles hepatitis B dengue fever chickenpox 2024 marked increase number confirmed hepatitis B cases 100 case 2023 256 2024 common parasitic disease scorpion sting malaria cutaneous leishmaniasis amebic dysentery number reported case malaria almost doubled 45 2023 88 2024 study highlight importance tracing infectious disease data identify outbreak early implement control measures 2024 increase number confirmed case hepatitis B pertussis cholera malaria situation requires urgent investigation",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40785957/"
    },
    {
        "pmid": "40785933",
        "title": "Differentiation of dual- and non-dual-phenotype hepatocellular carcinoma based on contrast-enhanced computed tomography and patient characteristics.",
        "abstract": "Dualphenotype hepatocellular carcinoma DPHCC associated higher risk recurrence little known clinicodemographic characteristic imaging features study aimed assess whether contrastenhanced computed tomography CECT patient characteristic facilitate preoperative differentiation DPHCC nonDPHCC Features CECT image clinicodemographic characteristic retrospectively analyzed consecutive series hepatocellular carcinoma HCC patient January 2020 December 2020 Disease confirmed based surgical pathology CECT performed within four week surgery Univariate multivariate logistic regression analysis performed identify independent risk factor DPHCC imaging model based CECT feature combined model based clinicodemographic characteristic CECT feature constructed respectively Delongs test used comparison area curve AUC value two models KaplanMeier survival analysis used assess overall survival OS DPHCC nonDPHCC groups total 29 patient DPHCC 140 nonDPHCC included study DPHCC significantly prevalent among female patient less prevalent among infected hepatitis B virus HBV CECT associated DPHCC rim arterial phase hyperenhancement APHE peripheral washout whereas associated nonDPHCC nonrim APHE nonperipheral washout Multivariate logistic regression identified one independent CECT feature DPHCC rim APHE odds ratio OR 11040 95 confidence interval CI 19863532 imaging model constructed based rim APHEpredicted DPHCC AUC 0562 95 CI 04390684 Multivariate logistic regression identified three independent clinicodemographic characteristic CECT feature DPHCC female sex OR 4519 95 CI 152913357 infection HBV OR 0234 95 CI 00840654 rim APHE OR 15016 95 CI 233596585 combined model constructed based three independent predictor DPHCC AUC 0716 95 CI 06030829 Delongs test showed AUC combined model higher imaging model difference statistically significant Z3207 P005 OS rate patient DPHCC nonDPHCC group 687 772 respectively KaplanMeier survival analysis showed statistical difference OS rate group P0362 combined model established based female sex infection HBV rim APHE CECT facilitate preoperative differentiation DPHCC nonDPHCC DPHCC likely cause death nonDPHCC suggesting active postoperative management patient DPHCC required",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40785933/"
    },
    {
        "pmid": "40785902",
        "title": "Donafenib <i>vs.</i> lenvatinib combined with transarterial chemoembolization as initial therapy for unresectable hepatocellular carcinoma: a retrospective real-world study.",
        "abstract": "combination tyrosine kinase inhibitor TKIs transarterial chemoembolization TACE hold promise unresectable hepatocellular carcinoma HCC study aimed directly compare efficacy safety donafenib DonaTACE ivsi lenvatinib LENTACE firstline therapies retrospective study 93 unresectable HCC patient 49 DonaTACE 44 LENTACE 93 hepatitis B virusinfected treated October 2020 May 2023 analyzed Patients received TACE conventional drugeluting beads combined Dona 200 mg twice daily LEN 812 mgday Outcomes included overall survival OS progressionfree survival PFS objective response rate ORR disease control rate DCR adverse event AEs Survival analysis employed KaplanMeier logrank tests Median OS mOS 1400 month DonaTACE ivsi 1900 month LENTACE hazard ratio HR 125 95 confidence interval CI 078199 P0330 Median PFS 737 ivsi 577 month HR 0785 95 CI 046133 P0354 significant differences ORR 5510 ivsi 6136 P0541 DCR 7551 ivsi 8182 P0460 comparable DonaTACE showed significantly lower overall AE rate any grade 8571 ivsi 10000 P0013 grade ≥3 2245 ivsi 4545 P0027 including reduced hypertension 204 ivsi 3636 P0001 diarrhea 612 ivsi 2500 P0011 vomiting 000 ivsi 4091 P0001 DonaTACE LENTACE demonstrated comparable efficacy unresectable HCC DonaTACE exhibited superior safety profile suggesting potential preferable option patient higher comorbidity risks prospective study warranted validate findings",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40785902/"
    },
    {
        "pmid": "40785381",
        "title": "Immunoinformatics study of CD40 ligand-targeting vaccine constructs: a novel immunotherapeutic approach.",
        "abstract": "Incorporating CD40 ligand CD40L vaccine strategy shown considerable potential enhancing immune responses study designed formulated CD40Lbased multiepitope vaccine construct using immunoinformatics approaches compared fulllength CD40Lbased vaccine construct study commenced identification screening potential Tcell Bcell epitope derived CD40L protein followed construction multiepitope vaccine selected epitopes analyzed validated physicochemical structural property vaccine constructs Further predicted disulfide bonds performed proteinprotein docking conducted molecular dynamic simulation evaluate constructs Comparative analysis ligandbinding site localization conducted using LigPlot Additionally simulation trajectory analyzed using multiple descriptors including root mean square deviations radius gyration root mean square fluctuations finding indicated CD40L multiepitope vaccine construct possessed favorable physicochemical property validated structural profile Immune simulation study showed stronger affinity multiepitope construct CD40 receptor compared fulllength CD40L construct Overall CD40L multiepitope vaccine construct demonstrated greater potency eliciting effective immune response fulllength CD40L construct result highlight promising approach vaccine design prevention treatment infection cancers",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40785381/"
    },
    {
        "pmid": "40785185",
        "title": "Preclinical development and a phase I trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer.",
        "abstract": "Autologous EpCAMtargeted CART cell therapy IMC001 developed advanced gastric cancer GC study evaluated specificity efficacy safety IMC001 preclinical model phase doseescalationexpansion trial patient failed least two line therapy IMC001 specifically recognized EpCAM exhibited potent antitumor activity EpCAMpositive tumor cells xenograft models patientderived organoids August 2021 May 2023 12 advanced GC patient received IMC001 patient experienced grade 3 4 treatmentrelated adverse events mainly lymphopenia related lymphodepletion treatmentrelated deaths Five patient experienced cytokine release syndrome n3 grade 34 two patient experienced immunerelated hepatitis n1 grade 3 middledose group n1 grade 4 highdose group Partial response observed 333 13 lowdose patient 40 25 middledose patients achieving objective response rate 30 disease control rate 70 Median progressionfree survival overall survival 45 84 months respectively One patient underwent conversion surgery week 27 remains alive 315 month postinfusion finding demonstrate acceptable safety profile promising efficacy IMC001 advanced GC supporting clinical development refractory GC patients",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40785185/"
    },
    {
        "pmid": "40784973",
        "title": "High risk of hepatic complications in kidney transplantation with chronic hepatitis C virus infection.",
        "abstract": "Data liver issue including liver cirrhosis hepatocellular carcinoma hepatic failure renal transplant patient HCV infection scarce present study conducted largescale populationbased analysis investigate longterm outcome renal recipient HCV infection Propensity score matching ratio 11 applied total 6473renal recipient HCV infection case group enrolled PSM finding showed subject HCV infection kidney transplant significantly higher risk hepatoma cirrhosis hepatic failure overall hepatic disease without HCV infection hepatoma HR 8957 95 CI 532415069 cirrhosis HR 5378 95 CI 43636631 hepatic failure HR 3258 95 CI 25274200 overall hepatic disease HR 4128 95 CI 34284971 present study finding show renal recipient HCV infection significantly associated remarkably high risk hepatic complication postkidney transplantation",
        "mesh_terms": [
            "Humans",
            "Kidney Transplantation",
            "Male",
            "Female",
            "Middle Aged",
            "Hepatitis C, Chronic",
            "Adult",
            "Risk Factors",
            "Liver Cirrhosis",
            "Postoperative Complications",
            "Liver Neoplasms",
            "Carcinoma, Hepatocellular",
            "Hepacivirus"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40784973/"
    },
    {
        "pmid": "40784876",
        "title": "Trained human bone marrow mesenchymal stem cells restore tissue immuno-microenvironment in fulminant hepatic failure mice.",
        "abstract": "Trained immunity human bone marrow mesenchymal stem cell hBMSC promising approach liver regeneration study aimed clarify trainedhBMSC ThBMSC restoring tissue immunomicroenvironment fulminant hepatic failure FHF mice hBMSC trained tumor necrosis factorα interferonγ phenotypically characterized vitro FHF mouse model established male Balbc mouse via tail vein injection concanavalin A therapeutic potential ThBMSC evaluated transplantation FHF mice Transcriptomic analysis performed elucidate mechanism liver regeneration posttransplantation ThBMSC ThBMSC characteristic trilineage differentiation potential showed proinflammatory IL1β IL8 p  00001 immunoregulatory gene PDL1 IDO1 p  00001 significantly upregulated compared untrainedhBMSC UThBMSC Timetrajectory analysis revealed downregulation proinflammatory gene IL6 IL8 IL1α upregulation immunomodulatory gene IDO1 ThBMSC upon mimicstimulation characterized distinct transcriptional programs liver function ALT AST inflammatory cytokine IL6 MCP1 p  001 level significantly improved ThBMSCtreated mice survival status ThBMSC group superior UThBMSC group although statistical significance Histological analysis confirmed reduced necrosis fewer infiltrating CD45supsup immune cell ThBMSCtreated mice Significant downregulation immune response TNF  IL17 signaling pathway neutrophil chemotaxis upregulation metabolic pathway observed ThBMSC group associated enhanced liver regeneration proportion antiinflammatory F480supsupCD163supsup macrophage increased liver ThBMSC group ThBMSC exhibited enhanced immunomodulation effectively rescuing liver failure reducing inflammation via restoring immunemicroenvironment finding highlighted potential trained immunity novel strategy treatment liver failure",
        "mesh_terms": [
            "Animals",
            "Liver Failure, Acute",
            "Mesenchymal Stem Cells",
            "Humans",
            "Mice",
            "Male",
            "Mesenchymal Stem Cell Transplantation",
            "Mice, Inbred BALB C",
            "Liver Regeneration",
            "Cell Differentiation",
            "Disease Models, Animal",
            "Cellular Microenvironment",
            "Liver",
            "Bone Marrow Cells"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40784876/"
    },
    {
        "pmid": "40784805",
        "title": "[Research progress on the impact of metabolic associated fatty liver disease on viral activity, treatment response, and prognosis in patients with chronic hepatitis B: current status and prospects].",
        "abstract": "Chronic hepatitis B CHB gradually progress lifethreatening disease cirrhosis hepatocellular carcinoma HCC recent years change peoples lifestyles incidence rate metabolic associated fatty liver disease steadily increasing patient combined CHB MAFLD significantly surged However impact MAFLD patient CHB aspect antiviral response clinical outcomes others still controversial article review research progress impact MAFLD regard natural course antiviral treatment response CHB survival rate combination CHB MAFLD provide certain theoretical reference prevention diagnosis treatment disease",
        "mesh_terms": [
            "Humans",
            "Hepatitis B, Chronic",
            "Antiviral Agents",
            "Prognosis",
            "Hepatitis B virus",
            "Fatty Liver",
            "Liver Neoplasms",
            "Non-alcoholic Fatty Liver Disease",
            "Carcinoma, Hepatocellular",
            "Survival Rate"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40784805/"
    },
    {
        "pmid": "40784802",
        "title": "[Analysis of liver histological characteristics and clinically related factors in patients with inactive HBsAg carriers].",
        "abstract": "bObjectiveb analyze liver histological characteristic clinically related factor inactive hepatitis B surface antigen HBsAg carrier IHC also explore whether antiviral treatment necessary IHC defined 2022 version hepatitis B prevention treatment guidelines bMethodsb multicenter retrospective cohort study conducted Two hundred thirtyone IHC case underwent liver biopsy histopathological examination nine medical institutions including Beijing Youan Hospital affiliated Capital Medical University January 2018 December 2023 included General informative data clinical serological markers transient elastography TE examination result collected Patients divided positive 148 cases negative group 83 cases according result hepatitis B virus HBV DNA detection difference liver pathological inflammatory activity G liver fibrosis stage S analyzed two group explore correlation liver tissue condition clinically related factors Comparsions normally distributed continwous data skeukd continuous data categorical data group performed using iti tests MannWhitney iUi test i􀱽isup2sup tests respectively bResultsb age 231 IHC case 43 38 51 year old 952 220231 aged ≥30 years male accounted 649 150231 HBsAg HBV DNA level 1319 208 4009 IUmL 940 0 4485 IUmL respectively 359 83231 HBV DNA negative 20 IUmL remarkable proportion G≥2 S≥2 liver injury G≥2 andor S≥2 liver tissue 165 38231 29 67231 359 83231 respectively S≥2 proportion significantly higher HBV DNAnegative group positive group 422 ivsi 216 iPi0001 mainly occurred population cohort 30 year old 449 ivsi 310 iPi004 liver stiffness measurement LSM aspartate transaminase platelet ratio index APRI platelet PLT significantly higher S≥2 group S2 group iPi005 bConclusionb Clinicians comprehensively evaluate degree liver fibrosis IHC based clinical factor age PLT APRI LSM even liver histological result lacking China 2022 version guideline define nearly half IHC histological indication antiviral therapy liver biopsy prompt treatment recommended",
        "mesh_terms": [
            "Humans",
            "Retrospective Studies",
            "Liver",
            "Hepatitis B Surface Antigens",
            "Male",
            "Female",
            "Hepatitis B virus",
            "Hepatitis B",
            "DNA, Viral",
            "Liver Cirrhosis",
            "Adult",
            "Middle Aged",
            "Carrier State",
            "Biopsy",
            "Hepatitis B, Chronic"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40784802/"
    },
    {
        "pmid": "40784798",
        "title": "[Clinical characteristics, diagnosis, and treatment strategies for drug-induced autoimmune hepatitis].",
        "abstract": "Druginduced liver injury DILI important adverse drug reaction diverse clinical manifestations Druginduced autoimmunelike hepatitis DIALH special type DILI possessing clinical serological histological feature similar autoimmune hepatitis AIH However significant difference DIALH AIH term treatment plan course disease prognosis therefore differential diagnosis DIALH AIH crucial article summarizes epidemiology pathogenesis clinical characteristics diagnosis differential diagnosis treatment prognosis DIALH analyzes existing problem order provide guidance diagnosis treatment future research direction",
        "mesh_terms": [
            "Humans",
            "Chemical and Drug Induced Liver Injury",
            "Diagnosis, Differential",
            "Hepatitis, Autoimmune",
            "Prognosis"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40784798/"
    },
    {
        "pmid": "40784795",
        "title": "[Diagnosis and treatment strategies of autoimmune hepatitis and future challenges].",
        "abstract": "Autoimmune hepatitis AIH kind immunemediated chronic liver disease specific pathogenesis yet fully elucidated recent years International Autoimmune Hepatitis Expert Group revised histology autoantibody evaluation criterion diagnosing AIH clarified definition treatment response current standard treatment regimen still glucocorticoid azathioprine novel biological agent offer new therapeutic option patient refractory AIH article review new progress diagnosis treatment AIH explores current challenge future research directions",
        "mesh_terms": [
            "Humans",
            "Hepatitis, Autoimmune",
            "Azathioprine",
            "Glucocorticoids",
            "Autoantibodies",
            "Immunosuppressive Agents"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40784795/"
    },
    {
        "pmid": "40784794",
        "title": "[Advances in clinical diagnosis and treatment of autoimmune liver diseases combined with viral hepatitis].",
        "abstract": "Autoimmune liver disease AILDs group chronic inflammatory liver disease mediated autoimmune disorders viral hepatitis group infectious disease mainly induced hepatotropic viruses resulting liver inflammation necrotic lesions viral infection risk factor AILDs two condition may coexist article provides review diagnosis treatment AILDs combined viral hepatitis recent years",
        "mesh_terms": [
            "Humans",
            "Hepatitis, Autoimmune",
            "Hepatitis, Viral, Human",
            "Autoimmune Diseases"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40784794/"
    },
    {
        "pmid": "40784334",
        "title": "Limited Prognostic Impact of Sustained Virologic Response on Atezolizumab plus Bevacizumab Therapy for HCV-related Unresectable Hepatocellular Carcinoma.",
        "abstract": "Sustained virologic response SVR favorable prognostic factor patient hepatocellular carcinoma HCC caused hepatitis C virus HCV treated curatively study aimed evaluate impact SVR atezolizumab plus bevacizumab AtezBev therapy unresectable HCC uHCC caused HCV retrospective analysis 364 uHCC patient treated AtezBev September 2020April 2025 divided SVR n284 nonSVR n80 group performed clinical characteristics prognosis adverse event compared significant difference group age sex platelet count AFP BCLC stage However SVR group showed significantly better ALBI score 250 vs 216 lower AST 33 vs 57 IUL ALT 23 vs 40 IUL level p001 Median progressionfree survival PFS 71 month SVR group 61 month nonSVR group p0443 median overall survival OS 209 month SVR group 189 month nonSVR group significant difference group p0560 Following IPW adjustment factor related OS significant difference regarding PFS p0921 OS p0927 Multivariate analysis identified age ≥75 year poor hepatic function mALBI grade 2b3 independent predictor poor OS SVR status independent factor Changes ALBI ChildPugh score time significantly different groups nonSVR group adverse event common compared SVR group including liver dysfunction 275 vs 130 p0001 edemaascites 125 vs 92 p0015 Although SVR independently associated better survival patient SVR preserved liver function experienced fewer adverse events factor may indirectly support improved tolerability therapeutic option AtezBev therapy HCVrelated uHCC",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40784334/"
    },
    {
        "pmid": "40784196",
        "title": "Heterogeneity of false reactivity profiles of HIV assays while optimizing national HIV testing algorithms: Findings from a multi-country analysis.",
        "abstract": "study highlight importance verifying HIV testing algorithm reduce risk misdiagnoses caused common false reactivity 2020 2023 supported 14 country assess rate false reactivity shared false reactivity across HIV rapid diagnostic test RDTs used HIV testing services study involved 26278 result 22 different RDT products sample size ranging 100 302 result per country number RDT product assessed varied 4 13 per country False reactivity rate ranged 0  332  one country reporting high false reactivity rate 4  one RDT Five country shared false reactivity RDTs remaining eight country shared false reactivity across one six pair RDT products finding used inform national policy 90  country introducing new RDT product HIV testing algorithm based results study concludes rate false reactivity shared false reactivity RDT product vary across countries Therefore conducting verification study crucial updating national HIV testing algorithm ensuring accurate diagnosis also facilitating market entry new HIV testing products",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40784196/"
    },
    {
        "pmid": "40782354",
        "title": "Community-Based Micro-Elimination of Hepatitis C Virus in a Defined Rural Cohort: Outcomes From the Nagawa Project.",
        "abstract": "Hepatitis C virus HCV infection remains global public health concern many carrier remaining undiagnosed asymptomatic nature Although Japan previously considered track national HCV elimination 2030 recent global modeling study updated elimination dashboard indicate Japan currently track underscore importance locally coordinated effort detect residual cases Microelimination recently emerged pragmatic scalable approach targeting defined population geographic areas Nagawa Project sought identify HCV positive individual communitywide screening directing viremic case appropriate directacting antiviral DAA therapy present study describes implementation outcome cohortbased HCV microelimination strategy 5027 adult resident Nagawa town Japan aged ≥ 20 year prospectively targeted HCV antibody testing routine health checkups outpatient visits mailed invitation June 2021 March 2024 HCV Antibody positive individual underwent additional HCV core antigen testing confirm viremia total 3121 resident 621 underwent HCV antibody testing Testing rate significantly higher earlystage elderly 6574 years 737 resident adult 2064 years 545 p  0001 latestage elderly ≥ 75 years 667 p  0001 residents Twentyeight individual 0897 HCV antibody positive three case 0096 confirmed viremic Antibody positivity significantly higher latestage elderly resident 191 p  0001 vs adult p  0031 vs earlystage elderly residents Two viremic individual received DAA therapy achieved sustained virological response adjusting age sex propensity score matching significant difference overall survival observed HCV antibody positive negative individuals Nagawa Project illustrates success locally coordinated HCV microelimination approach offer practical framework identifying managing residual HCV infections contributing progress toward Japans alignment World Health Organizations 2030 HCV elimination goals",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40782354/"
    },
    {
        "pmid": "40782323",
        "title": "Safety evaluation of deucravacitinib: a real-world analysis based on the FDA adverse event reporting system database.",
        "abstract": "Deucravacitinib novel highly selective tyrosine kinase 2 allosteric inhibitor recently approved treatment moderatetosevere psoriasis adults though postmarketing safety data remain limited purpose study perform postmarketing safety evaluation deucravacitinib based Food Drug Administration Adverse Event Reporting System FAERS database study collected adverse event AE report deucravacitinib primary suspected drug FAERS database third quarter 2022 fourth quarter 2024 Four main method disproportionality analysis including reporting odds ratio proportional reporting ratio Bayesian confidence propagation neural network multiitem gamma Poisson shrinker employed signal detection Potential risk signal deemed significant four algorithm simultaneously met thresholds important medical event IME term list used identify IMEs deucravacitinib Additionally Weibull distribution used evaluate timetoonset TTO characteristics Thirtynine preferred term identified potential risk signals commonly reported AE acne mouth ulceration folliculitis Sixteen AEs potential risk signal mentioned label also identified including urticaria oral pain oropharyngeal pain swelling face lip swelling eye swelling cellulitis ear pain pharyngeal swelling Bells palsy mouth swelling cheilitis mycobacterium tuberculosis complex test positive facial paralysis hepatitis A central nervous system CNS infection Rhabdomyolysis Bells palsy facial paralysis CNS infection identified IMEs associated deucravacitinib study Weibull distribution indicated TTO characteristic deucravacitinibassociated AEs followed early failure type study provides new safety data deucravacitinib realworld settings uncovering previously unrecognized risk identifying several IMEs finding somewhat supplemented safety data deucravacitinib Given limitation FAERS database postmarketing safety surveillance study deucravacitinib remain necessary future",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40782323/"
    },
    {
        "pmid": "40781975",
        "title": "Trends and disparities in human immunodeficiency virus and chronic liver disease mortality in the United States: A nationwide analysis.",
        "abstract": "ObjectivesWith advance antiretroviral therapy life expectancy individual living human immunodeficiency virus infection significantly improved Consequently nonacquired immunodeficiency syndromerelated conditions particularly chronic liver disease become increasingly prominent cause mortalityMethodsA retrospective analysis conducted using mortality data Centers Disease Control Prevention WideRanging Online Data Epidemiologic Research database spanning 1999 2020 identified death among adult aged 25 year older human immunodeficiency virus infection chronic liver disease listed cause death Data grouped gender age race region Ageadjusted mortality rate calculated per 1 million adult United States Annual percent change computed using Joinpoint regressionResultsFrom 1999 2020 13447 death United States human immunodeficiency virus infection chronic liver disease listed cause death overall ageadjusted mortality rate 249 Males higher ageadjusted mortality rate 385 female 108 NonHispanic Black population higher ageadjusted mortality rate 871 Hispanics 33 nonHispanic white 229ConclusionMortality human immunodeficiency virus infection chronic liver disease listed cause death declined racial disparity persist particularly among nonHispanic Black individuals Addressing disparity require policy improve care access reduce liver diseaserelated risk among people living human immunodeficiency virus infection",
        "mesh_terms": [
            "Humans",
            "Male",
            "Female",
            "United States",
            "HIV Infections",
            "Adult",
            "Middle Aged",
            "Retrospective Studies",
            "Aged",
            "Liver Diseases",
            "Cause of Death",
            "Health Status Disparities",
            "Chronic Disease"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40781975/"
    },
    {
        "pmid": "40781938",
        "title": "Five-Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal Impairment.",
        "abstract": "Longterm nucleostide analog NUC therapy essential chronic hepatitis B CHB management However data longterm outcomes particularly patient switching tenofovir alafenamide TAF patient chronic kidney disease CKD remain limited study aimed evaluate 5year virological effectiveness renal safety sequential TAF therapy focus preexisting CKD realworld multicenter retrospective study included 414 CHB patient aged ≥ 18 year switched prior NUC TAF followed least 5 years Patients stratified based renal function CKD nonCKD baseline Study endpoint included 5year virological efficacy biochemical fibrosis responses renal function changes Among patients 100 242 CKD time switching TAF 5 years HBV DNA suppression rate increased 850 100 HBV DNA suppression target detected rate rose 740 910 alanine aminotransferase normalization rate AASLD criteria improved 660 790 similar result patient nonCKD Estimated glomerular filtration rate remained stable regardless baseline renal status prior NUC regimen demonstrating longterm renal safety case HBV DNA breakthrough including among previously combination NUCs patient cirrhosis FIB4 index significantly improved time p  0008 Sequential TAF therapy demonstrated robust virological efficacy biochemical fibrosis improvements excellent renal safety 5 years irrespective baseline renal function",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40781938/"
    },
    {
        "pmid": "40781716",
        "title": "Targeting NOTCH1-KEAP1 axis retards chronic liver injury and liver cancer progression via regulating stabilization of NRF2.",
        "abstract": "Chronic liver injury key factor disease like hepatocellular carcinoma HCC steatohepatitis NASH viral hepatitis type B C HBV HCV Understanding molecular mechanism crucial effective treatment NOTCH1 signaling pathway though fully understood implicated liver injury may potential therapeutic target Clinical HCC HBV HCV NASH sample additional vitro vivo performance subjected confirm role NOTCH1 downstream target via series biochemical assays molecular analysis approach targeted signaling pathway assay etc RESULTS present study first verified abnormal elevation NOTCH1 hepatocytes patient steatohepatitis HCC HBV HCV mouse models Crucially discovered hepatocytespecific NOTCH1 knockout reduces hepatocellular damage chronic liver inflammation HCC mouse models whereas adenoassociated virus serotype 8 AAV8mediated NOTCH1 overexpression hepatocytes exacerbates liver injuryrelated phenotype onsetting Mechanistically showed NOTCH1 new role controlling ferroptosis oxidative damage hepatocytes interacts Kelchlike ECHassociated protein 1 KEAP1 directly recruited intracellular domain NICD1 Additionally KEAP1 recruited NOTCH1 impeded binding stability KEAP1NFE2 like BZIP transcription factor 2 Nrf2 promote separation KEAP1 Nrf2 thereby reducing stability Nrf2 hindering ubiquitinationrelated proteasome degradation Nrf2 Crucially also discovered NOTCH1s ANK domain essential NICD1KEAP1 contact signaling activation inability NOTCH1 ANK domain mutant ΔANK connect KEAP1 increase expression emphasizes importance ANK domain KEAP1NRF2 signaling reversing downregulation KEAP1 overexpression NRF2 ANK function linked ferroptosis ROS buildup ANK domain targeting may slow course HCC liver damage Targeting NOTCH1KEAP1NRF2 axis possible chronic hepatic injury therapy supported findings identify NOTCH1KEAP1 NRF2 suppressor accelerates progression liver injury",
        "mesh_terms": [
            "Humans",
            "Animals",
            "NF-E2-Related Factor 2",
            "Receptor, Notch1",
            "Liver Neoplasms",
            "Kelch-Like ECH-Associated Protein 1",
            "Mice",
            "Disease Progression",
            "Carcinoma, Hepatocellular",
            "Signal Transduction",
            "Male",
            "Disease Models, Animal"
        ],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40781716/"
    },
    {
        "pmid": "40781577",
        "title": "Description of Multicopy Recombinant Hepatitis B Surface Antigen: From Expression to Immune Analysis.",
        "abstract": "Hepatitis B virus HBV remains significant global health challenge Although antiviral treatment improved vaccine containing Hepatitis B surface antigen HBsAg still effective prevention method Since 1998 HBV vaccine part Turkiyes mandatory childhood vaccination program vaccine currently imported study primarily aim optimize recombinant HBsAg production Pichia pastoris evaluate immunological comparability commercial HBV vaccine thereby assessing potential locally produced vaccine candidate achieve this eightcopy tandem construct HBsAg gene created pPICZαA plasmid vitro multimerization production process recombinant HBsAg optimized presence HBsAg supernatant following induction confirmed antigen purified using various physical biochemical methods highest yield recombinant HBsAg achieved eightcopy construct following induction 1 methanol harvesting 120 h identified productive time point antigenic property produced HBsAg compared commercially available vaccine Engerix B™ Immunological testing using serum antiHBsAg positive individual immunized animal demonstrated recombinant rHBsAg exhibited similar antigenic characteristic commercial vaccine finding study indicate recombinant HBsAg exhibit immunological property comparable imported vaccine suggest may potential candidate future vaccine development",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40781577/"
    },
    {
        "pmid": "40780329",
        "title": "Mapping novel linear B-cell epitopes target Hepatitis C virus envelope proteins E1 and E2 by monoclonal antibodies for increasing the sensitive detection sites.",
        "abstract": "Since protective vaccine Hepatitis C timely diagnosis treatment early stage viral infection crucial prevent control hepatitis C virus HCV causing chronic infection E1 E2 protein HCV produce neutralizing antibody often used screen potential epitopes study human embryonic kidney 293 HEK293F cell used generate highly active HCV E1 E2 proteins used antigen producing mouse monoclonal antibody mAbs Novel B cell epitope E1 E2 disclosed using monoclonal antibody first time Based epitopes three multiepitope MEP antigen designed prepared including nonstructural protein novel identified B cell epitope E1 E2 HCV 1b 2a 3a 6a subtypes Double antigen sandwich enzyme immunoassay established based MEPs detect HCV serum antibodies showing potential diagnostic application study suggests Bcell epitope E1 E2 could contribute development diagnostic reagents provides important reference value theoretical support optimization diagnostic reagent HCV",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40780329/"
    },
    {
        "pmid": "40780235",
        "title": "Recompensation in decompensated cirrhosis.",
        "abstract": "Recompensation decompensated cirrhosis defined Baveno consensus control cure main underlying cause resolution clinical manifestations including ascites hepatic encephalopathy without use prophylactic medications without variceal bleeding 12 months restoration hepatic function Cure recompensation usually associated regression liver fibrosis Recompensation occur hepatitis C virus eradicated hepatitis B virus infection without hepatitis coinfection suppressed following persistent alcohol abstinence patient alcoholassociated cirrhosis Although cirrhosis related metabolic dysfunctionassociated steatotic liver disease improve following lifestyle pharmacotherapyassisted weight loss autoimmune liver disease respond immunosuppression unclear true recompensation achieved patients Recompensation cirrhosis could achievable clinical target offsetting cost management advanced liver disease decreasing need liver transplantation Consequently public health policy pursue programme promote alcohol cessation eliminate viral hepatitis address obesity",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40780235/"
    }
]